

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 July 2001 (26.07.2001)

PCT

(10) International Publication Number
WO 01/52902 A1

- (51) International Patent Classification⁷: **A61K 48/00**, C12N 15/09, 15/85, C07H 21/04
- (74) Agents: **LICATA, Jane, Massey** et al.; Licata & Tyrrell P.C., 66 E. Main Street, Marlton, NJ 08053 (US).
- (21) International Application Number: PCT/US01/01381
- (22) International Filing Date: 15 January 2001 (15.01.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
09/490,208 24 January 2000 (24.01.2000) US
- (71) Applicant (for all designated States except US): **ISIS PHARMACEUTICALS, INC.** [US/US]; 2292 Faraday Avenue, Carlsbad, CA 92008 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **BENNETT, C., Frank** [US/US]; 1347 Cassins Street, Carlsbad, CA 92008 (US). **DEAN, Nicholas, M.** [GB/US]; 2110 Whisperwind Lane, Olivenheim, CA 92024 (US). **COWSERT, Lex, M.** [US/US]; 3008 Newshire Street, Carlsbad, CA 92008 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
- with international search report
 - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/52902 A1

(54) Title: ANTISENSE MODULATION OF INDUCIBLE NITRIC OXIDE SYNTHASE EXPRESSION

(57) Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of inducible nitric oxide synthase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding inducible nitric oxide synthase. Methods of using these compounds for modulation of inducible nitric oxide synthase expression and for treatment of diseases associated with expression of inducible nitric oxide synthase are provided.

-1-

**ANTISENSE MODULATION OF INDUCIBLE
NITRIC OXIDE SYNTHASE EXPRESSION**

FIELD OF THE INVENTION

The present invention provides compositions and methods for modulating the expression of inducible nitric oxide synthase. In particular, this invention relates to antisense compounds, particularly oligonucleotides, specifically hybridizable with nucleic acids encoding inducible nitric oxide synthase. Such oligonucleotides have been shown to modulate the expression of inducible nitric oxide synthase.

BACKGROUND OF THE INVENTION

Nitric Oxide (NO) is a short-lived second messenger that exhibits a diverse array of effects within the normal cell including the regulation of neurotransmission, vasodilation, immunological processes and antimicrobial defenses. Due to its radical properties, however, NO has also been implicated in the onset and maintenance of several pathological conditions. Nitric oxide is produced constitutively in most cell types at low concentrations but levels are greatly increased in response to cellular stimulation by cytokines or bacterial products. Nitric oxide is generated from the amino acid L-arginine by the enzymatic activity of nitric oxide synthase (NOS) (Kroncke et al., *Clin. Exp. Immunol.*, **1998**, *113*, 147-156; Marletta et al., *Curr. Opin. Chem. Biol.*, **1998**, *2*, 656-663).

Three isoforms of the NOS enzyme have been isolated and the differential regulation of these isoforms mediates the fluctuating levels of nitric oxide present within quiescent and stimulated cells. Two of the three isoforms, found in brain and endothelium, are calcium and calmodulin dependent and are responsible for the constitutive levels of nitric oxide present in cells. The third isoform is calcium

-2-

independent and is expressed after transcriptional induction by several stimuli resulting in localized bursts of nitric oxide production. Because of the highly reactive and potentially toxic nature of the nitric oxide molecule and because relatively high concentrations are generated by the inducible form of the NOS enzyme, much effort has been focused on the control of nitric oxide levels in cells through the regulation of this enzyme (Kroncke et al., *Clin. Exp. Immunol.*, **1998**, *113*, 147-156; Marletta et al., *Curr. Opin. Chem. Biol.*, **1998**, *2*, 656-663).

Inducible nitric oxide synthase (also known as iNOS) was first isolated from human hepatocytes, articular chondrocytes and bone cells with mRNA levels being elevated upon stimulation with lipopolysaccharides (LPS) cytokines and interleukin 1 (IL-1) (Geller et al., *Proc. Natl. Acad. Sci. U. S. A.*, **1993**, *90*, 3491-3495; Maier et al., *Biochim. Biophys. Acta.*, **1994**, *1208*, 145-150). More recently, a splice variant of human iNOS (GenBank accession number AB022318) was isolated from an osteoblastoma cell line.

Mice lacking the iNOS gene have been developed and shown to be viable and fertile (Casey et al., *Transplantation*, **1997**, *64*, 589-593; Laubach et al., *Proc. Natl. Acad. Sci. U. S. A.*, **1995**, *92*, 10688-10692). However, lymphocytes from iNOS knockouts showed increased proliferative responses and production of cytokines (interferon-gamma, IL-2 and IL-12) in response to allogeneic antigen (Casey et al., *Transplantation*, **1997**, *64*, 589-593) and studies on macrophages from the null mice show a failure to restrict the growth of lymphoma cells post-infection (MacMicking et al., **1998**; MacMicking et al., *Cell*, **1995**, *81*, 641-650). In addition, disclosed in US Patent 5,766,909 are a DNA molecule encoding murine iNOS, an expression vector encoding iNOS and methods to produce recombinant iNOS (Xie et al., **1998**).

Manifestations of increased nitric oxide production and altered iNOS expression appear in both injury and disease states. Several studies have correlated increased iNOS expression with disorders such as congestive heart failure, CNS disorders, and diabetes (Lee and Brosnan, *Methods*, **1996**, *10*, 31-37; Rabinovitch et al., *Endocrinology*, **1996**, *137*, 2093-2099; Vejlstrup et al., *J. Mol. Cell. Cardiol.*, **1998**, *30*, 1215-1223).

Currently, strategies aimed at modulating iNOS expression and function involve the use of antibodies, antisense technology, chemical inhibitors and gene knock-outs in mice.

Studies using antisense oligonucleotides to effectively reduce the mRNA levels of iNOS in animal models have been reported in the literature. In a rat model of septic shock, antisense oligonucleotides targeted to iNOS were shown to prevent LPS-induced hyporeactivity to norepinephrine (Hoque et al., *Am. J. Physiol.*, **1998**, *275*, H1078-1083). In a mouse model of multiple sclerosis, administration of an antisense phosphorothioate oligonucleotides against mouse iNOS blocked the induction of iNOS mRNA and protein expression in glial cells and inhibited the induction of experimental autoimmune encephalomyelitis (EAE) (Ding et al., *J. Immunol.*, **1998**, *160*, 2560-2564; Ding et al., *Neurosci. Lett.*, **1996**, *220*, 89-92). Phosphorothioate antisense oligonucleotides targeting iNOS were also used to demonstrate the toxic role of nitric oxide in ischemic acute renal failure in the rat (Noiri et al., *J. Clin. Invest.*, **1996**, *97*, 2377-2383). In studies to investigate the role of nitric oxide in cell adhesion, macrophages expressing either the sense or antisense murine iNOS construct were characterized. It was found that cells expressing the antisense iNOS produced 22-97% less nitric oxide than sense lines (Cartwright et al., *Br. J. Pharmacol.*,

1997, 120, 146-152).

In human cell lines, an antisense oligonucleotide 32 nucleotides long targeted to iNOS has also been used to discern the role of iNOS in the processes of apoptosis (Selleri et al., *Br. J. Haematol.*, 1997, 99, 481-489). An antisense oligonucleotide targeted to nucleotides 62-85 of human iNOS has been used to study the role of this enzyme in oxidative stress injury (Peresleni et al., *Am. J. Physiol.*, 1996, 270, F971-977).

Various types of inhibitors of iNOS function, including chemical moieties and naturally occurring molecules such as amino acids and peptide fragments, have been investigated and characterized in the art. Disclosed in US Patents 5,028,627 and 5,216,025 are methods to treat systemic hypotension in septic and cytokine-treated patients using arginine derivatives to decrease nitrogen oxide production (Gross et al., 1993; Kilbourn et al., 1991). The use of arginine derivatives to suppress iNOS function is also reported in PCT publication number WO 98/48826 (Silverman et al., 1998). Disclosed in PCT publication numbers WO 93/13055 and WO 96/19440 are amidino and acetamide derivative inhibitors of iNOS, respectively (Beams et al., 1993; Oplinger et al., 1996).

Other inhibitors include a peptide nucleic acid derivative with a base sequence complementary to the homopurine region at nucleotides 238-251 of mouse iNOS (Giovine et al., *FEBS Lett.*, 1998, 426, 33-36), aminoguanidine (Corbett and McDaniel, *Methods*, 1996, 10, 21-30), N- α -Tosyl-L-Lysine chloromethylketone (Schini-Kerth et al., *Arterioscler. Thromb. Vasc. Biol.*, 1997, 17, 672-679), gadolinium chloride (Roland et al., *J. Leukoc. Biol.*, 1996, 60, 487-492), taurine chloramine (Park et al., *J. Leukoc. Biol.*, 1997, 61, 161-166), di-catechol rooperol (Bereta et

al., *Life Sci.*, 1997, 60, 325-334), tyrosine kinase inhibitors (Corbett et al., *Am. J. Physiol.*, 1996, 270, C1581-1587) and immunosuppressive drugs (Cai et al., *Int. J. Cardiol.*, 1995, 50, 243-251). Furthermore, disclosed in US Patent 5,789,395 are methods to inhibit nitric oxide production using tetracycline compounds (Amin et al., 1998) and in US Patent 5,695,761 methods of treating an inflammatory disease by administering epitopes of the protein osteopontin are disclosed (Denhardt et al., 1997).

Recently, iNOS inhibitors intended to treat various human conditions including CNS disease, ischemia/reperfusion injury and opioid tolerance that occurs as a result of sustained opioid usage during chronic pain have been reported in the art (Maeda et al., 1998; Salvemini, 1998; Singh, 1998).

Finally, disclosed in EP 94304174 is a pharmaceutical composition comprising a combination of an iNOS inhibitor and anti-inflammatory agent for the treatment of systemic inflammatory response syndrome (Teale, 1994).

Despite the variety of iNOS inhibitors disclosed in the art, there still remains a need for therapeutic agents capable of effectively and specifically inhibiting the function of the inducible isoform of the NOS enzyme (iNOS).

Antisense technology is emerging as an effective means for reducing the expression of specific gene products and may therefore prove to be uniquely useful in a number of therapeutic, diagnostic, and research applications for the modulation of iNOS expression.

SUMMARY OF THE INVENTION

The present invention is directed to antisense compounds, particularly oligonucleotides, which are targeted to a nucleic acid encoding inducible nitric oxide synthase, and which modulate the expression of inducible nitric oxide

synthase. Pharmaceutical and other compositions comprising the antisense compounds of the invention are also provided. Further provided are methods of modulating the expression of inducible nitric oxide synthase in cells or tissues comprising contacting said cells or tissues with one or more of the antisense compounds or compositions of the invention. Further provided are methods of treating an animal, particularly a human, suspected of having or being prone to a disease or condition associated with expression of inducible nitric oxide synthase by administering a therapeutically or prophylactically effective amount of one or more of the antisense compounds or compositions of the invention.

DETAILED DESCRIPTION OF THE INVENTION

The present invention employs oligomeric antisense compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid molecules encoding inducible nitric oxide synthase, ultimately modulating the amount of inducible nitric oxide synthase produced. This is accomplished by providing antisense compounds which specifically hybridize with one or more nucleic acids encoding inducible nitric oxide synthase. As used herein, the terms "target nucleic acid" and "nucleic acid encoding inducible nitric oxide synthase" encompass DNA encoding inducible nitric oxide synthase, RNA (including pre-mRNA and mRNA) transcribed from such DNA, and also cDNA derived from such RNA. The specific hybridization of an oligomeric compound with its target nucleic acid interferes with the normal function of the nucleic acid. This modulation of function of a target nucleic acid by compounds which specifically hybridize to it is generally referred to as "antisense". The functions of DNA to be interfered with include replication and transcription. The functions of RNA to be interfered with include all vital functions such as,

-7-

for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The overall effect of such interference with target nucleic acid function is modulation of the expression of inducible nitric oxide synthase. In the context of the present invention, "modulation" means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene. In the context of the present invention, inhibition is the preferred form of modulation of gene expression and mRNA is a preferred target.

It is preferred to target specific nucleic acids for antisense. "Targeting" an antisense compound to a particular nucleic acid, in the context of this invention, is a multistep process. The process usually begins with the identification of a nucleic acid sequence whose function is to be modulated. This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. In the present invention, the target is a nucleic acid molecule encoding inducible nitric oxide synthase. The targeting process also includes determination of a site or sites within this gene for the antisense interaction to occur such that the desired effect, e.g., detection or modulation of expression of the protein, will result. Within the context of the present invention, a preferred intragenic site is the region encompassing the translation initiation or termination codon of the open reading frame (ORF) of the gene. Since, as is known in the art, the translation initiation codon is typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation

codon is also referred to as the "AUG codon," the "start codon" or the "AUG start codon". A minority of genes have a translation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG, and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function in vivo. Thus, the terms "translation initiation codon" and "start codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, "start codon" and "translation initiation codon" refer to the codon or codons that are used in vivo to initiate translation of an mRNA molecule transcribed from a gene encoding inducible nitric oxide synthase, regardless of the sequence(s) of such codons.

It is also known in the art that a translation termination codon (or "stop codon") of a gene may have one of three sequences, i.e.; 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively). The terms "start codon region" and "translation initiation codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation termination codon.

The open reading frame (ORF) or "coding region," which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively. Other target regions include the 5' untranslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA or corresponding nucleotides on the gene, and the 3' untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3' end of an mRNA or corresponding nucleotides on the gene. The 5' cap of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent to the cap. The 5' cap region may also be a preferred target region.

Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as "introns," which are excised from a transcript before it is translated. The remaining (and therefore translated) regions are known as "exons" and are spliced together to form a continuous mRNA sequence. mRNA splice sites, i.e., intron-exon junctions, may also be preferred target regions, and are particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular mRNA splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also preferred targets. It has also been found that

introns can also be effective, and therefore preferred, target regions for antisense compounds targeted, for example, to DNA or pre-mRNA.

Once one or more target sites have been identified, oligonucleotides are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.

In the context of this invention, "hybridization" means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds. "Complementary," as used herein, refers to the capacity for precise pairing between two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of a DNA or RNA molecule, then the oligonucleotide and the DNA or RNA are considered to be complementary to each other at that position. The oligonucleotide and the DNA or RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. Thus, "specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the oligonucleotide and the DNA or RNA target. It is understood in the art that the sequence of an antisense compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. An antisense compound is specifically hybridizable when binding of the compound to the

-11-

target DNA or RNA molecule interferes with the normal function of the target DNA or RNA to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed.

Antisense compounds are commonly used as research reagents and diagnostics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes. Antisense compounds are also used, for example, to distinguish between functions of various members of a biological pathway. Antisense modulation has, therefore, been harnessed for research use.

The specificity and sensitivity of antisense is also harnessed by those of skill in the art for therapeutic uses. Antisense oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals and man. Antisense oligonucleotides have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans. In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent internucleoside (backbone)

linkages as well as oligonucleotides having non-naturally-occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target and increased stability in the presence of nucleases.

While antisense oligonucleotides are a preferred form of antisense compound, the present invention comprehends other oligomeric antisense compounds, including but not limited to oligonucleotide mimetics such as are described below. The antisense compounds in accordance with this invention preferably comprise from about 8 to about 30 nucleobases (i.e. from about 8 to about 30 linked nucleosides). Particularly preferred antisense compounds are antisense oligonucleotides, even more preferably those comprising from about 12 to about 25 nucleobases. As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn the respective ends of this linear polymeric structure can be further joined to form a circular structure, however, open linear structures are generally preferred. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal

-13-

linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.

Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Various salts, mixed salts and free acid forms are also included.

Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S.: 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253;

-14-

5,571,799; 5,587,361; and 5,625,050, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts.

Representative United States patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S.: 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such

-15-

oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S.: 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al., *Science*, **1991**, 254, 1497-1500.

Most preferred embodiments of the invention are oligonucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular $-\text{CH}_2-\text{NH}-\text{O}-\text{CH}_2-$, $-\text{CH}_2-\text{N}(\text{CH}_3)-\text{O}-\text{CH}_2-$ [known as a methylene (methylimino) or MMI backbone], $-\text{CH}_2-\text{O}-\text{N}(\text{CH}_3)-\text{CH}_2-$, $-\text{CH}_2-\text{N}(\text{CH}_3)-\text{N}(\text{CH}_3)-\text{CH}_2-$ and $-\text{O}-\text{N}(\text{CH}_3)-\text{CH}_2-\text{CH}_2-$ [wherein the native phosphodiester backbone is represented as $-\text{O}-\text{P}-\text{O}-\text{CH}_2-$] of the above referenced U.S. patent 5,489,677, and the amide backbones of the above referenced U.S. patent 5,602,240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced U.S. patent 5,034,506.

Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C_1 to C_{10} alkyl or C_2 to C_{10} alkenyl and alkynyl. Particularly preferred are $\text{O}[(\text{CH}_2)_n\text{O}]_m\text{CH}_3$, $\text{O}(\text{CH}_2)_n\text{OCH}_3$, $\text{O}(\text{CH}_2)_n\text{NH}_2$, $\text{O}(\text{CH}_2)_n\text{CH}_3$, $\text{O}(\text{CH}_2)_n\text{ONH}_2$,

-16-

and $O(CH_2)_nON[(CH_2)_mCH_3]_2$, where n and m are from 1 to about 10. Other preferred oligonucleotides comprise one of the following at the 2' position: C_1 to C_{10} lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH_3 , OCN, Cl, Br, CN, CF_3 , OCF_3 , $SOCH_3$, SO_2CH_3 , ONO_2 , NO_2 , N_3 , NH_2 , heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2'-methoxyethoxy ($2'-O-CH_2CH_2OCH_3$, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., *Helv. Chim. Acta*, **1995**, 78, 486-504) i.e., an alkoxyalkoxy group. A further preferred modification includes 2'-dimethylaminooxyethoxy, i.e., a $O(CH_2)_2ON(CH_3)_2$ group, also known as 2'-DMAOE, as described in examples hereinbelow, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethylaminoethoxyethyl or 2'-DMAEOE), i.e., $2'-O-CH_2-O-CH_2-N(CH_2)_2$, also described in examples hereinbelow.

Other preferred modifications include 2'-methoxy ($2'-O-CH_3$), 2'-aminopropoxy ($2'-OCH_2CH_2CH_2NH_2$) and 2'-fluoro ($2'-F$). Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S.: 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785;

-17-

5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

Oligonucleotides may also include nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in United States Patent No. 3,687,808, those disclosed in *The Concise Encyclopedia Of Polymer Science And Engineering*, pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., *Angewandte Chemie*, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y.S., Chapter 15, *Antisense Research and Applications*, pages 289-302, Crooke, S.T. and Lebleu, B., ed., CRC Press, 1993. Certain of these nucleobases are

particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S., Crooke, S.T. and Lebleu, B., eds., *Antisense Research and Applications*, CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. 3,687,808, as well as U.S.: 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; and 5,681,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference, and United States patent 5,750,692, which is commonly owned with the instant application and also herein incorporated by reference.

Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., *Proc. Natl. Acad. Sci. USA*, 1989, 86, 6553-6556), cholic acid (Manoharan et al., *Bioorg. Med. Chem. Lett.*, 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., *Ann. N.Y. Acad. Sci.*, 1992, 660, 306-309; Manoharan

-19-

et al., *Bioorg. Med. Chem. Lett.*, **1993**, 3, 2765-2770), a thiocholesterol (Oberhauser et al., *Nucl. Acids Res.*, **1992**, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., *EMBO J.*, **1991**, 10, 1111-1118; Kabanov et al., *FEBS Lett.*, **1990**, 259, 327-330; Svinarchuk et al., *Biochimie*, **1993**, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., *Tetrahedron Lett.*, **1995**, 36, 3651-3654; Shea et al., *Nucl. Acids Res.*, **1990**, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., *Nucleosides & Nucleotides*, **1995**, 14, 969-973), or adamantane acetic acid (Manoharan et al., *Tetrahedron Lett.*, **1995**, 36, 3651-3654), a palmityl moiety (Mishra et al., *Biochim. Biophys. Acta*, **1995**, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., *J. Pharmacol. Exp. Ther.*, **1996**, 277, 923-937).

Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S.: 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717; 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241; 5,391,723; 5,416,203; 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated

by reference.

It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide. The present invention also includes antisense compounds which are chimeric compounds. "Chimeric" antisense compounds or "chimeras," in the context of this invention, are antisense compounds, particularly oligonucleotides, which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide inhibition of gene expression. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

Chimeric antisense compounds of the invention may be formed as composite structures of two or more

oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S.: 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

The antisense compounds used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, CA). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives.

The antisense compounds of the invention are synthesized in vitro and do not include antisense compositions of biological origin, or genetic vector constructs designed to direct the in vivo synthesis of antisense molecules. The compounds of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States patents that teach the preparation of such uptake, distribution and/or absorption assisting formulations include, but are not limited to, U.S.: 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158; 5,547,932;

-22-

5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948; 5,580,575; and 5,595,756, each of which is herein incorporated by reference.

The antisense compounds of the invention encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to prodrugs and pharmaceutically acceptable salts of the compounds of the invention, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents.

The term "prodrug" indicates a therapeutic agent that is prepared in an inactive form that is converted to an active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE [(S-acetyl-2-thioethyl) phosphate] derivatives according to the methods disclosed in WO 93/24510 to Gosselin et al., published December 9, 1993 or in WO 94/26764 to Imbach et al.

The term "pharmaceutically acceptable salts" refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto.

Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the

-23-

like. Examples of suitable amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge et al., "Pharmaceutical Salts," *J. of Pharma Sci.*, 1977, 66, 1-19). The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention. As used herein, a "pharmaceutical addition salt" includes a pharmaceutically acceptable salt of an acid form of one of the components of the compositions of the invention. These include organic or inorganic acid salts of the amines. Preferred acid salts are the hydrochlorides, acetates, salicylates, nitrates and phosphates. Other suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of a variety of inorganic and organic acids, such as, for example, with inorganic acids, such as for example hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic, sulfo or phospho acids or N-substituted sulfamic acids, for example acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-phenoxybenzoic acid,

2-acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic acid; and with amino acids, such as the 20 alpha-amino acids involved in the synthesis of proteins in nature, for example glutamic acid or aspartic acid, and also with phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 2- or 3-phosphoglycerate, glucose-6-phosphate, N-cyclohexylsulfamic acid (with the formation of cyclamates), or with other acid organic compounds, such as ascorbic acid. Pharmaceutically acceptable salts of compounds may also be prepared with a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. Carbonates or hydrogen carbonates are also possible.

For oligonucleotides, preferred examples of pharmaceutically acceptable salts include but are not limited to (a) salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and spermidine, etc.; (b) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; (c) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts formed from elemental anions such as chlorine, bromine, and iodine.

The antisense compounds of the present invention can be utilized for diagnostics, therapeutics, prophylaxis and as research reagents and kits. For therapeutics, an animal, preferably a human, suspected of having a disease or disorder which can be treated by modulating the expression of inducible nitric oxide synthase is treated by administering antisense compounds in accordance with this invention. The compounds of the invention can be utilized in pharmaceutical compositions by adding an effective amount of an antisense compound to a suitable pharmaceutically acceptable diluent or carrier. Use of the antisense compounds and methods of the invention may also be useful prophylactically, e.g., to prevent or delay infection, inflammation or tumor formation, for example.

The antisense compounds of the invention are useful for research and diagnostics, because these compounds hybridize to nucleic acids encoding inducible nitric oxide synthase, enabling sandwich and other assays to easily be constructed to exploit this fact. Hybridization of the antisense oligonucleotides of the invention with a nucleic acid encoding inducible nitric oxide synthase can be detected by means known in the art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabelling of the oligonucleotide or any other suitable detection means. Kits using such detection means for detecting the level of inducible nitric oxide synthase in a sample may also be prepared.

The present invention also includes pharmaceutical compositions and formulations which include the antisense compounds of the invention. The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may

be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Oligonucleotides with at least one 2'-O-methoxyethyl modification are believed to be particularly useful for oral administration.

Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful.

Compositions and formulations for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable.

Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions may be generated from a variety of components that include, but are

not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids.

The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

The compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

In one embodiment of the present invention the pharmaceutical compositions may be formulated and used as foams. Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency of the final product. The preparation of such compositions and formulations is generally known to those skilled in the pharmaceutical and formulation arts and may be applied to the formulation of the compositions of the present invention.

Emulsions

The compositions of the present invention may be prepared and formulated as emulsions. Emulsions are typically heterogenous systems of one liquid dispersed in another in the form of droplets usually exceeding $0.1\ \mu\text{m}$ in diameter. (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199; Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., Volume 1, p. 245; Block in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 2, p. 335; Higuchi et al., in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, 1985, p. 301).

Emulsions are often biphasic systems comprising of two immiscible liquid phases intimately mixed and dispersed with each other. In general, emulsions may be either water-in-oil (w/o) or of the oil-in-water (o/w) variety. When an aqueous phase is finely divided into and dispersed as minute droplets into a bulk oily phase the resulting composition is called a water-in-oil (w/o) emulsion. Alternatively, when an oily phase is finely divided into and dispersed as minute droplets into a bulk aqueous phase the resulting composition is called an oil-in-water (o/w) emulsion. Emulsions may contain additional components in addition to the dispersed phases and the active drug which may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti-oxidants may also be present in emulsions as needed. Pharmaceutical emulsions may also be multiple emulsions that are comprised of more than two phases such as, for example, in the case of oil-in-water-in-oil (o/w/o) and water-in-oil-in-water (w/o/w) emulsions. Such complex

formulations often provide certain advantages that simple binary emulsions do not. Multiple emulsions in which individual oil droplets of an o/w emulsion enclose small water droplets constitute a w/o/w emulsion. Likewise a system of oil droplets enclosed in globules of water stabilized in an oily continuous provides an o/w/o emulsion.

Emulsions are characterized by little or no thermodynamic stability. Often, the dispersed or discontinuous phase of the emulsion is well dispersed into the external or continuous phase and maintained in this form through the means of emulsifiers or the viscosity of the formulation. Either of the phases of the emulsion may be a semisolid or a solid, as is the case of emulsion-style ointment bases and creams. Other means of stabilizing emulsions entail the use of emulsifiers that may be incorporated into either phase of the emulsion. Emulsifiers may broadly be classified into four categories: synthetic surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Synthetic surfactants, also known as surface active agents, have found wide applicability in the formulation of emulsions and have been reviewed in the literature (Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), Marcel Dekker, Inc., New York, N.Y., 1988, volume 1, p. 199). Surfactants are typically amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic nature of the surfactant has been termed the hydrophile/lipophile balance (HLB) and is a valuable tool in

categorizing and selecting surfactants in the preparation of formulations. Surfactants may be classified into different classes based on the nature of the hydrophilic group: nonionic, anionic, cationic and amphoteric (Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285).

Naturally occurring emulsifiers used in emulsion formulations include lanolin, beeswax, phosphatides, lecithin and acacia. Absorption bases possess hydrophilic properties such that they can soak up water to form w/o emulsions yet retain their semisolid consistencies, such as anhydrous lanolin and hydrophilic petrolatum. Finely divided solids have also been used as good emulsifiers especially in combination with surfactants and in viscous preparations. These include polar inorganic solids, such as heavy metal hydroxides, nonswelling clays such as bentonite, attapulgite, hectorite, kaolin, montmorillonite, colloidal aluminum silicate and colloidal magnesium aluminum silicate, pigments and nonpolar solids such as carbon or glyceryl tristearate.

A large variety of non-emulsifying materials are also included in emulsion formulations and contribute to the properties of emulsions. These include fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants, hydrophilic colloids, preservatives and antioxidants (Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Hydrophilic colloids or hydrocolloids include naturally occurring gums and synthetic polymers such as polysaccharides (for example, acacia, agar, alginic acid, carrageenan, guar

gum, karaya gum, and tragacanth), cellulose derivatives (for example, carboxymethylcellulose and carboxypropylcellulose), and synthetic polymers (for example, carbomers, cellulose ethers, and carboxyvinyl polymers). These disperse or swell in water to form colloidal solutions that stabilize emulsions by forming strong interfacial films around the dispersed-phase droplets and by increasing the viscosity of the external phase.

Since emulsions often contain a number of ingredients such as carbohydrates, proteins, sterols and phosphatides that may readily support the growth of microbes, these formulations often incorporate preservatives. Commonly used preservatives included in emulsion formulations include methyl paraben, propyl paraben, quaternary ammonium salts, benzalkonium chloride, esters of p-hydroxybenzoic acid, and boric acid. Antioxidants are also commonly added to emulsion formulations to prevent deterioration of the formulation. Antioxidants used may be free radical scavengers such as tocopherols, alkyl gallates, butylated hydroxyanisole, butylated hydroxytoluene, or reducing agents such as ascorbic acid and sodium metabisulfite, and antioxidant synergists such as citric acid, tartaric acid, and lecithin.

The application of emulsion formulations via dermatological, oral and parenteral routes and methods for their manufacture have been reviewed in the literature (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Emulsion formulations for oral delivery have been very widely used because of reasons of ease of formulation, efficacy from an absorption and bioavailability standpoint. (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Idson, in

Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Mineral-oil base laxatives, oil-soluble vitamins and high fat nutritive preparations are among the materials that have commonly been administered orally as o/w emulsions.

In one embodiment of the present invention, the compositions of oligonucleotides and nucleic acids are formulated as microemulsions. A microemulsion may be defined as a system of water, oil and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Typically microemulsions are systems that are prepared by first dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a fourth component, generally an intermediate chain-length alcohol to form a transparent system. Therefore, microemulsions have also been described as thermodynamically stable, isotropically clear dispersions of two immiscible liquids that are stabilized by interfacial films of surface-active molecules (Leung and Shah, in: *Controlled Release of Drugs: Polymers and Aggregate Systems*, Rosoff, M., Ed., 1989, VCH Publishers, New York, pages 185-215). Microemulsions commonly are prepared via a combination of three to five components that include oil, water, surfactant, cosurfactant and electrolyte. Whether the microemulsion is of the water-in-oil (w/o) or an oil-in-water (o/w) type is dependent on the properties of the oil and surfactant used and on the structure and geometric packing of the polar heads and hydrocarbon tails of the surfactant molecules (Schott, in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, 1985, p. 271).

The phenomenological approach utilizing phase diagrams

has been extensively studied and has yielded a comprehensive knowledge, to one skilled in the art, of how to formulate microemulsions (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335). Compared to conventional emulsions, microemulsions offer the advantage of solubilizing water-insoluble drugs in a formulation of thermodynamically stable droplets that are formed spontaneously.

Surfactants used in the preparation of microemulsions include, but are not limited to, ionic surfactants, non-ionic surfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fatty acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (MO310), hexaglycerol monooleate (PO310), hexaglycerol pentaoleate (PO500), decaglycerol monocaprate (MCA750), decaglycerol monooleate (MO750), decaglycerol sequioleate (SO750), decaglycerol decaoleate (DAO750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain alcohol such as ethanol, 1-propanol, and 1-butanol, serves to increase the interfacial fluidity by penetrating into the surfactant film and consequently creating a disordered film because of the void space generated among surfactant molecules. Microemulsions may, however, be prepared without the use of cosurfactants and alcohol-free self-emulsifying microemulsion systems are known in the art. The aqueous phase may typically be, but is not limited to, water, an aqueous solution of the drug, glycerol, PEG300, PEG400, polyglycerols, propylene glycols, and derivatives of ethylene glycol. The oil phase may include, but is not limited to, materials such as Captex 300, Captex 355, Capmul MCM, fatty

acid esters, medium chain (C8-C12) mono, di, and tri-glycerides, polyoxyethylated glyceryl fatty acid esters, fatty alcohols, polyglycolized glycerides, saturated polyglycolized C8-C10 glycerides, vegetable oils and silicone oil.

Microemulsions are particularly of interest from the standpoint of drug solubilization and the enhanced absorption of drugs. Lipid based microemulsions (both o/w and w/o) have been proposed to enhance the oral bioavailability of drugs, including peptides (Constantinides et al., *Pharmaceutical Research*, **1994**, *11*, 1385-1390; Ritschel, *Meth. Find. Exp. Clin. Pharmacol.*, **1993**, *13*, 205). Microemulsions afford advantages of improved drug solubilization, protection of drug from enzymatic hydrolysis, possible enhancement of drug absorption due to surfactant-induced alterations in membrane fluidity and permeability, ease of preparation, ease of oral administration over solid dosage forms, improved clinical potency, and decreased toxicity (Constantinides et al., *Pharmaceutical Research*, **1994**, *11*, 1385; Ho et al., *J. Pharm. Sci.*, **1996**, *85*, 138-143). Often microemulsions may form spontaneously when their components are brought together at ambient temperature. This may be particularly advantageous when formulating thermolabile drugs, peptides or oligonucleotides. Microemulsions have also been effective in the transdermal delivery of active components in both cosmetic and pharmaceutical applications. It is expected that the microemulsion compositions and formulations of the present invention will facilitate the increased systemic absorption of oligonucleotides and nucleic acids from the gastrointestinal tract, as well as improve the local cellular uptake of oligonucleotides and nucleic acids within the gastrointestinal tract, vagina, buccal cavity and other areas of administration.

Microemulsions of the present invention may also contain additional components and additives such as sorbitan monostearate (Grill 3), Labrasol, and penetration enhancers to improve the properties of the formulation and to enhance the absorption of the oligonucleotides and nucleic acids of the present invention. Penetration enhancers used in the microemulsions of the present invention may be classified as belonging to one of five broad categories - surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p. 92). Each of these classes has been discussed above.

Liposomes

There are many organized surfactant structures besides microemulsions that have been studied and used for the formulation of drugs. These include monolayers, micelles, bilayers and vesicles. Vesicles, such as liposomes, have attracted great interest because of their specificity and the duration of action they offer from the standpoint of drug delivery. As used in the present invention, the term "liposome" means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers.

Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the composition to be delivered. Cationic liposomes possess the advantage of being able to fuse to the cell wall. Non-cationic liposomes, although not able to fuse as efficiently with the cell wall, are taken up by macrophages *in vivo*.

In order to cross intact mammalian skin, lipid vesicles must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a suitable

transdermal gradient. Therefore, it is desirable to use a liposome which is highly deformable and able to pass through such fine pores.

Further advantages of liposomes include; liposomes obtained from natural phospholipids are biocompatible and biodegradable; liposomes can incorporate a wide range of water and lipid soluble drugs; liposomes can protect encapsulated drugs in their internal compartments from metabolism and degradation (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes.

Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomes start to merge with the cellular membranes. As the merging of the liposome and cell progresses, the liposomal contents are emptied into the cell where the active agent may act.

Liposomal formulations have been the focus of extensive investigation as the mode of delivery for many drugs. There is growing evidence that for topical administration, liposomes present several advantages over other formulations. Such advantages include reduced side-effects related to high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target, and the ability to administer a wide variety of drugs, both hydrophilic and hydrophobic, into the skin.

Several reports have detailed the ability of liposomes to deliver agents including high-molecular weight DNA into

the skin. Compounds including analgesics, antibodies, hormones and high-molecular weight DNAs have been administered to the skin. The majority of applications resulted in the targeting of the upper epidermis.

Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes which interact with the negatively charged DNA molecules to form a stable complex. The positively charged DNA/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang et al., *Biochem. Biophys. Res. Commun.*, **1987**, 147, 980-985).

Liposomes which are pH-sensitive or negatively-charged, entrap DNA rather than complex with it. Since both the DNA and the lipid are similarly charged, repulsion rather than complex formation occurs. Nevertheless, some DNA is entrapped within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver DNA encoding the thymidine kinase gene to cell monolayers in culture. Expression of the exogenous gene was detected in the target cells (Zhou et al., *Journal of Controlled Release*, **1992**, 19, 269-274).

One major type of liposomal composition includes phospholipids other than naturally-derived phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Anionic liposome compositions generally are formed from dimyristoyl phosphatidylglycerol, while anionic fusogenic liposomes are formed primarily from dioleoyl phosphatidylethanolamine (DOPE). Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC,

and egg PC. Another type is formed from mixtures of phospholipid and/or phosphatidylcholine and/or cholesterol.

Several studies have assessed the topical delivery of liposomal drug formulations to the skin. Application of liposomes containing interferon to guinea pig skin resulted in a reduction of skin herpes sores while delivery of interferon via other means (e.g. as a solution or as an emulsion) were ineffective (Weiner *et al.*, *Journal of Drug Targeting*, 1992, 2, 405-410). Further, an additional study tested the efficacy of interferon administered as part of a liposomal formulation to the administration of interferon using an aqueous system, and concluded that the liposomal formulation was superior to aqueous administration (du Plessis *et al.*, *Antiviral Research*, 1992, 18, 259-265).

Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and cholesterol. Non-ionic liposomal formulations comprising Novasome™ I (glyceryl dilaurate/cholesterol/polyoxyethylene-10-stearyl ether) and Novasome™ II (glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to deliver cyclosporin-A into the dermis of mouse skin. Results indicated that such non-ionic liposomal systems were effective in facilitating the deposition of cyclosporin-A into different layers of the skin (Hu *et al.* *S.T.P. Pharma. Sci.*, 1994, 4, 6, 466).

Liposomes also include "sterically stabilized" liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of

the liposome (A) comprises one or more glycolipids, such as monosialoganglioside G_{M1} , or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES) (Allen *et al.*, *FEBS Letters*, **1987**, 223, 42; Wu *et al.*, *Cancer Research*, **1993**, 53, 3765).

Various liposomes comprising one or more glycolipids are known in the art. Papahadjopoulos *et al.* (*Ann. N.Y. Acad. Sci.*, **1987**, 507, 64) reported the ability of monosialoganglioside G_{M1} , galactocerebroside sulfate and phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon *et al.* (*Proc. Natl. Acad. Sci. U.S.A.*, **1988**, 85, 6949). U.S. Patent No. 4,837,028 and WO 88/04924, both to Allen *et al.*, disclose liposomes comprising (1) sphingomyelin and (2) the ganglioside G_{M1} or a galactocerebroside sulfate ester. U.S. Patent No. 5,543,152 (Webb *et al.*) discloses liposomes comprising sphingomyelin. Liposomes comprising 1,2-*sn*-dimyristoylphosphatidylcholine are disclosed in WO 97/13499 (Lim *et al.*).

Many liposomes comprising lipids derivatized with one or more hydrophilic polymers, and methods of preparation thereof, are known in the art. Sunamoto *et al.* (*Bull. Chem. Soc. Jpn.*, **1980**, 53, 2778) described liposomes comprising a nonionic detergent, 2C₁₂15G, that contains a PEG moiety. Illum *et al.* (*FEBS Lett.*, **1984**, 167, 79) noted that hydrophilic coating of polystyrene particles with polymeric glycols results in significantly enhanced blood half-lives.

-40-

Synthetic phospholipids modified by the attachment of carboxylic groups of polyalkylene glycols (e.g., PEG) are described by Sears (U.S. Patent Nos. 4,426,330 and 4,534,899). Klibanov *et al.* (*FEBS Lett.*, **1990**, 268, 235) described experiments demonstrating that liposomes comprising phosphatidylethanolamine (PE) derivatized with PEG or PEG stearate have significant increases in blood circulation half-lives. Blume *et al.* (*Biochimica et Biophysica Acta*, **1990**, 1029, 91) extended such observations to other PEG-derivatized phospholipids, e.g., DSPE-PEG, formed from the combination of distearoylphosphatidylethanolamine (DSPE) and PEG. Liposomes having covalently bound PEG moieties on their external surface are described in European Patent No. EP 0 445 131 B1 and WO 90/04384 to Fisher. Liposome compositions containing 1-20 mole percent of PE derivatized with PEG, and methods of use thereof, are described by Woodle *et al.* (U.S. Patent Nos. 5,013,556 and 5,356,633) and Martin *et al.* (U.S. Patent No. 5,213,804 and European Patent No. EP 0 496 813 B1). Liposomes comprising a number of other lipid-polymer conjugates are disclosed in WO 91/05545 and U.S. Patent No. 5,225,212 (both to Martin *et al.*) and in WO 94/20073 (Zalipsky *et al.*) Liposomes comprising PEG-modified ceramide lipids are described in WO 96/10391 (Choi *et al.*). U.S. Patent Nos. 5,540,935 (Miyazaki *et al.*) and 5,556,948 (Tagawa *et al.*) describe PEG-containing liposomes that can be further derivatized with functional moieties on their surfaces.

A limited number of liposomes comprising nucleic acids are known in the art. WO 96/40062 to Thierry *et al.* discloses methods for encapsulating high molecular weight nucleic acids in liposomes. U.S. Patent No. 5,264,221 to Tagawa *et al.* discloses protein-bonded liposomes and asserts that the contents of such liposomes may include an antisense RNA. U.S. Patent No. 5,665,710 to Rahman *et al.* describes

certain methods of encapsulating oligodeoxynucleotides in liposomes. WO 97/04787 to Love *et al.* discloses liposomes comprising antisense oligonucleotides targeted to the raf gene.

Transfersomes are yet another type of liposomes, and are highly deformable lipid aggregates which are attractive candidates for drug delivery vehicles. Transfersomes may be described as lipid droplets which are so highly deformable that they are easily able to penetrate through pores which are smaller than the droplet. Transfersomes are adaptable to the environment in which they are used, e.g. they are self-optimizing (adaptive to the shape of pores in the skin), self-repairing, frequently reach their targets without fragmenting, and often self-loading. To make transfersomes it is possible to add surface edge-activators, usually surfactants, to a standard liposomal composition. Transfersomes have been used to deliver serum albumin to the skin. The transfersome-mediated delivery of serum albumin has been shown to be as effective as subcutaneous injection of a solution containing serum albumin.

Surfactants find wide application in formulations such as emulsions (including microemulsions) and liposomes. The most common way of classifying and ranking the properties of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the "head") provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, NY, 1988, p. 285).

If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic products

and are usable over a wide range of pH values. In general their HLB values range from 2 to about 18 depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class. The polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.

If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps.

If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class.

If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.

The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in *Pharmaceutical*

Dosage Forms, Marcel Dekker, Inc., New York, NY, 1988, p. 285).

Penetration Enhancers

In one embodiment, the present invention employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly oligonucleotides, to the skin of animals. Most drugs are present in solution in both ionized and nonionized forms. However, usually only lipid soluble or lipophilic drugs readily cross cell membranes. It has been discovered that even non-lipophilic drugs may cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs.

Penetration enhancers may be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92). Each of the above mentioned classes of penetration enhancers are described below in greater detail.

Surfactants: In connection with the present invention, surfactants (or "surface-active agents") are chemical entities which, when dissolved in an aqueous solution, reduce the surface tension of the solution or the interfacial tension between the aqueous solution and another liquid, with the result that absorption of oligonucleotides through the mucosa is enhanced. In addition to bile salts and fatty acids, these penetration enhancers include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92); and perfluorochemical emulsions, such as FC-43. Takahashi et al.,

J. Pharm. Pharmacol., **1988**, *40*, 252).

Fatty acids: Various fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprates, tricaprates, monoolein (1-monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glycerol 1-monocaprates, 1-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, C₁₋₁₀ alkyl esters thereof (e.g., methyl, isopropyl and *t*-butyl), and mono- and di-glycerides thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, **1991**, p.92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, **1990**, *7*, 1-33; El Hariri et al., *J. Pharm. Pharmacol.*, **1992**, *44*, 651-654).

Bile salts: The physiological role of bile includes the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (Brunton, Chapter 38 in: Goodman & Gilman's *The Pharmacological Basis of Therapeutics*, 9th Ed., Hardman et al. Eds., McGraw-Hill, New York, **1996**, pp. 934-935). Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus the term "bile salts" includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. The bile salts of the invention include, for example, cholic acid (or its pharmaceutically acceptable sodium salt, sodium cholate), dehydrocholic acid (sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucolic acid (sodium glucolate), glycholic acid (sodium glycocholate), glycodeoxycholic acid (sodium glycodeoxycholate), taurocholic acid (sodium taurocholate), taurodeoxycholic acid (sodium taurodeoxycholate), chenodeoxycholic acid (sodium

chenodeoxycholate), ursodeoxycholic acid (UDCA), sodium tauro-24,25-dihydro-fusidate (STDHF), sodium glycodihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92; Swinyard, Chapter 39 In: *Remington's Pharmaceutical Sciences*, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, PA, 1990, pages 782-783; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; Yamamoto et al., *J. Pharm. Exp. Ther.*, 1992, 263, 25; Yamashita et al., *J. Pharm. Sci.*, 1990, 79, 579-583).

Chelating Agents: Chelating agents, as used in connection with the present invention, can be defined as compounds that remove metallic ions from solution by forming complexes therewith, with the result that absorption of oligonucleotides through the mucosa is enhanced. With regards to their use as penetration enhancers in the present invention, chelating agents have the added advantage of also serving as DNase inhibitors, as most characterized DNA nucleases require a divalent metal ion for catalysis and are thus inhibited by chelating agents (Jarrett, *J. Chromatogr.*, 1993, 618, 315-339). Chelating agents of the invention include but are not limited to disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and homovanilate), N-acyl derivatives of collagen, laureth-9 and N-amino acyl derivatives of beta-diketones (enamines) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; Buur et al., *J. Control Rel.*, 1990, 14, 43-51).

Non-chelating non-surfactants: As used herein, non-chelating non-surfactant penetration enhancing compounds can be defined as compounds that demonstrate insignificant

activity as chelating agents or as surfactants but that nonetheless enhance absorption of oligonucleotides through the alimentary mucosa (Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33). This class of penetration enhancers include, for example, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacyclo-alkanone derivatives (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92); and non-steroidal anti-inflammatory agents such as diclofenac sodium, indomethacin and phenylbutazone (Yamashita et al., *J. Pharm. Pharmacol.*, 1987, 39, 621-626).

Agents that enhance uptake of oligonucleotides at the cellular level may also be added to the pharmaceutical and other compositions of the present invention. For example, cationic lipids, such as lipofectin (Junichi et al, U.S. Patent No. 5,705,188), cationic glycerol derivatives, and polycationic molecules, such as polylysine (Lollo et al., PCT Application WO 97/30731), are also known to enhance the cellular uptake of oligonucleotides.

Other agents may be utilized to enhance the penetration of the administered nucleic acids, including glycols such as ethylene glycol and propylene glycol, pyrrols such as 2-pyrrol, azones, and terpenes such as limonene and menthone.

Carriers

Certain compositions of the present invention also incorporate carrier compounds in the formulation. As used herein, "carrier compound" or "carrier" can refer to a nucleic acid, or analog thereof, which is inert (*i.e.*, does not possess biological activity *per se*) but is recognized as a nucleic acid by *in vivo* processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The

-47-

coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially phosphorothioate oligonucleotide in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4'-isothiocyano-stilbene-2,2'-disulfonic acid (Miyao et al., *Antisense Res. Dev.*, **1995**, *5*, 115-121; Takakura et al., *Antisense & Nucl. Acid Drug Dev.*, **1996**, *6*, 177-183).

Excipients

In contrast to a carrier compound, a "pharmaceutical carrier" or "excipient" is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The excipient may be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium

starch glycolate, etc.); and wetting agents (e.g., sodium lauryl sulphate, etc.).

Pharmaceutically acceptable organic or inorganic excipient suitable for non-parenteral administration which do not deleteriously react with nucleic acids can also be used to formulate the compositions of the present invention. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Formulations for topical administration of nucleic acids may include sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or solutions of the nucleic acids in liquid or solid oil bases. The solutions may also contain buffers, diluents and other suitable additives. Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously react with nucleic acids can be used.

Suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Other Components

The compositions of the present invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or

anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present invention. The formulations can be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously interact with the nucleic acid(s) of the formulation.

Aqueous suspensions may contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

Certain embodiments of the invention provide pharmaceutical compositions containing (a) one or more antisense compounds and (b) one or more other chemotherapeutic agents which function by a non-antisense mechanism. Examples of such chemotherapeutic agents include, but are not limited to, anticancer drugs such as daunorubicin, dactinomycin, doxorubicin, bleomycin, mitomycin, nitrogen mustard, chlorambucil, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine (CA), 5-fluorouracil (5-FU), floxuridine (5-FUdR), methotrexate (MTX), colchicine, vincristine, vinblastine, etoposide, teniposide, cisplatin and diethylstilbestrol (DES). See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds., 1987, Rahway, N.J., pages 1206-1228). Anti-inflammatory drugs, including but not

limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions of the invention. See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds., 1987, Rahway, N.J., pages 2499-2506 and 46-49, respectively). Other non-antisense chemotherapeutic agents are also within the scope of this invention. Two or more combined compounds may be used together or sequentially.

In another related embodiment, compositions of the invention may contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more additional antisense compounds targeted to a second nucleic acid target. Numerous examples of antisense compounds are known in the art. Two or more combined compounds may be used together or sequentially.

The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC_{50} s found to be effective in in vitro and in vivo animal models. In general, dosage is from 0.01 ug to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once

-51-

every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 ug to 100 g per kg of body weight, once or more daily, to once every 20 years.

While the present invention has been described with specificity in accordance with certain of its preferred embodiments, the following examples serve only to illustrate the invention and are not intended to limit the same.

EXAMPLES

Example 1

Nucleoside Phosphoramidites for Oligonucleotide Synthesis Deoxy and 2'-alkoxy amidites

2'-Deoxy and 2'-methoxy beta-cyanoethyl-diisopropyl phosphoramidites were purchased from commercial sources (e.g. Chemgenes, Needham MA or Glen Research, Inc. Sterling VA). Other 2'-O-alkoxy substituted nucleoside amidites are prepared as described in U.S. Patent 5,506,351, herein incorporated by reference. For oligonucleotides synthesized using 2'-alkoxy amidites, the standard cycle for unmodified oligonucleotides was utilized, except the wait step after pulse delivery of tetrazole and base was increased to 360 seconds.

Oligonucleotides containing 5-methyl-2'-deoxycytidine (5-Me-C) nucleotides were synthesized according to published methods [Sanghvi, et. al., *Nucleic Acids Research*, 1993, 21, 3197-3203] using commercially available phosphoramidites (Glen Research, Sterling VA or ChemGenes, Needham MA).

2'-Fluoro amidites

2'-Fluorodeoxyadenosine amidites

2'-fluoro oligonucleotides were synthesized as described previously [Kawasaki, et. al., *J. Med. Chem.*, **1993**, 36, 831-841] and United States patent 5,670,633, herein incorporated by reference. Briefly, the protected nucleoside N6-benzoyl-2'-deoxy-2'-fluoroadenosine was synthesized utilizing commercially available 9-beta-D-arabinofuranosyladenine as starting material and by modifying literature procedures whereby the 2'-alpha-fluoro atom is introduced by a S_N2-displacement of a 2'-beta-trityl group. Thus N6-benzoyl-9-beta-D-arabinofuranosyladenine was selectively protected in moderate yield as the 3',5'-ditetrahydropyranyl (THP) intermediate. Deprotection of the THP and N6-benzoyl groups was accomplished using standard methodologies and standard methods were used to obtain the 5'-dimethoxytrityl-(DMT) and 5'-DMT-3'-phosphoramidite intermediates.

2'-Fluorodeoxyguanosine

The synthesis of 2'-deoxy-2'-fluoroguanosine was accomplished using tetraisopropylidisiloxanyl (TPDS) protected 9-beta-D-arabinofuranosylguanine as starting material, and conversion to the intermediate diisobutyryl-arabinofuranosylguanosine. Deprotection of the TPDS group was followed by protection of the hydroxyl group with THP to give diisobutyryl di-THP protected arabinofuranosylguanine. Selective O-deacylation and triflation was followed by treatment of the crude product with fluoride, then deprotection of the THP groups. Standard methodologies were used to obtain the 5'-DMT- and 5'-DMT-3'-phosphoramidites.

2'-Fluorouridine

Synthesis of 2'-deoxy-2'-fluorouridine was accomplished by the modification of a literature procedure in which 2,2'-anhydro-1-beta-D-arabinofuranosyluracil was treated with 70%

hydrogen fluoride-pyridine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

2'-Fluorodeoxycytidine

2'-deoxy-2'-fluorocytidine was synthesized via amination of 2'-deoxy-2'-fluorouridine, followed by selective protection to give N4-benzoyl-2'-deoxy-2'-fluorocytidine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

2'-O-(2-Methoxyethyl) modified amidites

2'-O-Methoxyethyl-substituted nucleoside amidites are prepared as follows, or alternatively, as per the methods of Martin, P., *Helvetica Chimica Acta*, 1995, 78, 486-504.

2,2'-Anhydro[1-(beta-D-arabinofuranosyl)-5-methyluridine]

5-Methyluridine (ribosylthymine, commercially available through Yamasa, Choshi, Japan) (72.0 g, 0.279 M), diphenylcarbonate (90.0 g, 0.420 M) and sodium bicarbonate (2.0 g, 0.024 M) were added to DMF (300 mL). The mixture was heated to reflux, with stirring, allowing the evolved carbon dioxide gas to be released in a controlled manner. After 1 hour, the slightly darkened solution was concentrated under reduced pressure. The resulting syrup was poured into diethylether (2.5 L), with stirring. The product formed a gum. The ether was decanted and the residue was dissolved in a minimum amount of methanol (ca. 400 mL). The solution was poured into fresh ether (2.5 L) to yield a stiff gum. The ether was decanted and the gum was dried in a vacuum oven (60°C at 1 mm Hg for 24 h) to give a solid that was crushed to a light tan powder (57 g, 85% crude yield). The NMR spectrum was consistent with the structure, contaminated with phenol as its sodium salt (ca. 5%). The material was used as is for further reactions (or it can be purified further by column chromatography using a gradient of methanol in ethyl acetate

-54-

(10-25%) to give a white solid, mp 222-4°C).

2'-O-Methoxyethyl-5-methyluridine

2,2'-Anhydro-5-methyluridine (195 g, 0.81 M), tris(2-methoxyethyl)borate (231 g, 0.98 M) and 2-methoxyethanol (1.2 L) were added to a 2 L stainless steel pressure vessel and placed in a pre-heated oil bath at 160°C. After heating for 48 hours at 155-160°C, the vessel was opened and the solution evaporated to dryness and triturated with MeOH (200 mL). The residue was suspended in hot acetone (1 L). The insoluble salts were filtered, washed with acetone (150 mL) and the filtrate evaporated. The residue (280 g) was dissolved in CH₃CN (600 mL) and evaporated. A silica gel column (3 kg) was packed in CH₂Cl₂/acetone/MeOH (20:5:3) containing 0.5% Et₃NH. The residue was dissolved in CH₂Cl₂ (250 mL) and adsorbed onto silica (150 g) prior to loading onto the column. The product was eluted with the packing solvent to give 160 g (63%) of product. Additional material was obtained by reworking impure fractions.

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine

2'-O-Methoxyethyl-5-methyluridine (160 g, 0.506 M) was co-evaporated with pyridine (250 mL) and the dried residue dissolved in pyridine (1.3 L). A first aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the mixture stirred at room temperature for one hour. A second aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the reaction stirred for an additional one hour. Methanol (170 mL) was then added to stop the reaction. HPLC showed the presence of approximately 70% product. The solvent was evaporated and triturated with CH₃CN (200 mL). The residue was dissolved in CHCl₃ (1.5 L) and extracted with 2x500 mL of saturated NaHCO₃ and 2x500 mL of saturated NaCl. The organic phase was dried over Na₂SO₄, filtered and evaporated. 275 g of residue was obtained. The residue was

-55-

purified on a 3.5 kg silica gel column, packed and eluted with EtOAc/hexane/acetone (5:5:1) containing 0.5% Et₃NH. The pure fractions were evaporated to give 164 g of product. Approximately 20 g additional was obtained from the impure fractions to give a total yield of 183 g (57%).

3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (106 g, 0.167 M), DMF/pyridine (750 mL of a 3:1 mixture prepared from 562 mL of DMF and 188 mL of pyridine) and acetic anhydride (24.38 mL, 0.258 M) were combined and stirred at room temperature for 24 hours. The reaction was monitored by TLC by first quenching the TLC sample with the addition of MeOH. Upon completion of the reaction, as judged by TLC, MeOH (50 mL) was added and the mixture evaporated at 35°C. The residue was dissolved in CHCl₃ (800 mL) and extracted with 2x200 mL of saturated sodium bicarbonate and 2x200 mL of saturated NaCl. The water layers were back extracted with 200 mL of CHCl₃. The combined organics were dried with sodium sulfate and evaporated to give 122 g of residue (approx. 90% product). The residue was purified on a 3.5 kg silica gel column and eluted using EtOAc/hexane(4:1). Pure product fractions were evaporated to yield 96 g (84%). An additional 1.5 g was recovered from later fractions.

3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine

A first solution was prepared by dissolving 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (96 g, 0.144 M) in CH₃CN (700 mL) and set aside. Triethylamine (189 mL, 1.44 M) was added to a solution of triazole (90 g, 1.3 M) in CH₃CN (1 L), cooled to -5°C and stirred for 0.5 h using an overhead stirrer. POCl₃ was added dropwise, over a 30 minute period, to the stirred solution maintained at 0-10°C, and the

-56-

resulting mixture stirred for an additional 2 hours. The first solution was added dropwise, over a 45 minute period, to the latter solution. The resulting reaction mixture was stored overnight in a cold room. Salts were filtered from the reaction mixture and the solution was evaporated. The residue was dissolved in EtOAc (1 L) and the insoluble solids were removed by filtration. The filtrate was washed with 1x300 mL of NaHCO₃ and 2x300 mL of saturated NaCl, dried over sodium sulfate and evaporated. The residue was triturated with EtOAc to give the title compound.

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine

A solution of 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine (103 g, 0.141 M) in dioxane (500 mL) and NH₄OH (30 mL) was stirred at room temperature for 2 hours. The dioxane solution was evaporated and the residue azeotroped with MeOH (2x200 mL). The residue was dissolved in MeOH (300 mL) and transferred to a 2 liter stainless steel pressure vessel. MeOH (400 mL) saturated with NH₃ gas was added and the vessel heated to 100°C for 2 hours (TLC showed complete conversion). The vessel contents were evaporated to dryness and the residue was dissolved in EtOAc (500 mL) and washed once with saturated NaCl (200 mL). The organics were dried over sodium sulfate and the solvent was evaporated to give 85 g (95%) of the title compound.

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (85 g, 0.134 M) was dissolved in DMF (800 mL) and benzoic anhydride (37.2 g, 0.165 M) was added with stirring. After stirring for 3 hours, TLC showed the reaction to be approximately 95% complete. The solvent was evaporated and the residue azeotroped with MeOH (200 mL). The residue was dissolved in CHCl₃ (700 mL) and extracted with saturated

-57-

NaHCO₃ (2x300 mL) and saturated NaCl (2x300 mL), dried over MgSO₄ and evaporated to give a residue (96 g). The residue was chromatographed on a 1.5 kg silica column using EtOAc/hexane (1:1) containing 0.5% Et₃NH as the eluting solvent. The pure product fractions were evaporated to give 90 g (90%) of the title compound.

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine-3'-amidite

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (74 g, 0.10 M) was dissolved in CH₂Cl₂ (1 L). Tetrazole diisopropylamine (7.1 g) and 2-cyanoethoxy-tetra-(isopropyl)phosphite (40.5 mL, 0.123 M) were added with stirring, under a nitrogen atmosphere. The resulting mixture was stirred for 20 hours at room temperature (TLC showed the reaction to be 95% complete). The reaction mixture was extracted with saturated NaHCO₃ (1x300 mL) and saturated NaCl (3x300 mL). The aqueous washes were back-extracted with CH₂Cl₂ (300 mL), and the extracts were combined, dried over MgSO₄ and concentrated. The residue obtained was chromatographed on a 1.5 kg silica column using EtOAc/hexane (3:1) as the eluting solvent. The pure fractions were combined to give 90.6 g (87%) of the title compound.

2'-O-(Aminooxyethyl) nucleoside amidites and 2'-O-(dimethylaminooxyethyl) nucleoside amidites

2'-(Dimethylaminooxyethoxy) nucleoside amidites

2'-(Dimethylaminooxyethoxy) nucleoside amidites [also known in the art as 2'-O-(dimethylaminooxyethyl) nucleoside amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and guanosine nucleoside amidites are prepared similarly to the thymidine (5-methyluridine) except the exocyclic amines are protected with a benzoyl moiety in the case of adenosine and cytidine and with isobutyryl in the case of guanosine.

5'-O-tert-Butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine

O²-2'-anhydro-5-methyluridine (Pro. Bio. Sint., Varese, Italy, 100.0g, 0.416 mmol), dimethylaminopyridine (0.66g, 0.013eq, 0.0054mmol) were dissolved in dry pyridine (500 ml) at ambient temperature under an argon atmosphere and with mechanical stirring. tert-Butyldiphenylchlorosilane (125.8g, 119.0mL, 1.1eq, 0.458mmol) was added in one portion. The reaction was stirred for 16 h at ambient temperature. TLC (R_f 0.22, ethyl acetate) indicated a complete reaction. The solution was concentrated under reduced pressure to a thick oil. This was partitioned between dichloromethane (1 L) and saturated sodium bicarbonate (2x1 L) and brine (1 L). The organic layer was dried over sodium sulfate and concentrated under reduced pressure to a thick oil. The oil was dissolved in a 1:1 mixture of ethyl acetate and ethyl ether (600mL) and the solution was cooled to -10°C. The resulting crystalline product was collected by filtration, washed with ethyl ether (3x200 mL) and dried (40°C, 1mm Hg, 24 h) to 149g (74.8%) of white solid. TLC and NMR were consistent with pure product.

5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine

In a 2 L stainless steel, unstirred pressure reactor was added borane in tetrahydrofuran (1.0 M, 2.0 eq, 622 mL). In the fume hood and with manual stirring, ethylene glycol (350 mL, excess) was added cautiously at first until the evolution of hydrogen gas subsided. 5'-O-tert-Butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine (149 g, 0.311 mol) and sodium bicarbonate (0.074 g, 0.003 eq) were added with manual stirring. The reactor was sealed and heated in an oil bath until an internal temperature of 160 °C was reached and then maintained for 16 h (pressure < 100 psig). The reaction

-59-

vessel was cooled to ambient and opened. TLC (Rf 0.67 for desired product and Rf 0.82 for ara-T side product, ethyl acetate) indicated about 70% conversion to the product. In order to avoid additional side product formation, the reaction was stopped, concentrated under reduced pressure (10 to 1mm Hg) in a warm water bath (40-100°C) with the more extreme conditions used to remove the ethylene glycol. [Alternatively, once the low boiling solvent is gone, the remaining solution can be partitioned between ethyl acetate and water. The product will be in the organic phase.] The residue was purified by column chromatography (2kg silica gel, ethyl acetate-hexanes gradient 1:1 to 4:1). The appropriate fractions were combined, stripped and dried to product as a white crisp foam (84g, 50%), contaminated starting material (17.4g) and pure reusable starting material 20g. The yield based on starting material less pure recovered starting material was 58%. TLC and NMR were consistent with 99% pure product.

2'-O-([2-phthalimidoxy)ethyl]-5'-t-butylldiphenylsilyl-5-methyluridine

5'-O-tert-Butylldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine (20g, 36.98mmol) was mixed with triphenylphosphine (11.63g, 44.36mmol) and N-hydroxyphthalimide (7.24g, 44.36mmol). It was then dried over P₂O₅ under high vacuum for two days at 40°C. The reaction mixture was flushed with argon and dry THF (369.8mL, Aldrich, sure seal bottle) was added to get a clear solution. Diethyl-azodicarboxylate (6.98mL, 44.36mmol) was added dropwise to the reaction mixture. The rate of addition is maintained such that resulting deep red coloration is just discharged before adding the next drop. After the addition was complete, the reaction was stirred for 4 hrs. By that time TLC showed the completion of the reaction

-60-

(ethylacetate:hexane, 60:40). The solvent was evaporated in vacuum. Residue obtained was placed on a flash column and eluted with ethyl acetate:hexane (60:40), to get 2'-O-([2-phthalimidooxy)ethyl]-5'-*t*-butyldiphenylsilyl-5-methyluridine as white foam (21.819 g, 86%).

5'-O-*tert*-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine

2'-O-([2-phthalimidooxy)ethyl]-5'-*t*-butyldiphenylsilyl-5-methyluridine (3.1g, 4.5mmol) was dissolved in dry CH₂Cl₂ (4.5mL) and methylhydrazine (300mL, 4.64mmol) was added dropwise at -10°C to 0°C. After 1 h the mixture was filtered, the filtrate was washed with ice cold CH₂Cl₂ and the combined organic phase was washed with water, brine and dried over anhydrous Na₂SO₄. The solution was concentrated to get 2'-O-(aminooxyethyl) thymidine, which was then dissolved in MeOH (67.5mL). To this formaldehyde (20% aqueous solution, w/w, 1.1 eq.) was added and the resulting mixture was stirred for 1 h. Solvent was removed under vacuum; residue chromatographed to get 5'-O-*tert*-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine as white foam (1.95 g, 78%).

5'-O-*tert*-Butyldiphenylsilyl-2'-O-[N,N-dimethylaminooxyethyl]-5-methyluridine

5'-O-*tert*-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine (1.77g, 3.12mmol) was dissolved in a solution of 1M pyridinium *p*-toluenesulfonate (PPTS) in dry MeOH (30.6mL). Sodium cyanoborohydride (0.39g, 6.13mmol) was added to this solution at 10°C under inert atmosphere. The reaction mixture was stirred for 10 minutes at 10°C. After that the reaction vessel was removed from the ice bath and stirred at room temperature for 2 h, the reaction monitored by TLC (5% MeOH in CH₂Cl₂). Aqueous NaHCO₃ solution (5%, 10mL) was added and extracted with ethyl

-61-

acetate (2x20mL). Ethyl acetate phase was dried over anhydrous Na_2SO_4 , evaporated to dryness. Residue was dissolved in a solution of 1M PPTS in MeOH (30.6mL). Formaldehyde (20% w/w, 30mL, 3.37mmol) was added and the reaction mixture was stirred at room temperature for 10 minutes. Reaction mixture cooled to 10°C in an ice bath, sodium cyanoborohydride (0.39g, 6.13mmol) was added and reaction mixture stirred at 10°C for 10 minutes. After 10 minutes, the reaction mixture was removed from the ice bath and stirred at room temperature for 2 hrs. To the reaction mixture 5% NaHCO_3 (25mL) solution was added and extracted with ethyl acetate (2x25mL). Ethyl acetate layer was dried over anhydrous Na_2SO_4 and evaporated to dryness. The residue obtained was purified by flash column chromatography and eluted with 5% MeOH in CH_2Cl_2 to get 5'-O-*tert*-butyldiphenylsilyl-2'-O-[N,N-dimethylaminoxyethyl]-5-methyluridine as a white foam (14.6g, 80%).

2'-O-(dimethylaminoxyethyl)-5-methyluridine

Triethylamine trihydrofluoride (3.91mL, 24.0mmol) was dissolved in dry THF and triethylamine (1.67mL, 12mmol, dry, kept over KOH). This mixture of triethylamine-2HF was then added to 5'-O-*tert*-butyldiphenylsilyl-2'-O-[N,N-dimethylaminoxyethyl]-5-methyluridine (1.40g, 2.4mmol) and stirred at room temperature for 24 hrs. Reaction was monitored by TLC (5% MeOH in CH_2Cl_2). Solvent was removed under vacuum and the residue placed on a flash column and eluted with 10% MeOH in CH_2Cl_2 to get 2'-O-(dimethylaminoxyethyl)-5-methyluridine (766mg, 92.5%).

5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine

2'-O-(dimethylaminoxyethyl)-5-methyluridine (750mg, 2.17mmol) was dried over P_2O_5 under high vacuum overnight at 40°C . It was then co-evaporated with anhydrous pyridine (20mL). The residue obtained was dissolved in pyridine

-62-

(11mL) under argon atmosphere. 4-dimethylaminopyridine (26.5mg, 2.60mmol), 4,4'-dimethoxytrityl chloride (880mg, 2.60mmol) was added to the mixture and the reaction mixture was stirred at room temperature until all of the starting material disappeared. Pyridine was removed under vacuum and the residue chromatographed and eluted with 10% MeOH in CH₂Cl₂ (containing a few drops of pyridine) to get 5'-O-DMT-2'-O-(dimethylamino-oxyethyl)-5-methyluridine (1.13g, 80%).

5'-O-DMT-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]

5'-O-DMT-2'-O-(dimethylaminooxyethyl)-5-methyluridine (1.08g, 1.67mmol) was co-evaporated with toluene (20mL). To the residue N,N-diisopropylamine tetrazonide (0.29g, 1.67mmol) was added and dried over P₂O₅ under high vacuum overnight at 40°C. Then the reaction mixture was dissolved in anhydrous acetonitrile (8.4mL) and 2-cyanoethyl-N,N,N¹,N¹-tetraisopropylphosphoramidite (2.12mL, 6.08mmol) was added. The reaction mixture was stirred at ambient temperature for 4 hrs under inert atmosphere. The progress of the reaction was monitored by TLC (hexane:ethyl acetate 1:1). The solvent was evaporated, then the residue was dissolved in ethyl acetate (70mL) and washed with 5% aqueous NaHCO₃ (40mL). Ethyl acetate layer was dried over anhydrous Na₂SO₄ and concentrated. Residue obtained was chromatographed (ethyl acetate as eluent) to get 5'-O-DMT-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite] as a foam (1.04g, 74.9%).

2'-(Aminooxyethoxy) nucleoside amidites

2'-(Aminooxyethoxy) nucleoside amidites [also known in the art as 2'-O-(aminooxyethyl) nucleoside amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and thymidine nucleoside amidites are prepared

similarly.

N2-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]

The 2'-O-aminooxyethyl guanosine analog may be obtained by selective 2'-O-alkylation of diaminopurine riboside. Multigram quantities of diaminopurine riboside may be purchased from Schering AG (Berlin) to provide 2'-O-(2-ethylacetyl) diaminopurine riboside along with a minor amount of the 3'-O-isomer. 2'-O-(2-ethylacetyl) diaminopurine riboside may be resolved and converted to 2'-O-(2-ethylacetyl)guanosine by treatment with adenosine deaminase. (McGee, D. P. C., Cook, P. D., Guinasso, C. J., WO 94/02501 A1 940203.) Standard protection procedures should afford 2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine and 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine which may be reduced to provide 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine. As before the hydroxyl group may be displaced by N-hydroxyphthalimide via a Mitsunobu reaction, and the protected nucleoside may phosphitylated as usual to yield 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite].

2'-dimethylaminoethoxyethoxy (2'-DMAEOE) nucleoside amidites

2'-dimethylaminoethoxyethoxy nucleoside amidites (also known in the art as 2'-O-dimethylaminoethoxyethyl, i.e., 2'-O-CH₂-O-CH₂-N(CH₂)₂, or 2'-DMAEOE nucleoside amidites) are prepared as follows. Other nucleoside amidites are prepared similarly.

2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine

2[2-(Dimethylamino)ethoxy]ethanol (Aldrich, 6.66 g, 50

-64-

mmol) is slowly added to a solution of borane in tetrahydrofuran (1 M, 10 mL, 10 mmol) with stirring in a 100 mL bomb. Hydrogen gas evolves as the solid dissolves. O²-, 2'-anhydro-5-methyluridine (1.2 g, 5 mmol), and sodium bicarbonate (2.5 mg) are added and the bomb is sealed, placed in an oil bath and heated to 155°C for 26 hours. The bomb is cooled to room temperature and opened. The crude solution is concentrated and the residue partitioned between water (200 mL) and hexanes (200 mL). The excess phenol is extracted into the hexane layer. The aqueous layer is extracted with ethyl acetate (3x200 mL) and the combined organic layers are washed once with water, dried over anhydrous sodium sulfate and concentrated. The residue is columned on silica gel using methanol/methylene chloride 1:20 (which has 2% triethylamine) as the eluent. As the column fractions are concentrated a colorless solid forms which is collected to give the title compound as a white solid.

5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]]-5-methyl uridine

To 0.5 g (1.3 mmol) of 2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]]-5-methyl uridine in anhydrous pyridine (8 mL), triethylamine (0.36 mL) and dimethoxytrityl chloride (DMT-Cl, 0.87 g, 2 eq.) are added and stirred for 1 hour. The reaction mixture is poured into water (200 mL) and extracted with CH₂Cl₂ (2x200 mL). The combined CH₂Cl₂ layers are washed with saturated NaHCO₃ solution, followed by saturated NaCl solution and dried over anhydrous sodium sulfate. Evaporation of the solvent followed by silica gel chromatography using MeOH:CH₂Cl₂:Et₃N (20:1, v/v, with 1% triethylamine) gives the title compound.

5'-O-Dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)-ethyl]]-5-methyl uridine-3'-O-(cyanoethyl-N,N-diisopropyl)phosphoramidite

Diisopropylaminotetrazolide (0.6 g) and 2-cyanoethoxy-N,N-diisopropyl phosphoramidite (1.1 mL, 2 eq.) are added to a solution of 5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]]-5-methyluridine (2.17 g, 3 mmol) dissolved in CH_2Cl_2 (20 mL) under an atmosphere of argon. The reaction mixture is stirred overnight and the solvent evaporated. The resulting residue is purified by silica gel flash column chromatography with ethyl acetate as the eluent to give the title compound.

Example 2

Oligonucleotide synthesis

Unsubstituted and substituted phosphodiester (P=O) oligonucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using standard phosphoramidite chemistry with oxidation by iodine.

Phosphorothioates (P=S) are synthesized as for the phosphodiester oligonucleotides except the standard oxidation bottle was replaced by 0.2 M solution of 3H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the stepwise thiation of the phosphite linkages. The thiation wait step was increased to 68 sec and was followed by the capping step. After cleavage from the CPG column and deblocking in concentrated ammonium hydroxide at 55°C (18 h), the oligonucleotides were purified by precipitating twice with 2.5 volumes of ethanol from a 0.5 M NaCl solution. Phosphinate oligonucleotides are prepared as described in U.S. Patent 5,508,270, herein incorporated by reference.

Alkyl phosphonate oligonucleotides are prepared as described in U.S. Patent 4,469,863, herein incorporated by reference.

3'-Deoxy-3'-methylene phosphonate oligonucleotides are prepared as described in U.S. Patents 5,610,289 or 5,625,050, herein incorporated by reference.

Phosphoramidite oligonucleotides are prepared as described in U.S. Patent, 5,256,775 or U.S. Patent 5,366,878, herein incorporated by reference.

Alkylphosphonothioate oligonucleotides are prepared as described in published PCT applications PCT/US94/00902 and PCT/US93/06976 (published as WO 94/17093 and WO 94/02499, respectively), herein incorporated by reference.

3'-Deoxy-3'-amino phosphoramidate oligonucleotides are prepared as described in U.S. Patent 5,476,925, herein incorporated by reference.

Phosphotriester oligonucleotides are prepared as described in U.S. Patent 5,023,243, herein incorporated by reference.

Borano phosphate oligonucleotides are prepared as described in U.S. Patents 5,130,302 and 5,177,198, both herein incorporated by reference.

Example 3

Oligonucleoside Synthesis

Methylenemethylimino linked oligonucleosides, also identified as MMI linked oligonucleosides, methylenedimethylhydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified as amide-3 linked oligonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified as amide-4 linked oligonucleosides, as well as mixed backbone compounds having, for instance, alternating MMI and P=O or P=S linkages are prepared as described in U.S. Patents 5,378,825, 5,386,023, 5,489,677, 5,602,240 and 5,610,289, all of which are herein incorporated by reference.

Formacetal and thioformacetal linked oligonucleosides are prepared as described in U.S. Patents 5,264,562 and 5,264,564, herein incorporated by reference.

Ethylene oxide linked oligonucleosides are prepared as described in U.S. Patent 5,223,618, herein incorporated by reference.

Example 4

PNA Synthesis

Peptide nucleic acids (PNAs) are prepared in accordance with any of the various procedures referred to in *Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential Applications, Bioorganic & Medicinal Chemistry, 1996, 4, 5-23*. They may also be prepared in accordance with U.S. Patents 5,539,082, 5,700,922, and 5,719,262, herein incorporated by reference.

Example 5

Synthesis of Chimeric Oligonucleotides

Chimeric oligonucleotides, oligonucleosides or mixed oligonucleotides/oligonucleosides of the invention can be of several different types. These include a first type wherein the "gap" segment of linked nucleosides is positioned between 5' and 3' "wing" segments of linked nucleosides and a second "open end" type wherein the "gap" segment is located at either the 3' or the 5' terminus of the oligomeric compound. Oligonucleotides of the first type are also known in the art as "gapmers" or gapped oligonucleotides. Oligonucleotides of the second type are also known in the art as "hemimers" or "wingmers".

[2'-O-Me]--[2'-deoxy]--[2'-O-Me] Chimeric

Phosphorothioate Oligonucleotides

Chimeric oligonucleotides having 2'-O-alkyl phosphorothioate and 2'-deoxy phosphorothioate oligonucleotide segments are synthesized using an Applied

-68-

Biosystems automated DNA synthesizer Model 380B, as above. Oligonucleotides are synthesized using the automated synthesizer and 2'-deoxy-5'-dimethoxytrityl-3'-O-phosphoramidite for the DNA portion and 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite for 5' and 3' wings. The standard synthesis cycle is modified by increasing the wait step after the delivery of tetrazole and base to 600 s repeated four times for RNA and twice for 2'-O-methyl. The fully protected oligonucleotide is cleaved from the support and the phosphate group is deprotected in 3:1 ammonia/ethanol at room temperature overnight then lyophilized to dryness. Treatment in methanolic ammonia for 24 hrs at room temperature is then done to deprotect all bases and sample was again lyophilized to dryness. The pellet is resuspended in 1M TBAF in THF for 24 hrs at room temperature to deprotect the 2' positions. The reaction is then quenched with 1M TEAA and the sample is then reduced to 1/2 volume by rotovac before being desalted on a G25 size exclusion column. The oligo recovered is then analyzed spectrophotometrically for yield and for purity by capillary electrophoresis and by mass spectrometry.

[2'-O-(2-Methoxyethyl)]--[2'-deoxy]--[2'-O-(Methoxyethyl)] Chimeric Phosphorothioate Oligonucleotides

[2'-O-(2-methoxyethyl)]--[2'-deoxy]--[2'-O-(methoxyethyl)] chimeric phosphorothioate oligonucleotides were prepared as per the procedure above for the 2'-O-methyl chimeric oligonucleotide, with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites.

[2'-O-(2-Methoxyethyl) Phosphodiester]--[2'-deoxy Phosphorothioate]--[2'-O-(2-Methoxyethyl) Phosphodiester] Chimeric Oligonucleotides

[2'-O-(2-methoxyethyl phosphodiester)]--[2'-deoxy phos-

phosphorothioate]--[2'-O-(methoxyethyl) phosphodiester] chimeric oligonucleotides are prepared as per the above procedure for the 2'-O-methyl chimeric oligonucleotide with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites, oxidization with iodine to generate the phosphodiester internucleotide linkages within the wing portions of the chimeric structures and sulfurization utilizing 3,4,5-benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) to generate the phosphorothioate internucleotide linkages for the center gap.

Other chimeric oligonucleotides, chimeric oligonucleosides and mixed chimeric oligonucleotides/oligonucleosides are synthesized according to United States patent 5,623,065, herein incorporated by reference.

Example 6

Oligonucleotide Isolation

After cleavage from the controlled pore glass column (Applied Biosystems) and deblocking in concentrated ammonium hydroxide at 55°C for 18 hours, the oligonucleotides or oligonucleosides are purified by precipitation twice out of 0.5 M NaCl with 2.5 volumes ethanol. Synthesized oligonucleotides were analyzed by polyacrylamide gel electrophoresis on denaturing gels and judged to be at least 85% full length material. The relative amounts of phosphorothioate and phosphodiester linkages obtained in synthesis were periodically checked by ³¹P nuclear magnetic resonance spectroscopy, and for some studies oligonucleotides were purified by HPLC, as described by Chiang et al., *J. Biol. Chem.* **1991**, 266, 18162-18171. Results obtained with HPLC-purified material were similar to those obtained with non-HPLC purified material.

Example 7**Oligonucleotide Synthesis - 96 Well Plate Format**

Oligonucleotides were synthesized via solid phase P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a standard 96 well format. Phosphodiester internucleotide linkages were afforded by oxidation with aqueous iodine. Phosphorothioate internucleotide linkages were generated by sulfurization utilizing 3,4-dihydro-2H-benzothiole-3-one 1,1-dioxide (Beaucage Reagent) in anhydrous acetonitrile. Standard base-protected beta-cyanoethyl-diisopropyl phosphoramidites were purchased from commercial vendors (e.g. PE-Applied Biosystems, Foster City, CA, or Pharmacia, Piscataway, NJ). Non-standard nucleosides are synthesized as per known literature or patented methods. They are utilized as base protected beta-cyanoethyl-diisopropyl phosphoramidites.

Oligonucleotides were cleaved from support and deprotected with concentrated NH_4OH at elevated temperature ($55\text{-}60^\circ\text{C}$) for 12-16 hours and the released product then dried in vacuo. The dried product was then re-suspended in sterile water to afford a master plate from which all analytical and test plate samples are then diluted utilizing robotic pipettors.

Example 8**Oligonucleotide Analysis - 96 Well Plate Format**

The concentration of oligonucleotide in each well was assessed by dilution of samples and UV absorption spectroscopy. The full-length integrity of the individual products was evaluated by capillary electrophoresis (CE) in either the 96 well format (Beckman P/ACE™ MDQ) or, for individually prepared samples, on a commercial CE apparatus (e.g., Beckman P/ACE™ 5000, ABI 270). Base and backbone composition was confirmed by mass analysis of the compounds

-71-

utilizing electrospray-mass spectroscopy. All assay test plates were diluted from the master plate using single and multi-channel robotic pipettors. Plates were judged to be acceptable if at least 85% of the compounds on the plate were at least 85% full length.

Example 9**Cell culture and oligonucleotide treatment**

The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid is present at measurable levels. This can be routinely determined using, for example, PCR or Northern blot analysis. The following 6 cell types are provided for illustrative purposes, but other cell types can be routinely used, provided that the target is expressed in the cell type chosen. This can be readily determined by methods routine in the art, for example Northern blot analysis, Ribonuclease protection assays, or RT-PCR.

T-24 cells:

The human transitional cell bladder carcinoma cell line T-24 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). T-24 cells were routinely cultured in complete McCoy's 5A basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analysis, cells may be seeded onto 100 mm or other standard tissue culture plates

-72-

and treated similarly, using appropriate volumes of medium and oligonucleotide.

A549 cells:

The human lung carcinoma cell line A549 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). A549 cells were routinely cultured in DMEM basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence.

NHDF cells:

Human neonatal dermal fibroblast (NHDF) were obtained from the Clonetics Corporation (Walkersville MD). NHDFs were routinely maintained in Fibroblast Growth Medium (Clonetics Corporation, Walkersville MD) supplemented as recommended by the supplier. Cells were maintained for up to 10 passages as recommended by the supplier.

HEK cells:

Human embryonic keratinocytes (HEK) were obtained from the Clonetics Corporation (Walkersville MD). HEKs were routinely maintained in Keratinocyte Growth Medium (Clonetics Corporation, Walkersville MD) formulated as recommended by the supplier. Cells were routinely maintained for up to 10 passages as recommended by the supplier.

MCF-7 cells:

The human breast carcinoma cell line MCF-7 was obtained from the American Type Culture Collection (Manassas, VA). MCF-7 cells were routinely cultured in DMEM low glucose (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and

-73-

dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analyses, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

LA4 cells:

The mouse lung epithelial cell line LA4 was obtained from the American Type Culture Collection (Manassas, VA). LA4 cells were routinely cultured in F12K medium (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 15% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 3000-6000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analyses, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

Treatment with antisense compounds:

When cells reached 80% confluency, they were treated with oligonucleotide. For cells grown in 96-well plates, wells were washed once with 200 μ L OPTI-MEM™-1 reduced-serum medium (Gibco BRL) and then treated with 130 μ L of OPTI-MEM™-1 containing 3.75 μ g/mL LIPOFECTIN™ (Gibco BRL) and the desired concentration of oligonucleotide. After 4-7 hours of treatment, the medium was replaced with fresh medium. Cells were harvested 16-24 hours after oligonucleotide treatment.

The concentration of oligonucleotide used varies from cell line to cell line. To determine the optimal

-74-

oligonucleotide concentration for a particular cell line, the cells are treated with a positive control oligonucleotide at a range of concentrations. For human cells the positive control oligonucleotide is ISIS 13920, **TCCGTCATCGCTCCTCAGGG**, SEQ ID NO: 1, a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to human H-ras. For mouse or rat cells the positive control oligonucleotide is ISIS 15770, **ATGCATTCTGCCCCCAAGGA**, SEQ ID NO: 2, a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to both mouse and rat c-raf. The concentration of positive control oligonucleotide that results in 80% inhibition of c-Ha-ras (for ISIS 13920) or c-raf (for ISIS 15770) mRNA is then utilized as the screening concentration for new oligonucleotides in subsequent experiments for that cell line. If 80% inhibition is not achieved, the lowest concentration of positive control oligonucleotide that results in 60% inhibition of H-ras or c-raf mRNA is then utilized as the oligonucleotide screening concentration in subsequent experiments for that cell line. If 60% inhibition is not achieved, that particular cell line is deemed as unsuitable for oligonucleotide transfection experiments.

Example 10

Analysis of oligonucleotide inhibition of inducible nitric oxide synthase expression

Antisense modulation of inducible nitric oxide synthase expression can be assayed in a variety of ways known in the art. For example, inducible nitric oxide synthase mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or real-time PCR (RT-PCR). Real-time quantitative PCR is presently preferred. RNA analysis can be performed on total cellular RNA or

-75-

poly(A)+ mRNA. Methods of RNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.1.1-4.2.9 and 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Northern blot analysis is routine in the art and is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.2.1-4.2.9, John Wiley & Sons, Inc., 1996. Real-time quantitative (PCR) can be conveniently accomplished using the commercially available ABI PRISM™ 7700 Sequence Detection System, available from PE-Applied Biosystems, Foster City, CA and used according to manufacturer's instructions. Prior to quantitative PCR analysis, primer-probe sets specific to the target gene being measured are evaluated for their ability to be "multiplexed" with a GAPDH amplification reaction. In multiplexing, both the target gene and the internal standard gene GAPDH are amplified concurrently in a single sample. In this analysis, mRNA isolated from untreated cells is serially diluted. Each dilution is amplified in the presence of primer-probe sets specific for GAPDH only, target gene only ("single-plexing"), or both (multiplexing). Following PCR amplification, standard curves of GAPDH and target mRNA signal as a function of dilution are generated from both the single-plexed and multiplexed samples. If both the slope and correlation coefficient of the GAPDH and target signals generated from the multiplexed samples fall within 10% of their corresponding values generated from the single-plexed samples, the primer-probe set specific for that target is deemed as multiplexable. Other methods of PCR are also known in the art.

Protein levels of inducible nitric oxide synthase can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), ELISA or fluorescence-activated cell

-76-

sorting (FACS). Antibodies directed to inducible nitric oxide synthase can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, MI), or can be prepared via conventional antibody generation methods. Methods for preparation of polyclonal antisera are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.12.1-11.12.9, John Wiley & Sons, Inc., 1997. Preparation of monoclonal antibodies is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.4.1-11.11.5, John Wiley & Sons, Inc., 1997.

Immunoprecipitation methods are standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.16.1-10.16.11, John Wiley & Sons, Inc., 1998. Western blot (immunoblot) analysis is standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.8.1-10.8.21, John Wiley & Sons, Inc., 1997. Enzyme-linked immunosorbent assays (ELISA) are standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.2.1-11.2.22, John Wiley & Sons, Inc., 1991.

Example 11

Poly(A)+ mRNA isolation

Poly(A)+ mRNA was isolated according to Miura et al., *Clin. Chem.*, 1996, 42, 1758-1764. Other methods for poly(A)+ mRNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μ L cold PBS. 60 μ L lysis buffer (10 mM Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M

NaCl, 0.5% NP-40, 20 mM vanadyl-ribonucleoside complex) was added to each well, the plate was gently agitated and then incubated at room temperature for five minutes. 55 μ L of lysate was transferred to Oligo d(T) coated 96-well plates (AGCT Inc., Irvine CA). Plates were incubated for 60 minutes at room temperature, washed 3 times with 200 μ L of wash buffer (10 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.3 M NaCl). After the final wash, the plate was blotted on paper towels to remove excess wash buffer and then air-dried for 5 minutes. 60 μ L of elution buffer (5 mM Tris-HCl pH 7.6), preheated to 70°C was added to each well, the plate was incubated on a 90°C hot plate for 5 minutes, and the eluate was then transferred to a fresh 96-well plate.

Cells grown on 100 mm or other standard plates may be treated similarly, using appropriate volumes of all solutions.

Example 12

Total RNA Isolation

Total mRNA was isolated using an RNEASY 96™ kit and buffers purchased from Qiagen Inc. (Valencia CA) following the manufacturer's recommended procedures. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μ L cold PBS. 100 μ L Buffer RLT was added to each well and the plate vigorously agitated for 20 seconds. 100 μ L of 70% ethanol was then added to each well and the contents mixed by pipetting three times up and down. The samples were then transferred to the RNEASY 96™ well plate attached to a QIAVAC™ manifold fitted with a waste collection tray and attached to a vacuum source. Vacuum was applied for 15 seconds. 1 mL of Buffer RW1 was added to each well of the RNEASY 96™ plate and the vacuum again applied for 15 seconds. 1 mL of Buffer RPE was then added to each well of the RNEASY 96™ plate and the vacuum

applied for a period of 15 seconds. The Buffer RPE wash was then repeated and the vacuum was applied for an additional 10 minutes. The plate was then removed from the QIAVAC™ manifold and blotted dry on paper towels. The plate was then re-attached to the QIAVAC™ manifold fitted with a collection tube rack containing 1.2 mL collection tubes. RNA was then eluted by pipetting 60 µL water into each well, incubating 1 minute, and then applying the vacuum for 30 seconds. The elution step was repeated with an additional 60 µL water.

The repetitive pipetting and elution steps may be automated using a QIAGEN Bio-Robot 9604 (Qiagen, Inc., Valencia CA). Essentially, after lysing of the cells on the culture plate, the plate is transferred to the robot deck where the pipetting, DNase treatment and elution steps are carried out.

Example 13

Real-time Quantitative PCR Analysis of inducible nitric oxide synthase mRNA Levels

Quantitation of inducible nitric oxide synthase mRNA levels was determined by real-time quantitative PCR using the ABI PRISM™ 7700 Sequence Detection System (PE-Applied Biosystems, Foster City, CA) according to manufacturer's instructions. This is a closed-tube, non-gel-based, fluorescence detection system which allows high-throughput quantitation of polymerase chain reaction (PCR) products in real-time. As opposed to standard PCR, in which amplification products are quantitated after the PCR is completed, products in real-time quantitative PCR are quantitated as they accumulate. This is accomplished by including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye (e.g., JOE, FAM, or VIC, obtained from either Operon

-79-

Technologies Inc., Alameda, CA or PE-Applied Biosystems, Foster City, CA) is attached to the 5' end of the probe and a quencher dye (e.g., TAMRA, obtained from either Operon Technologies Inc., Alameda, CA or PE-Applied Biosystems, Foster City, CA) is attached to the 3' end of the probe. When the probe and dyes are intact, reporter dye emission is quenched by the proximity of the 3' quencher dye. During amplification, annealing of the probe to the target sequence creates a substrate that can be cleaved by the 5'-exonuclease activity of Taq polymerase. During the extension phase of the PCR amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated. With each cycle, additional reporter dye molecules are cleaved from their respective probes, and the fluorescence intensity is monitored at regular intervals by laser optics built into the ABI PRISM™ 7700 Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples.

PCR reagents were obtained from PE-Applied Biosystems, Foster City, CA. RT-PCR reactions were carried out by adding 25 μ L PCR cocktail (1x TAQMAN™ buffer A, 5.5 mM MgCl₂, 300 μ M each of dATP, dCTP and dGTP, 600 μ M of dUTP, 100 nM each of forward primer, reverse primer, and probe, 20 Units RNase inhibitor, 1.25 Units AMPLITAQ GOLD™, and 12.5 Units MuLV reverse transcriptase) to 96 well plates containing 25 μ L poly(A) mRNA solution. The RT reaction was carried out by incubation for 30 minutes at 48°C. Following a 10 minute incubation at 95°C to activate the AMPLITAQ GOLD™, 40 cycles of a two-step PCR protocol were carried out: 95°C for 15

-80-

seconds (denaturation) followed by 60°C for 1.5 minutes (annealing/extension).

Probes and primers to human inducible nitric oxide synthase were designed to hybridize to a human inducible nitric oxide synthase sequence, using published sequence information (GenBank accession number L09210, incorporated herein as SEQ ID NO:3). For human inducible nitric oxide synthase the PCR primers were:

forward primer: GGTGGAAGCGGTAACAAAGGA (SEQ ID NO: 4)

reverse primer: TGCTTGGTGGCGAAGATGA (SEQ ID NO: 5) and the PCR probe was: FAM-AACAACAGGAACCTACCAACTGACGGGAGA-TAMRA

(SEQ ID NO: 6) where FAM (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye. For human GAPDH the PCR primers were:

forward primer: GAAGGTGAAGGTCGGAGTC (SEQ ID NO: 7)

reverse primer: GAAGATGGTGATGGGATTTC (SEQ ID NO: 8) and the PCR probe was: 5' JOE-CAAGCTTCCCGTTCTCAGCC- TAMRA 3' (SEQ ID NO: 9) where JOE (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye.

Probes and primers to mouse inducible nitric oxide synthase were designed to hybridize to a mouse inducible nitric oxide synthase sequence, using published sequence information (GenBank accession number M92649, incorporated herein as SEQ ID NO:10). For mouse inducible nitric oxide synthase the PCR primers were:

forward primer: CGTCCACAGTATGTGAGGATCAA (SEQ ID NO:11)

reverse primer: CAAGCAAGACTTGGACTTGCAA (SEQ ID NO: 12) and the PCR probe was: FAM-TCTTCACCACAAGGCCACATCGGATT-TAMRA (SEQ ID NO: 13) where FAM (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye.

-81-

For mouse GAPDH the PCR primers were:

forward primer: GGCAAATTCAACGGCACAGT (SEQ ID NO: 14)

reverse primer: GGGTCTCGCTCCTGGAAGCT (SEQ ID NO: 15) and the

PCR probe was: 5' JOE-AAGGCCGAGAATGGGAAGCTTGTTCATC- TAMRA 3'

(SEQ ID NO: 16) where JOE (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye.

Example 14

Northern blot analysis of inducible nitric oxide synthase mRNA levels

Eighteen hours after antisense treatment, cell monolayers were washed twice with cold PBS and lysed in 1 mL RNAZOL™ (TEL-TEST "B" Inc., Friendswood, TX). Total RNA was prepared following manufacturer's recommended protocols. Twenty micrograms of total RNA was fractionated by electrophoresis through 1.2% agarose gels containing 1.1% formaldehyde using a MOPS buffer system (AMRESCO, Inc. Solon, OH). RNA was transferred from the gel to HYBOND™-N+ nylon membranes (Amersham Pharmacia Biotech, Piscataway, NJ) by overnight capillary transfer using a Northern/Southern Transfer buffer system (TEL-TEST "B" Inc., Friendswood, TX). RNA transfer was confirmed by UV visualization. Membranes were fixed by UV cross-linking using a STRATALINKER™ UV Crosslinker 2400 (Stratagene, Inc, La Jolla, CA) and then probed using QUICKHYB™ hybridization solution (Stratagene, La Jolla, CA) using manufacturer's recommendations for stringent conditions.

To detect human inducible nitric oxide synthase, a human inducible nitric oxide synthase specific probe was prepared by PCR using the forward primer GGTGGAAGCGGTAACAAAGGA (SEQ ID NO: 4) and the reverse primer TGCTTGGTGGCGAAGATGA (SEQ ID NO: 5). To normalize for variations in loading and transfer efficiency membranes were stripped and probed for human

- 82 -

glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, CA).

To detect mouse inducible nitric oxide synthase, a mouse inducible nitric oxide synthase specific probe was prepared by PCR using the forward primer CGTCCACAGTATGTGAGGATCAA (SEQ ID NO:11) and the reverse primer CAAGCAAGACTTGGACTTGCAA (SEQ ID NO: 12). To normalize for variations in loading and transfer efficiency membranes were stripped and probed for mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, CA).

Hybridized membranes were visualized and quantitated using a PHOSPHORIMAGER™ and IMAGEQUANT™ Software V3.3 (Molecular Dynamics, Sunnyvale, CA). Data was normalized to GAPDH levels in untreated controls.

Example 15

Antisense inhibition of human inducible nitric oxide synthase expression by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

In accordance with the present invention, a series of oligonucleotides were designed to target different regions of the human inducible nitric oxide synthase RNA, using published sequences (GenBank accession number L09210, incorporated herein as SEQ ID NO: 3, and GenBank accession number L07868, incorporated herein as SEQ ID NO: 17). The oligonucleotides are shown in Table 1. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 1 are chimeric oligonucleotides ("gapmers") 18 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by four-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE) nucleotides. The

- 83 -

internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. Cytidine residues in the 2'-MOE wings are 5-methylcytidines for ISIS 24032 through 24071. All cytidine residues are 5-methylcytidines for ISIS 19631 through 19714. The compounds were analyzed for their effect on human inducible nitric oxide synthase mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments. If present, "N.D." indicates "no data".

Table 1

Inhibition of human inducible nitric oxide synthase mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	%INHIB	SEQ ID NO
24032	5'UTR	3	14	catcaaaggtggcccgaga	76	19
24033	5'UTR	3	38	ctgtctagaactgcccag	50	20
24034	5'UTR	3	57	tgccttgagaacttcggg	41	21
24035	5'UTR	3	160	tgtcacttatctggattt	17	22
24036	Coding	3	219	cttgaacagaaatttcca	34	23
24037	Coding	3	277	tctccacattgttgattga	43	24
24038	Coding	3	338	ctgagggttgatgatactga	16	25
24039	Coding	3	410	agcttgaccagagattct	19	26
24040	Coding	3	492	gtgaagtgtgtccttgga	13	27
24041	Coding	3	534	gcaagatttggacctgca	0	28
24042	Coding	3	580	cctgggtcctctgggtca	74	29
24043	Coding	3	645	gccgtaaatattggttgac	55	30
24044	Coding	3	705	ctcctttgttaccgcttc	53	31
24045	Coding	3	745	gctcatctcccgtcagtt	55	32
24046	Coding	3	823	agacctgcagggttgacc	42	33
24047	Coding	3	880	cgtgtctgcagatgtgtt	0	34
24048	Coding	3	959	aagtcgtgcttgccatca	0	35
24049	Coding	3	1025	cctctgatgctgccatct	33	36
24050	Coding	3	1098	atcgaagcggccgtactt	12	37
24051	Coding	3	1184	tccatggccacctcaagc	59	38
24052	Coding	3	1240	caggcagggcgctaccact	0	39
24053	Coding	3	1320	ctctgtgcccattgtacca	3	40
24054	Coding	3	1379	ctgcccacttcctccagg	15	41
24055	Coding	3	1445	ttgatctcaacgacagcc	32	42
24056	Coding	3	1493	tccatgatgggtcacattc	49	43
24057	Coding	3	1548	ggaccgggtattcattctg	57	44
24058	Coding	3	1640	acgtagttcagcatctcc	65	45
24059	Coding	3	1713	gggtctccgcttctcgtc	58	46
24060	Coding	3	1772	agcatacaggcaaagagc	0	47
24061	Coding	3	1830	tgtctctgtcgcaaagag	21	48

- 84 -

24062	Coding	3	1938	ttcctcctccaggcagct	48	49
24063	Coding	3	1994	ccattgccaggggcagtct	38	50
24064	Coding	3	2059	acacagcgtacctgaatt	11	51
24065	Coding	3	2122	gcttctgatcaatgtcat	52	52
24066	Coding	3	2317	tgtagtgggtgcgggtccc	30	53
24067	Coding	3	2435	ctggatgtcggacttttgt	35	54
24068	Coding	3	2642	ctcttgtcactgacccag	0	55
24069	3'UTR	3	3673	ctttaacccctcctgtag	19	56
24070	3'UTR	3	3689	agttctgtgccggcagct	45	57
24071	3'UTR	3	3722	acctcagataaatgcagag	31	58
19631	5'UTR	17	2	agatcccgtgctgacaat	48	59
19632	Coding	17	51	ctcaccagacccaaagt	33	60
19633	Coding	17	72	gtccccgccgccacgaga	42	61
19634	Coding	17	99	actgactgagaatcgctg	51	62
19635	Coding	17	151	ctgctgttccagggtcaga	73	63
19636	Coding	17	213	gttatctccagggttgccc	44	64
19637	Coding	17	232	ccggttgctcaatgct	47	65
19638	Coding	17	307	caggtaacgaaactgatt	40	66
19639	Coding	17	319	attctccagaggcaggta	68	67
19640	Coding	17	351	tcataaagttttgtccca	40	68
19641	Coding	17	408	agtccaaagtttccatct	59	69
19642	Coding	17	447	tttaggattttctgtcaag	35	70
19643	Coding	17	463	tacatagactccaccatt	30	71
19644	Coding	17	566	aactaccatttggtgaca	0	72
19645	Coding	17	577	tccacatcctgaactacc	26	73
19646	Coding	17	632	ggcaatgattttctgtgg	34	74
19647	Coding	17	648	gtccttgtcaaagtctgg	61	75
19648	Coding	17	682	gtagcatctgccgtcaca	52	76
19649	Coding	17	727	gcctccagcacattctcg	82	77
19650	Coding	17	738	ggtcctgagcagcctcca	95	78
19651	Coding	17	760	ggcaaagcagtctgtgtc	65	79
19652	Coding	17	833	aggtggttggtattgtaga	47	80
19653	Coding	17	850	attgtgctccagttgaaa	40	81
19654	Coding	17	900	tgtggacatttcttgaca	44	82
19655	Coding	17	944	tagggcaggcacgcacac	47	83
19656	Coding	17	978	ttaatcccattttcttct	36	84
19657	Coding	17	1039	tgatcctgtgccaatgcc	61	85
19658	Coding	17	1175	ctgggtctatggcttcaa	66	86
19659	Coding	17	1189	gacgttcagtttctctgg	69	87
19660	Coding	17	1325	ggataagcaaggacaggc	49	88
19661	Coding	17	1361	actggaactgtagagagg	35	89
19662	Coding	17	1413	aggttgctgttgtcagta	56	90
19663	Coding	17	1435	gttaatggtatgataata	24	91
19664	Coding	17	1469	ttctctggttgattgtgc	44	92
19665	Coding	17	1475	ttactattctctggttga	52	93
19666	Coding	17	1542	ctggaacacagatgggttg	41	94
19667	Coding	17	1562	caggcccccaacagccat	16	95
19668	Coding	17	1598	tactgaagcggcgacacg	44	96
19669	Coding	17	1629	aggttacaagactctatg	0	97
19670	Coding	17	1667	tggagccattctcaaact	35	98
19671	Coding	17	1713	aggccatcttccatcttc	49	99
19672	Coding	17	1905	ctagtgggaccgttacac	44	100
19673	Coding	17	2024	tcagaccacaatgacca	29	101
19674	Coding	17	2055	atgctcttccttctaaca	12	102
19675	Coding	17	2126	ctgtgccactgggagtta	55	103

-85-

19676	Coding	17	2205	ccaaaagcacctgagcca	1	104
19677	Coding	17	2262	gccacaggaatcttcaca	55	105
19678	Coding	17	2390	tgggttgggctcagacaca	30	106
19679	Coding	17	2464	tccaatgttatccttgtg	21	107
19680	Coding	17	2568	actaagacattacgggct	1	108
19681	Coding	17	2656	tcctccatcagcattgta	36	109
19682	Coding	17	2766	ccaaaggtcatcagttcc	19	110
19683	Coding	17	2890	catccaacatttgaccat	12	111
19684	Coding	17	2936	actcagcagccagttcct	0	112
19685	Coding	17	3016	gtcatttggactgggaag	32	113
19686	Coding	17	3058	ttccaaatcctcttcac	0	114
19687	Coding	17	3113	gaggtgggatgttgaaag	0	115
19688	Coding	17	3233	cagcaaaacctccatctc	15	116
19689	Coding	17	3316	ctcagcagtagcaccctg	31	117
19690	Coding	17	3393	tgggtgctactgtcctct	28	118
19691	Coding	17	3488	gtttgtctcgcataaggag	14	119
19692	Coding	17	3515	ccactggattcaggtatt	0	120
19693	Coding	17	3633	ggctcattcacataactca	13	121
19694	Coding	17	3701	ttgacagtattgttgttct	0	122
19695	Coding	17	3747	ttccagtagtcagggttg	16	123
19696	Coding	17	3780	tgctgaaggggtgctccga	0	124
19697	Coding	17	3870	aggtattcaggattctct	22	125
19698	Coding	17	3922	tctgtaaggtggaggcgg	15	126
19699	3'UTR	17	4052	agtgtcaaaaactactggc	25	127
19700	3'UTR	17	4107	gttcaagttaggtaagca	0	128
19701	3'UTR	17	4138	ctatctttctctttcagt	0	129
19702	3'UTR	17	4171	atgcagagaaatgaagaa	0	130
19703	3'UTR	17	4229	cagcattgccttacattt	29	131
19704	3'UTR	17	4334	gtgtttcaaccatctgct	31	132
19705	3'UTR	17	4420	tttgttctaattggaaact	0	133
19706	3'UTR	17	4608	cagagcaaaaacaaaatga	0	134
19707	3'UTR	17	4809	aggatgaggggtgaagata	25	135
19708	3'UTR	17	4880	tactcttcagacaaccaa	0	136
19709	3'UTR	17	4921	gttttcctgaaccacaga	29	137
19710	3'UTR	17	4993	acatacccaatccagtgt	53	138
19711	3'UTR	17	5069	aaaatggagttcagaaaa	0	139
19712	3'UTR	17	5218	gcctctcatcatagtccc	36	140
19713	3'UTR	17	5365	gagttaccttctacttca	17	141
19714	3'UTR	17	5455	cacatttatattacaactt	10	142

As shown in Table 1, SEQ ID NOs 19, 20, 21, 23, 24, 29, 30, 31, 32, 33, 36, 38, 42, 43, 44, 45, 46, 48, 49, 50, 52, 53, 54, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 96, 98, 99, 100, 101, 103, 105, 106, 107, 109, 113, 117, 118, 125, 127, 131, 132, 135, 137, 138 and 140 demonstrated at least 20% inhibition of human inducible nitric oxide synthase expression in this assay and are therefore preferred.

Example 17

Antisense inhibition of mouse inducible nitric oxide synthase expression by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap.

In accordance with the present invention, a second series of oligonucleotides were designed to target different regions of the mouse inducible nitric oxide synthase RNA, using published sequences (GenBank accession number M87039, incorporated herein as SEQ ID NO: 18). The oligonucleotides are shown in Table 2. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 2 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on mouse inducible nitric oxide synthase mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments. If present, "N.D." indicates "no data".

Table 2

Inhibition of mouse inducible nitric oxide synthase mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	%INHIB	SEQ ID NO
105449	5'UTR	18	30	gtaaagttgtgaccctggca	0	143
105450	5'UTR	18	226	ttgcacttctgctccaaatc	0	144
105451	Coding	18	281	ttggtaggatttgactttga	0	145

-87-

105452	Coding	18	373	ctcttaggggtcatcttgtat	6	146
105453	Coding	18	456	tcgatgtcacatgcagcttg	16	147
105454	Coding	18	543	tgaaatccgatgtggccttg	52	148
105455	Coding	18	621	gggtaggcttgtctctgggt	0	149
105456	Coding	18	646	gcatgaggcaggagctcctc	0	150
105457	Coding	18	805	ttcctccaggccatcttgggt	0	151
105458	Coding	18	1012	atgagctgtgaattccagag	26	152
105459	Coding	18	1106	cttcagcctaggtcgatgc	22	153
105460	Coding	18	1180	atttcaaagacctctggatc	0	154
105461	Coding	18	1292	ctccagtagcatgttggcca	0	155
105462	Coding	18	1448	ccagagggaggccagtgtgt	8	156
105463	Coding	18	1511	cacattctgcttctggaaac	13	157
105464	Coding	18	1577	ggcccgggtactcattctgca	5	158
105465	Coding	18	1678	ggagataggacatagttcaa	0	159
105466	Coding	18	1721	ccagatgtgggtcttccagg	3	160
105467	Coding	18	1766	tctaaatcggatctctctcc	5	161
105468	Coding	18	1853	agtagcaaaggagactgtgg	6	162
105469	Coding	18	1992	tgcttgtcaccaccagcagt	0	163
105470	Coding	18	2118	actgagggtacatgctggag	0	164
105471	Coding	18	2231	gctgcggaaggcatcctcct	0	165
105472	Coding	18	2357	ctggatgagcctatatattgt	4	166
105473	Coding	18	2394	tgctgagggtctctgttgagg	0	167
105474	Coding	18	2466	ggctggacttttcaactctgc	22	168
105475	Coding	18	2519	gtagctgggcccctcggtgc	0	169
105476	Coding	18	2607	gtgtaggacaatccacaact	12	170
105477	Coding	18	2703	tgagggtctggctgagtgg	0	171
105478	Coding	18	2802	aggcctccaatctctgccta	0	172
105479	Coding	18	2873	ctcttcaagcacctccagga	16	173
105480	Coding	18	2925	agataggagctgcgacagc	0	174
105481	Coding	18	3021	catctcgggtgcggtagggtg	0	175
105482	Coding	18	3117	agccactgacacttcgcaca	12	176
105483	Coding	18	3266	gcacccaaacaccaagctca	0	177
105484	Coding	18	3351	agcctgtgtgcacctggaac	0	178
105485	Coding	18	3389	ctgaacgtagaccttgggtt	2	179
105486	Coding	18	3514	accagcttcttcaatgtggt	25	180
105487	Coding	18	3601	aagatatcttcatgataacg	20	181
105488	Coding	18	3669	agagcctcgtggcttgggc	0	182

As shown in Table 2, SEQ ID NOs 148, 152, 153, 168 and 180 demonstrated at least 20% inhibition of mouse inducible nitric oxide synthase expression in this experiment and are therefore preferred.

Example 17

Western blot analysis of inducible nitric oxide synthase protein levels

Western blot analysis (immunoblot analysis) is carried out using standard methods. Cells are harvested 16-20 h after oligonucleotide treatment, washed once with PBS,

-88-

suspended in Laemmli buffer (100 ul/well), boiled for 5 minutes and loaded on a 16% SDS-PAGE gel. Gels are run for 1.5 hours at 150 V, and transferred to membrane for western blotting. Appropriate primary antibody directed to inducible nitric oxide synthase is used, with a radiolabelled or fluorescently labeled secondary antibody directed against the primary antibody species. Bands are visualized using a PHOSPHORIMAGER™ (Molecular Dynamics, Sunnyvale CA).

What is claimed is:

1. An antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding inducible nitric oxide synthase, wherein said antisense compound specifically hybridizes with and inhibits the expression of inducible nitric oxide synthase.

2. The antisense compound of claim 1 which is an antisense oligonucleotide.

3. The antisense compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 19, 20, 21, 23, 24, 29, 30, 31, 32, 33, 36, 38, 42, 43, 44, 45, 46, 48, 49, 50, 52, 53, 54, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 96, 98, 99, 100, 101, 103, 105, 106, 107, 109, 113, 117, 118, 125, 127, 131, 132, 135, 137, 138, 140, 148, 152, 153, 168 or 180.

4. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

5. The antisense compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

6. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

7. The antisense compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

8. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

9. The antisense compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

10. The antisense compound of claim 2 wherein the

antisense oligonucleotide is a chimeric oligonucleotide.

11. A composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

12. The composition of claim 11 further comprising a colloidal dispersion system.

13. The composition of claim 11 wherein the antisense compound is an antisense oligonucleotide.

14. A method of inhibiting the expression of inducible nitric oxide synthase in cells or tissues comprising contacting said cells or tissues with the antisense compound of claim 1 so that expression of inducible nitric oxide synthase is inhibited.

15. A method of treating a human having a disease or condition associated with inducible nitric oxide synthase comprising administering to said animal a therapeutically or prophylactically effective amount of the antisense compound of claim 1 so that expression of inducible nitric oxide synthase is inhibited.

16. The method of claim 15 wherein the disease or condition is diabetes.

17. The method of claim 15 wherein the disease or condition is an immunological disorder.

18. The method of claim 15 wherein the disease or condition is a cardiovascular disorder.

19. The method of claim 15 wherein the disease or condition is a neurologic disorder.

20. The method of claim 15 wherein the disease or condition is ischemia/reperfusion injury.

SEQUENCE LISTING

<110> Isis Pharmaceuticals, Inc.
 C. Frank Bennett
 Nicholas M. Dean
 Lex M. Cowsert

<120> ANTISENSE MODULATION OF INDUCIBLE NITRIC OXIDE SYNTHASE
 EXPRESSION

<130> RTSP-0098

<150> 09/490,208

<151> 2000-01-24

<160> 182

<210> 1

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 1

tccgtcatcg ctcttcaggg

20

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 2

atgcattctg cccccaagga

20

<210> 3

<211> 4145

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (207)...(3668)

<400> 3

ctgctttaaa atctctcggc cacctttgat gaggggactg ggcagttcta gacagtcccg

60

aagttctcaa ggcacaggtc tcttcctggg ttgactgtcc ttaccccgagg gaggcagtgc

120

agccagctgc aagccccaca gtgaagaaca tctgagctca aatccagata agtgacataa

180

gtgacctgct ttgtaaagcc atagag atg gcc tgt cct tgg aaa ttt ctg ttc
 Met Ala Cys Pro Trp Lys Phe Leu Phe

233

1

5

aag acc aaa ttc cac cag tat gca atg aat ggg gaa aaa gac atc aac

281

Lys Thr Lys Phe His Gln Tyr Ala Met Asn Gly Glu Lys Asp Ile Asn

10

15

20

25

aac aat gtg gag aaa gcc ccc tgt gcc acc tcc agt cca gtg aca cag

329

Asn Asn Val Glu Lys Ala Pro Cys Ala Thr Ser Ser Pro Val Thr Gln

30										35										40											
gat	gac	ctt	cag	tat	cac	aac	ctc	agc	aag	cag	cag	aat	gag	tcc	ccg																377
Asp	Asp	Leu	Gln	Tyr	His	Asn	Leu	Ser	Lys	Gln	Gln	Asn	Glu	Ser	Pro																
			45					50					55																		
cag	ccc	ctc	gtg	gag	acg	gga	aag	aag	tct	cca	gaa	tct	ctg	gtc	aag																425
Gln	Pro	Leu	Val	Glu	Thr	Gly	Lys	Lys	Ser	Pro	Glu	Ser	Leu	Val	Lys																
		60					65					70																			
ctg	gat	gca	acc	cca	ttg	tcc	tcc	cca	cgg	cat	gtg	agg	atc	aaa	aac																473
Leu	Asp	Ala	Thr	Pro	Leu	Ser	Ser	Pro	Arg	His	Val	Arg	Ile	Lys	Asn																
	75					80					85																				
tgg	ggc	agc	ggg	atg	act	ttc	caa	gac	aca	ctt	cac	cat	aag	gcc	aaa																521
Trp	Gly	Ser	Gly	Met	Thr	Phe	Gln	Asp	Thr	Leu	His	His	Lys	Ala	Lys																
	90				95					100				105																	
ggg	att	tta	act	tgc	agg	tcc	aaa	tct	tgc	ctg	ggg	tcc	att	atg	act																569
Gly	Ile	Leu	Thr	Cys	Arg	Ser	Lys	Ser	Cys	Leu	Gly	Ser	Ile	Met	Thr																
			110						115					120																	
ccc	aaa	agt	ttg	acc	aga	gga	ccc	agg	gac	aag	cct	acc	cct	cca	gat																617
Pro	Lys	Ser	Leu	Thr	Arg	Gly	Pro	Arg	Asp	Lys	Pro	Thr	Pro	Pro	Asp																
			125					130					135																		
gag	ctt	cta	cct	caa	gct	atc	gaa	ttt	gtc	aac	caa	tat	tac	ggc	tcc																665
Glu	Leu	Leu	Pro	Gln	Ala	Ile	Glu	Phe	Val	Asn	Gln	Tyr	Tyr	Gly	Ser																
		140					145					150																			
ttc	aaa	gag	gca	aaa	ata	gag	gaa	cat	ctg	gcc	agg	gtg	gaa	gcg	gta																713
Phe	Lys	Glu	Ala	Lys	Ile	Glu	Glu	His	Leu	Ala	Arg	Val	Glu	Ala	Val																
	155					160					165																				
aca	aag	gag	ata	gaa	aca	aca	gga	acc	tac	caa	ctg	acg	gga	gat	gag																761
Thr	Lys	Glu	Ile	Glu	Thr	Thr	Gly	Thr	Tyr	Gln	Leu	Thr	Gly	Asp	Glu																
	170				175					180				185																	
ctc	atc	ttc	gcc	acc	aag	cag	gcc	tgg	cgc	aat	gcc	cca	cgc	tgc	att																809
Leu	Ile	Phe	Ala	Thr	Lys	Gln	Ala	Trp	Arg	Asn	Ala	Pro	Arg	Cys	Ile																
			190						195					200																	
ggg	agg	atc	cag	tgg	tcc	aac	ctg	cag	gtc	ttc	gat	gcc	cgc	agc	tgt																857
Gly	Arg	Ile	Gln	Trp	Ser	Asn	Leu	Gln	Val	Phe	Asp	Ala	Arg	Ser	Cys																
			205					210					215																		
tcc	act	gcc	cgg	gaa	atg	ttt	gaa	cac	atc	tgc	aga	cac	gtg	cgt	tac																905
Ser	Thr	Ala	Arg	Glu	Met	Phe	Glu	His	Ile	Cys	Arg	His	Val	Arg	Tyr																
		220					225					230																			
tcc	acc	aac	aat	ggc	aac	atc	agg	tcg	gcc	atc	acc	gtg	ttc	ccc	cag																953
Ser	Thr	Asn	Asn	Gly	Asn	Ile	Arg	Ser	Ala	Ile	Thr	Val	Phe	Pro	Gln																
		235				240					245																				
cgg	agt	gat	ggc	aag	cac	gac	ttc	cgg	gtg	tgg	aat	gct	cag	ctc	atc																1001
Arg	Ser	Asp	Gly	Lys	His	Asp	Phe	Arg	Val	Trp	Asn	Ala	Gln	Leu	Ile																
	250				255				260					265																	
cgc	tat	gct	ggc	tac	cag	atg	cca	gat	ggc	agc	atc	aga	ggg	gac	cct																1049
Arg	Tyr	Ala	Gly	Tyr	Gln	Met	Pro	Asp	Gly	Ser	Ile	Arg	Gly	Asp	Pro																
			270						275					280																	
gcc	aac	gtg	gaa	ttc	act	cag	ctg	tgc	atc	gac	ctg	ggc	tgg	aag	ccc																1097
Ala	Asn	Val	Glu	Phe	Thr	Gln	Leu	Cys	Ile	Asp	Leu	Gly	Trp	Lys	Pro																
			285					290					295																		

aag tac ggc cgc ttc gat gtg gtc ccc ctg gtc ctg cag gcc aat ggc	1145
Lys Tyr Gly Arg Phe Asp Val Val Pro Leu Val Leu Gln Ala Asn Gly	
300 305 310	
cgt gac cct gag ctc ttc gaa atc cca cct gac ctt gtg ctt gag gtg	1193
Arg Asp Pro Glu Leu Phe Glu Ile Pro Pro Asp Leu Val Leu Glu Val	
315 320 325	
gcc atg gaa cat ccc aaa tac gag tgg ttt cgg gaa ctg gag cta aag	1241
Ala Met Glu His Pro Lys Tyr Glu Trp Phe Arg Glu Leu Glu Leu Lys	
330 335 340 345	
tgg tac gcc ctg cct gca gtg gcc aac atg ctg ctt gag gtg ggc ggc	1289
Trp Tyr Ala Leu Pro Ala Val Ala Asn Met Leu Leu Glu Val Gly Gly	
350 355 360	
ctg gag ttc cca ggg tgc ccc ttc aat ggc tgg tac atg ggc aca gag	1337
Leu Glu Phe Gly Cys Pro Phe Asn Gly Trp Tyr Met Gly Thr Glu	
365 370 375	
atc gga gtc cgg gac ttc tgt gac gtc cag cgc tac aac atc ctg gag	1385
Ile Gly Val Arg Asp Phe Cys Asp Val Gln Arg Tyr Asn Ile Leu Glu	
380 385 390	
gaa gtg ggc agg aga atg ggc ctg gaa acg cac aag ctg gcc tcg ctc	1433
Glu Val Gly Arg Arg Met Gly Leu Glu Thr His Lys Leu Ala Ser Leu	
395 400 405	
tgg aaa gac cag gct gtc gtt gag atc aac att gct gtg atc cat agt	1481
Trp Lys Asp Gln Ala Val Val Glu Ile Asn Ile Ala Val Ile His Ser	
410 415 420 425	
ttt cag aag cag aat gtg acc atc atg gac cac cac tcg gct gca gaa	1529
Phe Gln Lys Gln Asn Val Thr Ile Met Asp His His Ser Ala Ala Glu	
430 435 440	
tcc ttc atg aag tac atg cag aat gaa tac cgg tcc cgt ggg ggc tgc	1577
Ser Phe Met Lys Tyr Met Gln Asn Glu Tyr Arg Ser Arg Gly Gly Cys	
445 450 455	
ccg gca gac tgg att tgg ctg gtc cct ccc atg tct ggg agc atc acc	1625
Pro Ala Asp Trp Ile Trp Leu Val Pro Pro Met Ser Gly Ser Ile Thr	
460 465 470	
ccc gtg ttt cac cag gag atg ctg aac tac gtc ctg tcc cct ttc tac	1673
Pro Val Phe His Gln Glu Met Leu Asn Tyr Val Leu Ser Pro Phe Tyr	
475 480 485	
tac tat cag gta gag gcc tgg aaa acc cat gtc tgg cag gac gag aag	1721
Tyr Tyr Gln Val Glu Ala Trp Lys Thr His Val Trp Gln Asp Glu Lys	
490 495 500 505	
cgg aga ccc aag aga aga gag att cca ttg aaa gtc ttg gtc aaa gct	1769
Arg Arg Pro Lys Arg Arg Glu Ile Pro Leu Lys Val Leu Val Lys Ala	
510 515 520	
gtg ctc ttt gcc tgt atg ctg atg cgc aag aca atg gcg tcc cga gtc	1817
Val Leu Phe Ala Cys Met Leu Met Arg Lys Thr Met Ala Ser Arg Val	
525 530 535	
aga gtc acc atc ctc ttt gcg aca gag aca gga aaa tca gag gcg ctg	1865
Arg Val Thr Ile Leu Phe Ala Thr Glu Thr Gly Lys Ser Glu Ala Leu	
540 545 550	
gcc tgg gac ctg ggg gcc tta ttc agc tgt gcc ttc aac ccc aag gtt	1913
Ala Trp Asp Leu Gly Ala Leu Phe Ser Cys Ala Phe Asn Pro Lys Val	

555	560	565	
gtc tgc atg gat aag tac agg ctg agc tgc ctg gag gag gaa cgg ctg Val Cys Met Asp Lys Tyr Arg Leu Ser Cys Leu Glu Glu Glu Arg Leu 570 575 580 585			1961
ctg ttg gtg gtg acc agt acg ttt ggc aat gga gac tgc cct ggc aat Leu Leu Val Val Thr Ser Thr Phe Gly Asn Gly Asp Cys Pro Gly Asn 590 595 600			2009
gga gag aaa ctg aag aaa tcg ctc ttc atg ctg aaa gag ctc aac aac Gly Glu Lys Leu Lys Lys Ser Leu Phe Met Leu Lys Glu Leu Asn Asn 605 610 615			2057
aaa ttc agg tac gct gtg ttt ggc ctc ggc tcc agc atg tac cct cgg Lys Phe Arg Tyr Ala Val Phe Gly Leu Gly Ser Ser Met Tyr Pro Arg 620 625 630			2105
ttc tgc gcc ttt gct cat gac att gat cag aag ctg tcc cac ctg ggg Phe Cys Ala Phe Ala His Asp Ile Asp Gln Lys Leu Ser His Leu Gly 635 640 645			2153
gcc tct cag ctc acc ccg atg gga gaa ggg gat gag ctc agt ggg cag Ala Ser Gln Leu Thr Pro Met Gly Glu Gly Asp Glu Leu Ser Gly Gln 650 655 660 665			2201
gag gac gcc ttc cgc agc tgg gcc gtg caa acc ttc aag gca gcc tgt Glu Asp Ala Phe Arg Ser Trp Ala Val Gln Thr Phe Lys Ala Ala Cys 670 675 680			2249
gag acg ttt gat gtc cga ggc aaa cag cac att cag atc ccc aag ctc Glu Thr Phe Asp Val Arg Gly Lys Gln His Ile Gln Ile Pro Lys Leu 685 690 695			2297
tac acc tcc aat gtg acc tgg gac ccg cac cac tac agg ctc gtg cag Tyr Thr Ser Asn Val Thr Trp Asp Pro His His Tyr Arg Leu Val Gln 700 705 710			2345
gac tca cag cct ttg gac ctc agc aaa gcc ctc agc agc atg cat gcc Asp Ser Gln Pro Leu Asp Leu Ser Lys Ala Leu Ser Ser Met His Ala 715 720 725			2393
aag aac gtg ttc acc atg agg ctc aaa tct cgg cag aat cta caa agt Lys Asn Val Phe Thr Met Arg Leu Lys Ser Arg Gln Asn Leu Gln Ser 730 735 740 745			2441
ccg aca tcc agc cgt gcc acc atc ctg gtg gaa ctc tcc tgt gag gat Pro Thr Ser Ser Arg Ala Thr Ile Leu Val Glu Leu Ser Cys Glu Asp 750 755 760			2489
ggc caa ggc ctg aac tac ctg ccg ggg gag cac ctt ggg gtt tgc cca Gly Gln Gly Leu Asn Tyr Leu Pro Gly Glu His Leu Gly Val Cys Pro 765 770 775			2537
ggc aac cag ccg gcc ctg gtc caa ggc atc ctg gag cga gtg gtg gat Gly Asn Gln Pro Ala Leu Val Gln Gly Ile Leu Glu Arg Val Val Asp 780 785 790			2585
ggc ccc aca ccc cac cag aca gtg cgc ctg gag gac ctg gat gag agt Gly Pro Thr Pro His Gln Thr Val Arg Leu Glu Asp Leu Asp Glu Ser 795 800 805			2633
ggc agc tac tgg gtc agt gac aag agg ctg ccc ccc tgc tca ctc agc Gly Ser Tyr Trp Val Ser Asp Lys Arg Leu Pro Pro Cys Ser Leu Ser 810 815 820 825			2681

cag gcc ctc acc tac tcc ccg gac atc acc aca ccc cca acc cag ctg	2729
Gln Ala Leu Thr Tyr Ser Pro Asp Ile Thr Thr Pro Pro Thr Gln Leu	
830 835 840	
ctg ctc caa aag ctg gcc cag gtg gcc aca gaa gag cct gag aga cag	2777
Leu Leu Gln Lys Leu Ala Gln Val Ala Thr Glu Glu Pro Glu Arg Gln	
845 850 855	
agg ctg gag gcc ctg tgc cag ccc tca gag tac agc aag tgg aag ttc	2825
Arg Leu Glu Ala Leu Cys Gln Pro Ser Glu Tyr Ser Lys Trp Lys Phe	
860 865 870	
acc aac agc ccc aca ttc ctg gag gtg cta gag gag ttc ccg tcc ctg	2873
Thr Asn Ser Pro Thr Phe Leu Glu Val Leu Glu Glu Phe Pro Ser Leu	
875 880 885	
cgg gtg tct gct ggc ttc ctg ctt tcc cag ctc ccc att ctg aag ccc	2921
Arg Val Ser Ala Gly Phe Leu Leu Ser Gln Leu Pro Ile Leu Lys Pro	
890 895 900 905	
agg ttc tac tcc atc agc tcc tcc cgg gat cac acg ccc acg gag atc	2969
Arg Phe Tyr Ser Ile Ser Ser Ser Arg Asp His Thr Pro Thr Glu Ile	
910 915 920	
cac ctg act gtg gcc gtg gtc acc tac cac acc gga gat ggc cag ggt	3017
His Leu Thr Val Ala Val Val Thr Tyr His Thr Gly Asp Gly Gln Gly	
925 930 935	
ccc ctg cac cac ggt gtc tgc agc aca tgg ctc aac agc ctg aag ccc	3065
Pro Leu His His Gly Val Cys Ser Thr Trp Leu Asn Ser Leu Lys Pro	
940 945 950	
caa gac cca gtg ccc tgc ttt gtg cgg aat gcc agc gcc ttc cac ctc	3113
Gln Asp Pro Val Pro Cys Phe Val Arg Asn Ala Ser Ala Phe His Leu	
955 960 965	
ccc gag gat ccc tcc cat cct tgc atc ctc atc ggg cct ggc aca ggc	3161
Pro Glu Asp Pro Ser His Pro Cys Ile Leu Ile Gly Pro Gly Thr Gly	
970 975 980 985	
atc gtg ccc ttc cgc agt ttc tgg cag caa cgg ctc cat gac tcc cag	3209
Ile Val Pro Phe Arg Ser Phe Trp Gln Gln Arg Leu His Asp Ser Gln	
990 995 1000	
cac aag gga gtg cgg gga ggc cgc atg acc ttg gtg ttt ggg tgc cgc	3257
His Lys Gly Val Arg Gly Gly Arg Met Thr Leu Val Phe Gly Cys Arg	
1005 1010 1015	
cgc cca gat gag gac cac atc tac cag gag gag atg ctg gag atg gcc	3305
Arg Pro Asp Glu Asp His Ile Tyr Gln Glu Glu Met Leu Glu Met Ala	
1020 1025 1030	
cag aag ggg gtg ctg cat gcg gtg cac aca gcc tat tcc cgc ctg cct	3353
Gln Lys Gly Val Leu His Ala Val His Thr Ala Tyr Ser Arg Leu Pro	
1035 1040 1045	
ggc aag ccc aag gtc tat gtt cag gac atc ctg cgg cag cag ctg gcc	3401
Gly Lys Pro Lys Val Tyr Val Gln Asp Ile Leu Arg Gln Gln Leu Ala	
1050 1055 1060 1065	
agc gag gtg ctc cgt gtg ctc cac aag gag cca ggc cac ctc tat gtt	3449
Ser Glu Val Leu Arg Val Leu His Lys Glu Pro Gly His Leu Tyr Val	
1070 1075 1080	
tgc ggg gat gtg cgc atg gcc cgg gac gtg gcc cac acc ctg aag cag	3497
Cys Gly Asp Val Arg Met Ala Arg Asp Val Ala His Thr Leu Lys Gln	

1085	1090	1095	
ctg gtg gct gcc aag ctg aaa ttg aat gag gag cag gtc gag gac tat			3545
Leu Val Ala Ala Lys Leu Lys	Leu Asn Glu Glu Gln Val Glu Asp Tyr		
1100	1105	1110	
ttc ttt cag ctc aag agc cag aag cgc tat cac gaa gat atc ttc ggt			3593
Phe Phe Gln Leu Lys Ser Gln Lys Arg Tyr His Glu Asp Ile Phe Gly			
1115	1120	1125	
gct gta ttt cct tac gag gcg aag aag gac agg gtg gcg gtg cag ccc			3641
Ala Val Phe Pro Tyr Glu Ala Lys Lys Asp Arg Val Ala Val Gln Pro			
1130	1135	1140	1145
agc agc ctg gag atg tca gcg ctc tga gggcctacag gaggggttaa			3688
Ser Ser Leu Glu Met Ser Ala Leu			
1150			
agctgccggc acagaactta aggatggagc cagctctgca ttatctgagg tcacagggcc			3748
tggggagatg gaggaagtgt atatccccca gcctcaagtc ttatttcctc aacgttgctc			3808
cccatcaagc cctttacttg acctcctaac aagtagcacc ctggattgat cggagcctcc			3868
tctctcaaac tggggcctcc ctggtccctt ggagacaaaa tcttaaattgc caggcctggc			3928
gagtgggtga aagatggaac ttgctgctga gtgcaccact tcaagtgacc accaggaggt			3988
gctatcgcac cactgtgtat ttaactgcct tgtgtacagt tatttatgcc tctgtattta			4048
aaaaactaac acccagtcctg ttcccatgg ccacttgggt cttccctgta tgattccttg			4108
atggagatat ttacatgaat tgcattttac tttaatc			4145
<210> 4			
<211> 21			
<212> DNA			
<213> Artificial Sequence			
<223> PCR Primer			
<400> 4			
ggtggaagcg gtaacaaagg a			21
<210> 5			
<211> 19			
<212> DNA			
<213> Artificial Sequence			
<223> PCR Primer			
<400> 5			
tgcttgggtgg cgaagatga			19
<210> 6			
<211> 30			
<212> DNA			
<213> Artificial Sequence			
<223> PCR Probe			
<400> 6			
aacaacagga acctaccaac tgacgggaga			30

<210> 7
 <211> 19
 <212> DNA
 <213> Artificial Sequence

<223> PCR Primer

<400> 7
 gaaggtgaag gtcggagtc 19

<210> 8
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> PCR Primer

<400> 8
 gaagatggtg atgggatttc 20

<210> 9
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> PCR Probe

<400> 9
 caagcttccc gttctcagcc 20

<210> 10
 <211> 4145
 <212> DNA
 <213> Mus musculus

<220>
 <221> mRNA
 <222> (1)...(4110)

<400> 10
 ctgctttaaa atctctcggc cacctttgat gaggggactg ggcagttcta gacagtcccg 60

aagttctcaa ggcacaggtc tcttctcggg ttgactgtcc ttaccccgagg gaggcagtgc 120

agccagctgc aagccccaca gtgaagaaca tctgagctca aatccagata agtgacataa 180

gtgacctgct ttgtaaagcc atagag atg gcc tgt cct tgg aaa ttt ctg ttc 233
 Met Ala Cys Pro Trp Lys Phe Leu Phe
 1 5

aag acc aaa ttc cac cag tat gca atg aat ggg gaa aaa gac atc aac 281
 Lys Thr Lys Phe His Gln Tyr Ala Met Asn Gly Glu Lys Asp Ile Asn
 10 15 20 25

aac aat gtg gag aaa gcc ccc tgt gcc acc tcc agt cca gtg aca cag 329
 Asn Asn Val Glu Lys Ala Pro Cys Ala Thr Ser Ser Pro Val Thr Gln
 30 35 40

gat gac ctt cag tat cac aac ctc agc aag cag cag aat gag tcc ccg 377
 Asp Asp Leu Gln Tyr His Asn Leu Ser Lys Gln Gln Asn Glu Ser Pro
 45 50 55

cag	ccc	ctc	gtg	gag	acg	gga	aag	aag	tct	cca	gaa	tct	ctg	gtc	aag	425
Gln	Pro	Leu	Val	Glu	Thr	Gly	Lys	Lys	Ser	Pro	Glu	Ser	Leu	Val	Lys	
		60					65					70				
ctg	gat	gca	acc	cca	ttg	tcc	tcc	cca	cgg	cat	gtg	agg	atc	aaa	aac	473
Leu	Asp	Ala	Thr	Pro	Leu	Ser	Ser	Pro	Arg	His	Val	Arg	Ile	Lys	Asn	
	75					80					85					
tgg	ggc	agc	ggg	atg	act	ttc	caa	gac	aca	ctt	cac	cat	aag	gcc	aaa	521
Trp	Gly	Ser	Gly	Met	Thr	Phe	Gln	Asp	Thr	Leu	His	His	Lys	Ala	Lys	
	90				95					100					105	
ggg	att	tta	act	tgc	agg	tcc	aaa	tct	tgc	ctg	ggg	tcc	att	atg	act	569
Gly	Ile	Leu	Thr	Cys	Arg	Ser	Lys	Ser	Cys	Leu	Gly	Ser	Ile	Met	Thr	
				110					115					120		
ccc	aaa	agt	ttg	acc	aga	gga	ccc	agg	gac	aag	cct	acc	cct	cca	gat	617
Pro	Lys	Ser	Leu	Thr	Arg	Gly	Pro	Arg	Asp	Lys	Pro	Thr	Pro	Pro	Asp	
			125					130					135			
gag	ctt	cta	cct	caa	gct	atc	gaa	ttt	gtc	aac	caa	tat	tac	ggc	tcc	665
Glu	Leu	Leu	Pro	Gln	Ala	Ile	Glu	Phe	Val	Asn	Gln	Tyr	Tyr	Gly	Ser	
		140					145					150				
ttc	aaa	gag	gca	aaa	ata	gag	gaa	cat	ctg	gcc	agg	gtg	gaa	gcg	gta	713
Phe	Lys	Glu	Ala	Lys	Ile	Glu	Glu	His	Leu	Ala	Arg	Val	Glu	Ala	Val	
	155					160					165					
aca	aag	gag	ata	gaa	aca	aca	gga	acc	tac	caa	ctg	acg	gga	gat	gag	761
Thr	Lys	Glu	Ile	Glu	Thr	Thr	Gly	Thr	Tyr	Gln	Leu	Thr	Gly	Asp	Glu	
	170				175					180					185	
ctc	atc	ttc	gcc	acc	aag	cag	gcc	tgg	cgc	aat	gcc	cca	cgc	tgc	att	809
Leu	Ile	Phe	Ala	Thr	Lys	Gln	Ala	Trp	Arg	Asn	Ala	Pro	Arg	Cys	Ile	
				190					195					200		
ggg	agg	atc	cag	tgg	tcc	aac	ctg	cag	gtc	ttc	gat	gcc	cgc	agc	tgt	857
Gly	Arg	Ile	Gln	Trp	Ser	Asn	Leu	Gln	Val	Phe	Asp	Ala	Arg	Ser	Cys	
			205					210					215			
tcc	act	gcc	cgg	gaa	atg	ttt	gaa	cac	atc	tgc	aga	cac	gtg	cgt	tac	905
Ser	Thr	Ala	Arg	Glu	Met	Phe	Glu	His	Ile	Cys	Arg	His	Val	Arg	Tyr	
		220					225					230				
tcc	acc	aac	aat	ggc	aac	atc	agg	tcg	gcc	atc	acc	gtg	ttc	ccc	cag	953
Ser	Thr	Asn	Asn	Gly	Asn	Ile	Arg	Ser	Ala	Ile	Thr	Val	Phe	Pro	Gln	
	235					240					245					
cgg	agt	gat	ggc	aag	cac	gac	ttc	cgg	gtg	tgg	aat	gct	cag	ctc	atc	1001
Arg	Ser	Asp	Gly	Lys	His	Asp	Phe	Arg	Val	Trp	Asn	Ala	Gln	Leu	Ile	
	250				255					260					265	
cgc	tat	gct	ggc	tac	cag	atg	cca	gat	ggc	agc	atc	aga	ggg	gac	cct	1049
Arg	Tyr	Ala	Gly	Tyr	Gln	Met	Pro	Asp	Gly	Ser	Ile	Arg	Gly	Asp	Pro	
				270					275					280		
gcc	aac	gtg	gaa	ttc	act	cag	ctg	tgc	atc	gac	ctg	ggc	tgg	aag	ccc	1097
Ala	Asn	Val	Glu	Phe	Thr	Gln	Leu	Cys	Ile	Asp	Leu	Gly	Trp	Lys	Pro	
			285					290					295			
aag	tac	ggc	cgc	ttc	gat	gtg	gtc	ccc	ctg	gtc	ctg	cag	gcc	aat	ggc	1145
Lys	Tyr	Gly	Arg	Phe	Asp	Val	Val	Pro	Leu	Val	Leu	Gln	Ala	Asn	Gly	
		300					305					310				
cgt	gac	cct	gag	ctc	ttc	gaa	atc	cca	cct	gac	ctt	gtg	ctt	gag	gtg	1193
Arg	Asp	Pro	Glu	Leu	Phe	Glu	Ile	Pro	Pro	Asp	Leu	Val	Leu	Glu	Val	

315	320	325	
gcc atg gaa cat ccc aaa tac gag tgg ttt cgg gaa ctg gag cta aag Ala Met Glu His Pro Lys Tyr Glu Trp Phe Arg Glu Leu Glu Leu Lys 330 335 340 345			1241
tgg tac gcc ctg cct gca gtg gcc aac atg ctg ctt gag gtg ggc ggc Trp Tyr Ala Leu Pro Ala Val Ala Asn Met Leu Leu Glu Val Gly Gly 350 355 360			1289
ctg gag ttc cca ggg tgc ccc ttc aat ggc tgg tac atg ggc aca gag Leu Glu Phe Pro Gly Cys Pro Phe Asn Gly Trp Tyr Met Gly Thr Glu 365 370 375			1337
atc gga gtc cgg gac ttc tgt gac gtc cag cgc tac aac atc ctg gag Ile Gly Val Arg Asp Phe Cys Asp Val Gln Arg Tyr Asn Ile Leu Glu 380 385 390			1385
gaa gtg ggc agg aga atg ggc ctg gaa acg cac aag ctg gcc tcg ctc Glu Val Gly Arg Arg Met Gly Leu Glu Thr His Lys Leu Ala Ser Leu 395 400 405			1433
tgg aaa gac cag gct gtc gtt gag atc aac att gct gtg atc cat agt Trp Lys Asp Gln Ala Val Val Glu Ile Asn Ile Ala Val Ile His Ser 410 415 420 425			1481
ttt cag aag cag aat gtg acc atc atg gac cac cac tcg gct gca gaa Phe Gln Lys Gln Asn Val Thr Ile Met Asp His His Ser Ala Ala Glu 430 435 440			1529
tcc ttc atg aag tac atg cag aat gaa tac cgg tcc cgt ggg ggc tgc Ser Phe Met Lys Tyr Met Gln Asn Glu Tyr Arg Ser Arg Gly Gly Cys 445 450 455			1577
ccg gca gac tgg att tgg ctg gtc cct ccc atg tct ggg agc atc acc Pro Ala Asp Trp Ile Trp Leu Val Pro Pro Met Ser Gly Ser Ile Thr 460 465 470			1625
ccc gtg ttt cac cag gag atg ctg aac tac gtc ctg tcc cct ttc tac Pro Val Phe His Gln Glu Met Leu Asn Tyr Val Leu Ser Pro Phe Tyr 475 480 485			1673
tac tat cag gta gag gcc tgg aaa acc cat gtc tgg cag gac gag aag Tyr Tyr Gln Val Glu Ala Trp Lys Thr His Val Trp Gln Asp Glu Lys 490 495 500 505			1721
cgg aga ccc aag aga aga gag att cca ttg aaa gtc ttg gtc aaa gct Arg Arg Pro Lys Arg Arg Glu Ile Pro Leu Lys Val Leu Val Lys Ala 510 515 520			1769
gtg ctc ttt gcc tgt atg ctg atg cgc aag aca atg gcg tcc cga gtc Val Leu Phe Ala Cys Met Leu Met Arg Lys Thr Met Ala Ser Arg Val 525 530 535			1817
aga gtc acc atc ctc ttt gcg aca gag aca gga aaa tca gag gcg ctg Arg Val Thr Ile Leu Phe Ala Thr Glu Thr Gly Lys Ser Glu Ala Leu 540 545 550			1865
gcc tgg gac ctg ggg gcc tta ttc agc tgt gcc ttc aac ccc aag gtt Ala Trp Asp Leu Gly Ala Leu Phe Ser Cys Ala Phe Asn Pro Lys Val 555 560 565			1913
gtc tgc atg gat aag tac agg ctg agc tgc ctg gag gag gaa cgg ctg Val Cys Met Asp Lys Tyr Arg Leu Ser Cys Leu Glu Glu Glu Arg Leu 570 575 580 585			1961

ctg	ttg	gtg	gtg	acc	agt	acg	ttt	ggc	aat	gga	gac	tgc	cct	ggc	aat	2009
Leu	Leu	Val	Val	Thr	Ser	Thr	Phe	Gly	Asn	Gly	Asp	Cys	Pro	Gly	Asn	
				590					595					600		
gga	gag	aaa	ctg	aag	aaa	tgc	ctc	ttc	atg	ctg	aaa	gag	ctc	aac	aac	2057
Gly	Glu	Lys	Leu	Lys	Lys	Ser	Leu	Phe	Met	Leu	Lys	Glu	Leu	Asn	Asn	
			605					610					615			
aaa	ttc	agg	tac	gct	gtg	ttt	ggc	ctc	ggc	tcc	agc	atg	tac	cct	cgg	2105
Lys	Phe	Arg	Tyr	Ala	Val	Phe	Gly	Leu	Gly	Ser	Ser	Met	Tyr	Pro	Arg	
		620					625					630				
ttc	tgc	gcc	ttt	gct	cat	gac	att	gat	cag	aag	ctg	tcc	cac	ctg	ggg	2153
Phe	Cys	Ala	Phe	Ala	His	Asp	Ile	Asp	Gln	Lys	Leu	Ser	His	Leu	Gly	
	635					640					645					
gcc	tct	cag	ctc	acc	ccg	atg	gga	gaa	ggg	gat	gag	ctc	agt	ggg	cag	2201
Ala	Ser	Gln	Leu	Thr	Pro	Met	Gly	Glu	Gly	Asp	Glu	Leu	Ser	Gly	Gln	
650					655				660						665	
gag	gac	gcc	ttc	cgc	agc	tgg	gcc	gtg	caa	acc	ttc	aag	gca	gcc	tgt	2249
Glu	Asp	Ala	Phe	Arg	Ser	Trp	Ala	Val	Gln	Thr	Phe	Lys	Ala	Ala	Cys	
				670					675					680		
gag	acg	ttt	gat	gtc	cga	ggc	aaa	cag	cac	att	cag	atc	ccc	aag	ctc	2297
Glu	Thr	Phe	Asp	Val	Arg	Gly	Lys	Gln	His	Ile	Gln	Ile	Pro	Lys	Leu	
			685					690					695			
tac	acc	tcc	aat	gtg	acc	tgg	gac	ccg	cac	cac	tac	agg	ctc	gtg	cag	2345
Tyr	Thr	Ser	Asn	Val	Thr	Trp	Asp	Pro	His	His	Tyr	Arg	Leu	Val	Gln	
		700					705					710				
gac	tca	cag	cct	ttg	gac	ctc	agc	aaa	gcc	ctc	agc	agc	atg	cat	gcc	2393
Asp	Ser	Gln	Pro	Leu	Asp	Leu	Ser	Lys	Ala	Leu	Ser	Ser	Met	His	Ala	
	715					720					725					
aag	aac	gtg	ttc	acc	atg	agg	ctc	aaa	tct	cgg	cag	aat	cta	caa	agt	2441
Lys	Asn	Val	Phe	Thr	Met	Arg	Leu	Lys	Ser	Arg	Gln	Asn	Leu	Gln	Ser	
730					735					740					745	
ccg	aca	tcc	agc	cgt	gcc	acc	atc	ctg	gtg	gaa	ctc	tcc	tgt	gag	gat	2489
Pro	Thr	Ser	Ser	Arg	Ala	Thr	Ile	Leu	Val	Glu	Leu	Ser	Cys	Glu	Asp	
				750					755					760		
ggc	caa	ggc	ctg	aac	tac	ctg	ccg	ggg	gag	cac	ctt	ggg	gtt	tgc	cca	2537
Gly	Gln	Gly	Leu	Asn	Tyr	Leu	Pro	Gly	Glu	His	Leu	Gly	Val	Cys	Pro	
			765					770					775			
ggc	aac	cag	ccg	gcc	ctg	gtc	caa	ggc	atc	ctg	gag	cga	gtg	gtg	gat	2585
Gly	Asn	Gln	Pro	Ala	Leu	Val	Gln	Gly	Ile	Leu	Glu	Arg	Val	Val	Asp	
		780					785					790				
ggc	ccc	aca	ccc	cac	cag	aca	gtg	cgc	ctg	gag	gac	ctg	gat	gag	agt	2633
Gly	Pro	Thr	Pro	His	Gln	Thr	Val	Arg	Leu	Glu	Asp	Leu	Asp	Glu	Ser	
	795					800					805					
ggc	agc	tac	tgg	gtc	agt	gac	aag	agg	ctg	ccc	ccc	tgc	tca	ctc	agc	2681
Gly	Ser	Tyr	Trp	Val	Ser	Asp	Lys	Arg	Leu	Pro	Pro	Cys	Ser	Leu	Ser	
810					815					820					825	
cag	gcc	ctc	acc	tac	tcc	ccg	gac	atc	acc	aca	ccc	cca	acc	cag	ctg	2729
Gln	Ala	Leu	Thr	Tyr	Ser	Pro	Asp	Ile	Thr	Thr	Pro	Pro	Thr	Gln	Leu	
				830					835					840		
ctg	ctc	caa	aag	ctg	gcc	cag	gtg	gcc	aca	gaa	gag	cct	gag	aga	cag	2777
Leu	Leu	Gln	Lys	Leu	Ala	Gln	Val	Ala	Thr	Glu	Glu	Pro	Glu	Arg	Gln	

845				850				855								
agg	ctg	gag	gcc	ctg	tgc	cag	ccc	tca	gag	tac	agc	aag	tgg	aag	ttc	2825
Arg	Leu	Glu	Ala	Leu	Cys	Gln	Pro	Ser	Glu	Tyr	Ser	Lys	Trp	Lys	Phe	
860				865				870								
acc	aac	agc	ccc	aca	ttc	ctg	gag	gtg	cta	gag	gag	ttc	ccg	tcc	ctg	2873
Thr	Asn	Ser	Pro	Thr	Phe	Leu	Glu	Val	Leu	Glu	Glu	Phe	Pro	Ser	Leu	
875				880				885								
cgg	gtg	tct	gct	ggc	ttc	ctg	ctt	tcc	cag	ctc	ccc	att	ctg	aag	ccc	2921
Arg	Val	Ser	Ala	Gly	Phe	Leu	Leu	Ser	Gln	Leu	Pro	Ile	Leu	Lys	Pro	
890				895				900				905				
agg	ttc	tac	tcc	atc	agc	tcc	tcc	cgg	gat	cac	acg	ccc	acg	gag	atc	2969
Arg	Phe	Tyr	Ser	Ile	Ser	Ser	Ser	Arg	Asp	His	Thr	Pro	Thr	Glu	Ile	
910				915				920								
cac	ctg	act	gtg	gcc	gtg	gtc	acc	tac	cac	acc	gga	gat	ggc	cag	ggc	3017
His	Leu	Thr	Val	Ala	Val	Val	Thr	Tyr	His	Thr	Gly	Asp	Gly	Gln	Gly	
925				930				935								
ccc	ctg	cac	cac	ggc	gtc	tgc	agc	aca	tgg	ctc	aac	agc	ctg	aag	ccc	3065
Pro	Leu	His	His	Gly	Val	Cys	Ser	Thr	Trp	Leu	Asn	Ser	Leu	Lys	Pro	
940				945				950								
caa	gac	cca	gtg	ccc	tgc	ttt	gtg	cgg	aat	gcc	agc	gcc	ttc	cac	ctc	3113
Gln	Asp	Pro	Val	Pro	Cys	Phe	Val	Arg	Asn	Ala	Ser	Ala	Phe	His	Leu	
955				960				965								
ccc	gag	gat	ccc	tcc	cat	cct	tgc	atc	ctc	atc	ggg	cct	ggc	aca	ggc	3161
Pro	Glu	Asp	Pro	Ser	His	Pro	Cys	Ile	Leu	Ile	Gly	Pro	Gly	Thr	Gly	
970				975				980				985				
atc	gtg	ccc	ttc	cgc	agt	ttc	tgg	cag	caa	cgg	ctc	cat	gac	tcc	cag	3209
Ile	Val	Pro	Phe	Arg	Ser	Phe	Trp	Gln	Gln	Arg	Leu	His	Asp	Ser	Gln	
990				995				1000								
cac	aag	gga	gtg	cgg	gga	ggc	cgc	atg	acc	ttg	gtg	ttt	ggg	tgc	cgc	3257
His	Lys	Gly	Val	Arg	Gly	Gly	Arg	Met	Thr	Leu	Val	Phe	Gly	Cys	Arg	
1005				1010				1015								
cgc	cca	gat	gag	gac	cac	atc	tac	cag	gag	gag	atg	ctg	gag	atg	gcc	3305
Arg	Pro	Asp	Glu	Asp	His	Ile	Tyr	Gln	Glu	Glu	Met	Leu	Glu	Met	Ala	
1020				1025				1030								
cag	aag	ggg	gtg	ctg	cat	gcg	gtg	cac	aca	gcc	tat	tcc	cgc	ctg	cct	3353
Gln	Lys	Gly	Val	Leu	His	Ala	Val	His	Thr	Ala	Tyr	Ser	Arg	Leu	Pro	
1035				1040				1045								
ggc	aag	ccc	aag	gtc	tat	gtt	cag	gac	atc	ctg	cgg	cag	cag	ctg	gcc	3401
Gly	Lys	Pro	Lys	Val	Tyr	Val	Gln	Asp	Ile	Leu	Arg	Gln	Gln	Leu	Ala	
1050				1055				1060				1065				
agc	gag	gtg	ctc	cgt	gtg	ctc	cac	aag	gag	cca	ggc	cac	ctc	tat	gtt	3449
Ser	Glu	Val	Leu	Arg	Val	Leu	His	Lys	Glu	Pro	Gly	His	Leu	Tyr	Val	
1070				1075				1080								
tgc	ggg	gat	gtg	cgc	atg	gcc	cgg	gac	gtg	gcc	cac	acc	ctg	aag	cag	3497
Cys	Gly	Asp	Val	Arg	Met	Ala	Arg	Asp	Val	Ala	His	Thr	Leu	Lys	Gln	
1085				1090				1095								
ctg	gtg	gct	gcc	aag	ctg	aaa	ttg	aat	gag	gag	cag	gtc	gag	gac	tat	3545
Leu	Val	Ala	Ala	Lys	Leu	Lys	Leu	Asn	Glu	Glu	Gln	Val	Glu	Asp	Tyr	
1100				1105				1110								

ttc ttt cag ctc aag agc cag aag cgc tat cac gaa gat atc ttc ggt 3593
 Phe Phe Gln Leu Lys Ser Gln Lys Arg Tyr His Glu Asp Ile Phe Gly
 1115 1120 1125

gct gta ttt cct tac gag gcg aag aag gac agg gtg gcg gtg cag ccc 3641
 Ala Val Phe Pro Tyr Glu Ala Lys Lys Asp Arg Val Ala Val Gln Pro
 1130 1135 1140 1145

agc agc ctg gag atg tca gcg ctc tga gggcctacag gaggggttaa 3688
 Ser Ser Leu Glu Met Ser Ala Leu
 1150

agctgccggc acagaactta aggatggagc cagctctgca ttatctgagg tcacagggcc 3748

tggggagatg gaggaaagtg atatccccc gcctcaagtc ttatttcctc aacgttgctc 3808

cccatcaagc cctttacttg acctcctaac aagtagcacc ctggattgat cggagcctcc 3868

tctctcaaac tggggcctcc ctggtcctct ggagacaaaa tcttaaatgc caggcctggc 3928

gagtgggtga aagatggaac ttgctgctga gtgcaccact tcaagtgacc accaggaggt 3988

gctatcgcac cactgtgtat ttaactgcct tgtgtacagt tatttatgcc tctgtattta 4048

aaaaactaac acccagtctg ttcccatgg ccacttgggt cttccctgta tgattccttg 4108

atggagatat ttacatgaat tgcattttac tttaatc 4145

<210> 11

<211> 23

<212> DNA

<213> Artificial Sequence

<223> PCR Primer

<400> 11

cgtccacagt atgtgaggat caa

23

<210> 12

<211> 22

<212> DNA

<213> Artificial Sequence

<223> PCR Primer

<400> 12

caagcaagac ttggacttgc aa

22

<210> 13

<211> 26

<212> DNA

<213> Artificial Sequence

<223> PCR Probe

<400> 13

tcttcaccac aaggccacat cggatt

26

<210> 14

<211> 20

<212> DNA

<213> Artificial Sequence

<223> PCR Primer

<400> 14

ggcaaattca acggcacagt

20

<210> 15

<211> 20

<212> DNA

<213> Artificial Sequence

<223> PCR Primer

<400> 15

gggtctcgct cctggaagct

20

<210> 16

<211> 27

<212> DNA

<213> Artificial Sequence

<223> PCR Probe

<400> 16

aaggccgaga atgggaagct tgtcatc

27

<210> 17

<211> 5484

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (34)...(3960)

<400> 17

aattgtcagc acgggatctg agacttccaa aaa atg aag ccg gcg aca gga ctt
Met Lys Pro Ala Thr Gly Leu
1 5

54

tgg gtc tgg gtg agc ctt ctc gtg gcg gcg ggg acc gtc cag ccc agc
Trp Val Trp Val Ser Leu Leu Val Ala Ala Gly Thr Val Gln Pro Ser
10 15 20

102

gat tct cag tca gtg tgt gca gga acg gag aat aaa ctg agc tct ctc
Asp Ser Gln Ser Val Cys Ala Gly Thr Glu Asn Lys Leu Ser Ser Leu
25 30 35

150

tct gac ctg gaa cag cag tac cga gcc ttg cgc aag tac tat gaa aac
Ser Asp Leu Glu Gln Gln Tyr Arg Ala Leu Arg Lys Tyr Tyr Glu Asn
40 45 50 55

198

tgt gag gtt gtc atg ggc aac ctg gag ata acc agc att gag cac aac
Cys Glu Val Val Met Gly Asn Leu Glu Ile Thr Ser Ile Glu His Asn
60 65 70

246

cgg gac ctc tcc ttc ctg cgg tct gtt cga gaa gtc aca ggc tac gtg
Arg Asp Leu Ser Phe Leu Arg Ser Val Arg Glu Val Thr Gly Tyr Val
75 80 85

294

tta gtg gct ctt aat cag ttt cgt tac ctg cct ctg gag aat tta cgc
Leu Val Ala Leu Asn Gln Phe Arg Tyr Leu Pro Leu Glu Asn Leu Arg
90 95 100

342

att Ile 105	att Ile 105	cgt Arg	ggg Gly	aca Thr	aaa Lys	ctt Leu 110	tat Tyr	gag Glu	gat Asp	cga Arg	tat Tyr 115	gcc Ala	ttg Leu	gca Ala	ata Ile	390
ttt Phe 120	tta Leu	aac Asn	tac Tyr	aga Arg	aaa Lys 125	gat Asp	gga Gly	aac Asn	ttt Phe	gga Gly 130	ctt Leu	caa Gln	gaa Glu	ctt Leu	gga Gly 135	438
tta Leu	aag Lys	aac Asn	ttg Leu	aca Thr 140	gaa Glu	atc Ile	cta Leu	aat Asn	ggg Gly 145	gga Gly	gtc Val	tat Tyr	gta Val	gac Asp 150	cag Gln	486
aac Asn	aaa Lys	ttc Phe 155	ctt Leu	tgt Cys	tat Tyr	gca Ala	gac Asp	acc Thr 160	att Ile	cat His	tgg Trp	caa Gln	gat Asp 165	att Ile	gtt Val	534
cgg Arg	aac Asn	cca Pro 170	tgg Trp	cct Pro	tcc Ser	aac Asn	ttg Leu 175	act Thr	ctt Leu	gtg Val	tca Ser 180	aca Thr	aat Asn	ggg Gly	agt Ser	582
tca Ser 185	gga Gly	tgt Cys	gga Gly	cgt Arg	tgc Cys	cat His 190	aag Lys	tcc Ser	tgt Cys	act Thr 195	ggc Gly 195	cgt Arg	tgc Cys	tgg Trp	gga Gly	630
ccc Pro 200	aca Thr	gaa Glu	aat Asn	cat His	tgc Cys 205	cag Gln	act Thr	ttg Leu	aca Thr	agg Arg 210	acg Thr	gtg Val	tgt Cys	gca Ala	gaa Glu 215	678
caa Gln	tgt Cys	gac Asp	ggc Gly	aga Arg 220	tgc Cys	tac Tyr	gga Gly	cct Pro	tac Tyr 225	gtc Val	agt Ser	gac Asp	tgc Cys	tgc Cys 230	cat His	726
cga Arg	gaa Glu	tgt Cys	gct Ala 235	gga Gly	ggc Gly	tgc Cys	tca Ser	gga Gly 240	cct Pro	aag Lys	gac Asp	aca Thr	gac Asp 245	tgc Cys	ttt Phe	774
gcc Ala	tgc Cys	atg Met 250	aat Asn	ttc Phe	aat Asn	gac Asp	agt Ser 255	gga Gly	gca Ala	tgt Cys	gtt Val	act Thr 260	cag Gln	tgt Cys	ccc Pro	822
caa Gln 265	acc Thr	ttt Phe	gtc Val	tac Tyr	aat Asn 270	cca Pro	acc Thr	acc Thr	ttt Phe	caa Gln	ctg Leu 275	gag Glu	cac His	aat Asn	ttc Phe	870
aat Asn 280	gca Ala	aag Lys	tac Tyr	aca Thr	tat Tyr 285	gga Gly	gca Ala	ttc Phe	tgt Cys	gtc Val 290	aag Lys	aaa Lys	tgt Cys	cca Pro	cat His 295	918
aac Asn	ttt Phe	gtg Val	gta Val	gat Asp 300	tcc Ser	agt Ser	tct Ser	tgt Cys	gtg Val 305	cgt Arg	gcc Ala	tgc Cys	cct Pro	agt Ser 310	tcc Ser	966
aag Lys	atg Met	gaa Glu 315	gta Val	gaa Glu	gaa Glu	aat Asn	ggg Gly 320	att Ile	aaa Lys	atg Met	tgt Cys	aaa Lys	cct Pro 325	tgc Cys	act Thr	1014
gac Asp	att Ile 330	tgc Cys	cca Pro	aaa Lys	gct Ala	tgt Cys	gat Asp 335	ggc Gly	att Ile	ggc Gly	aca Thr	gga Gly 340	tca Ser	ttg Leu	atg Met	1062
tca Ser 345	gct Ala	cag Gln	act Thr	gtg Val	gat Asp	tcc Ser	agt Ser	aac Asn	att Ile	gac Asp	aaa Lys 355	ttc Phe	ata Ile	aac Asn	tgt Cys	1110
acc Thr	aag Lys	atc Ile	aat Asn	ggg Gly	aat Asn	ttg Leu	atc Ile	ttt Phe	cta Leu	gtc Val	act Thr	ggg Gly	att Ile	cat His	ggg Gly	1158

360	365	370	375	
gac cct tac aat gca att gaa gcc ata gac cca gag aaa ctg aac gtc Asp Pro Tyr Asn Ala Ile Glu Ala Ile Asp Pro Glu Lys Leu Asn Val 380 385 390				1206
ttt cgg aca gtc aga gag ata aca ggt ttc ctg aac ata cag tca tgg Phe Arg Thr Val Arg Glu Ile Thr Gly Phe Leu Asn Ile Gln Ser Trp 395 400 405				1254
cca cca aac atg act gac ttc agt gtt ttt tct aac ctg gtg acc att Pro Pro Asn Met Thr Asp Phe Ser Val Phe Ser Asn Leu Val Thr Ile 410 415 420				1302
ggt gga aga gta ctc tat agt ggc ctg tcc ttg ctt atc ctc aag caa Gly Gly Arg Val Leu Tyr Ser Gly Leu Ser Leu Leu Ile Leu Lys Gln 425 430 435				1350
cag ggc atc acc tct cta cag ttc cag tcc ctg aag gaa atc agc gca Gln Gly Ile Thr Ser Leu Gln Phe Gln Ser Leu Lys Glu Ile Ser Ala 440 445 450 455				1398
gga aac atc tat att act gac aac agc aac ctg tgt tat tat cat acc Gly Asn Ile Tyr Ile Thr Asp Asn Ser Asn Leu Cys Tyr Tyr His Thr 460 465 470				1446
att aac tgg aca aca ctc ttc agc aca atc aac cag aga ata gta atc Ile Asn Trp Thr Thr Leu Phe Ser Thr Ile Asn Gln Arg Ile Val Ile 475 480 485				1494
cgg gac aac aga aaa gct gaa aat tgt act gct gaa gga atg gtg tgc Arg Asp Asn Arg Lys Ala Glu Asn Cys Thr Ala Glu Gly Met Val Cys 490 495 500				1542
aac cat ctg tgt tcc agt gat ggc tgt tgg gga cct ggg cca gac caa Asn His Leu Cys Ser Ser Asp Gly Cys Trp Gly Pro Gly Pro Asp Gln 505 510 515				1590
tgt ctg tcg tgt cgc cgc ttc agt aga gga agg atc tgc ata gag tct Cys Leu Ser Cys Arg Arg Phe Ser Arg Gly Arg Ile Cys Ile Glu Ser 520 525 530 535				1638
tgt aac ctc tat gat ggt gaa ttt cgg gag ttt gag aat ggc tcc atc Cys Asn Leu Tyr Asp Gly Glu Phe Arg Glu Phe Glu Asn Gly Ser Ile 540 545 550				1686
tgt gtg gag tgt gac ccc cag tgt gag aag atg gaa gat ggc ctc ctc Cys Val Glu Cys Asp Pro Gln Cys Glu Lys Met Glu Asp Gly Leu Leu 555 560 565				1734
aca tgc cat gga ccg ggt cct gac aac tgt aca aag tgc tct cat ttt Thr Cys His Gly Pro Gly Pro Asp Asn Cys Thr Lys Cys Ser His Phe 570 575 580				1782
aaa gat ggc cca aac tgt gtg gaa aaa tgt cca gat ggc tta cag ggg Lys Asp Gly Pro Asn Cys Val Glu Lys Cys Pro Asp Gly Leu Gln Gly 585 590 595				1830
gca aac agt ttc att ttc aag tat gct gat cca gat cgg gag tgc cac Ala Asn Ser Phe Ile Phe Lys Tyr Ala Asp Pro Asp Arg Glu Cys His 600 605 610 615				1878
cca tgc cat cca aac tgc acc caa ggg tgt aac ggt ccc act agt cat Pro Cys His Pro Asn Cys Thr Gln Gly Cys Asn Gly Pro Thr Ser His 620 625 630				1926

gac tgc att tac tac cca tgg acg ggc cat tcc act tta cca caa cat	1974
Asp Cys Ile Tyr Tyr Pro Trp Thr Gly His Ser Thr Leu Pro Gln His	
635 640 645	
gct aga act ccc ctg att gca gct gga gta att ggt ggg ctc ttc att	2022
Ala Arg Thr Pro Leu Ile Ala Ala Gly Val Ile Gly Gly Leu Phe Ile	
650 655 660	
ctg gtc att gtg ggt ctg aca ttt gct gtt tat gtt aga agg aag agc	2070
Leu Val Ile Val Gly Leu Thr Phe Ala Val Tyr Val Arg Arg Lys Ser	
665 670 675	
atc aaa aag aaa aga gcc ttg aga aga ttc ttg gaa aca gag ttg gtg	2118
Ile Lys Lys Lys Arg Ala Leu Arg Arg Phe Leu Glu Thr Glu Leu Val	
680 685 690 695	
gaa cca tta act ccc agt ggc aca gca ccc aat caa gct caa ctt cgt	2166
Glu Pro Leu Thr Pro Ser Gly Thr Ala Pro Asn Gln Ala Gln Leu Arg	
700 705 710	
att ttg aaa gaa act gag ctg aag agg gta aaa gtc ctt ggc tca ggt	2214
Ile Leu Lys Glu Thr Glu Leu Lys Arg Val Lys Val Leu Gly Ser Gly	
715 720 725	
gct ttt gga acg gtt tat aaa ggt att tgg gta cct gaa gga gaa act	2262
Ala Phe Gly Thr Val Tyr Lys Gly Ile Trp Val Pro Glu Gly Glu Thr	
730 735 740	
gtg aag att cct gtg gct att aag att ctt aat gag aca act ggt ccc	2310
Val Lys Ile Pro Val Ala Ile Lys Ile Leu Asn Glu Thr Thr Gly Pro	
745 750 755	
aag gca aat gtg gag ttc atg gat gaa gct ctg atc atg gca agt atg	2358
Lys Ala Asn Val Glu Phe Met Asp Glu Ala Leu Ile Met Ala Ser Met	
760 765 770 775	
gat cat cca cac cta gtc cgg ttg ctg ggt gtg tgt ctg agc cca acc	2406
Asp His Pro His Leu Val Arg Leu Leu Gly Val Cys Leu Ser Pro Thr	
780 785 790	
atc cag ctg gtt act caa ctt atg ccc cat ggc tgc ctg ttg gag tat	2454
Ile Gln Leu Val Thr Gln Leu Met Pro His Gly Cys Leu Leu Glu Tyr	
795 800 805	
gtc cac gag cac aag gat aac att gga tca caa ctg ctg ctt aac tgg	2502
Val His Glu His Lys Asp Asn Ile Gly Ser Gln Leu Leu Leu Asn Trp	
810 815 820	
tgt gtc cag ata gct aag gga atg atg tac ctg gaa gaa aga cga ctc	2550
Cys Val Gln Ile Ala Lys Gly Met Met Tyr Leu Glu Glu Arg Arg Leu	
825 830 835	
gtt cat cgg gat ttg gca gcc cgt aat gtc tta gtg aaa tct cca aac	2598
Val His Arg Asp Leu Ala Ala Arg Asn Val Leu Val Lys Ser Pro Asn	
840 845 850 855	
cat gtg aaa atc aca gat ttt ggg cta gcc aga ctc ttg gaa gga gat	2646
His Val Lys Ile Thr Asp Phe Gly Leu Ala Arg Leu Leu Glu Gly Asp	
860 865 870	
gaa aaa gag tac aat gct gat gga gga aag atg cca att aaa tgg atg	2694
Glu Lys Glu Tyr Asn Ala Asp Gly Gly Lys Met Pro Ile Lys Trp Met	
875 880 885	
gct ctg gag tgt ata cat tac agg aaa ttc acc cat cag agt gac gtt	2742
Ala Leu Glu Cys Ile His Tyr Arg Lys Phe Thr His Gln Ser Asp Val	

890						895						900						
tgg	agc	tat	gga	gtt	act	ata	tgg	gaa	ctg	atg	acc	ttt	gga	gga	aaa	2790		
Trp	Ser	Tyr	Gly	Val	Thr	Ile	Trp	Glu	Leu	Met	Thr	Phe	Gly	Gly	Lys			
	905					910					915							
ccc	tat	gat	gga	att	cca	acg	cga	gaa	atc	cct	gat	tta	tta	gag	aaa	2838		
Pro	Tyr	Asp	Gly	Ile	Pro	Thr	Arg	Glu	Ile	Pro	Asp	Leu	Leu	Glu	Lys			
920					925					930					935			
gga	gaa	cgt	ttg	cct	cag	cct	ccc	atc	tgc	act	att	gac	gtt	tac	atg	2886		
Gly	Glu	Arg	Leu	Pro	Gln	Pro	Pro	Ile	Cys	Thr	Ile	Asp	Val	Tyr	Met			
				940					945					950				
gtc	atg	gtc	aaa	tgt	tgg	atg	att	gat	gct	gac	agt	aga	cct	aaa	ttt	2934		
Val	Met	Val	Lys	Cys	Trp	Met	Ile	Asp	Ala	Asp	Ser	Arg	Pro	Lys	Phe			
			955					960					965					
aag	gaa	ctg	gct	gct	gag	ttt	tca	agg	atg	gct	cga	gac	cct	caa	aga	2982		
Lys	Glu	Leu	Ala	Ala	Glu	Phe	Ser	Arg	Met	Ala	Arg	Asp	Pro	Gln	Arg			
		970					975					980						
tac	cta	gtt	att	cag	ggc	gat	gat	cgt	atg	aag	ctt	ccc	agt	cca	aat	3030		
Tyr	Leu	Val	Ile	Gln	Gly	Asp	Asp	Arg	Met	Lys	Leu	Pro	Ser	Pro	Asn			
	985					990					995							
gac	agc	aag	ttc	ttt	cag	aat	ctc	ttg	gat	gaa	gag	gat	ttg	gaa	gat	3078		
Asp	Ser	Lys	Phe	Phe	Gln	Asn	Leu	Leu	Asp	Glu	Glu	Asp	Leu	Glu	Asp			
1000					1005					1010					1015			
atg	atg	gat	gct	gag	gag	tac	ttg	gtc	cct	cag	gct	ttc	aac	atc	cca	3126		
Met	Met	Asp	Ala	Glu	Glu	Tyr	Leu	Val	Pro	Gln	Ala	Phe	Asn	Ile	Pro			
				1020					1025					1030				
cct	ccc	atc	tat	act	tcc	aga	gca	aga	att	gac	tcg	aat	agg	agt	gaa	3174		
Pro	Pro	Ile	Tyr	Thr	Ser	Arg	Ala	Arg	Ile	Asp	Ser	Asn	Arg	Ser	Glu			
			1035					1040					1045					
att	gga	cac	agc	cct	cct	cct	gcc	tac	acc	ccc	atg	tca	gga	aac	cag	3222		
Ile	Gly	His	Ser	Pro	Pro	Pro	Ala	Tyr	Thr	Pro	Met	Ser	Gly	Asn	Gln			
		1050					1055				1060							
ttt	gta	tac	cga	gat	gga	ggc	ttt	gct	gct	gaa	caa	gga	gtg	tct	gtg	3270		
Phe	Val	Tyr	Arg	Asp	Gly	Gly	Phe	Ala	Ala	Glu	Gln	Gly	Val	Ser	Val			
	1065					1070					1075							
ccc	tac	aga	gcc	cca	act	agc	aca	att	cca	gaa	gct	cct	gtg	gca	cag	3318		
Pro	Tyr	Arg	Ala	Pro	Thr	Ser	Thr	Ile	Pro	Glu	Ala	Pro	Val	Ala	Gln			
1080					1085					1090					1095			
ggc	gct	act	gct	gag	att	ttt	gat	gac	tcc	tgc	tgt	aat	ggc	acc	cta	3366		
Gly	Ala	Thr	Ala	Glu	Ile	Phe	Asp	Asp	Ser	Cys	Cys	Asn	Gly	Thr	Leu			
				1100					1105					1110				
cgc	aag	cca	gtg	gca	ccc	cat	gtc	caa	gag	gac	agt	agc	acc	cag	agg	3414		
Arg	Lys	Pro	Val	Ala	Pro	His	Val	Gln	Glu	Asp	Ser	Ser	Thr	Gln	Arg			
			1115					1120					1125					
tac	agt	gct	gac	ccc	acc	gtg	ttt	gcc	cca	gaa	cgg	agc	cca	cga	gga	3462		
Tyr	Ser	Ala	Asp	Pro	Thr	Val	Phe	Ala	Pro	Glu	Arg	Ser	Pro	Arg	Gly			
		1130					1135					1140						
gag	ctg	gat	gag	gaa	ggc	tac	atg	act	cct	atg	cga	gac	aaa	ccc	aaa	3510		
Glu	Leu	Asp	Glu	Glu	Gly	Tyr	Met	Thr	Pro	Met	Arg	Asp	Lys	Pro	Lys			
	1145					1150					1155							

caa gaa tac ctg aat cca gtg gag gag aac cct ttt gtt tct cgg aga	3558
Gln Glu Tyr Leu Asn Pro Val Glu Glu Asn Pro Phe Val Ser Arg Arg	
1160 1165 1170 1175	
aaa aat gga gac ctt caa gca ttg gat aat ccc gaa tat cac aat gca	3606
Lys Asn Gly Asp Leu Gln Ala Leu Asp Asn Pro Glu Tyr His Asn Ala	
1180 1185 1190	
tcc aat ggt cca ccc aag gcc gag gat gag tat gtg aat gag cca ctg	3654
Ser Asn Gly Pro Pro Lys Ala Glu Asp Glu Tyr Val Asn Glu Pro Leu	
1195 1200 1205	
tac ctc aac acc ttt gcc aac acc ttg gga aaa gct gag tac ctg aag	3702
Tyr Leu Asn Thr Phe Ala Asn Thr Leu Gly Lys Ala Glu Tyr Leu Lys	
1210 1215 1220	
aac aac ata ctg tca atg cca gag aag gcc aag aaa gcg ttt gac aac	3750
Asn Asn Ile Leu Ser Met Pro Glu Lys Ala Lys Lys Ala Phe Asp Asn	
1225 1230 1235	
cct gac tac tgg aac cac agc ctg cca cct cgg agc acc ctt cag cac	3798
Pro Asp Tyr Trp Asn His Ser Leu Pro Pro Arg Ser Thr Leu Gln His	
1240 1245 1250 1255	
cca gac tac ctg cag gag tac agc aca aaa tat ttt tat aaa cag aat	3846
Pro Asp Tyr Leu Gln Glu Tyr Ser Thr Lys Tyr Phe Tyr Lys Gln Asn	
1260 1265 1270	
ggg cgg atc cgg cct att gtg gca gag aat cct gaa tac ctc tct gag	3894
Gly Arg Ile Arg Pro Ile Val Ala Glu Asn Pro Glu Tyr Leu Ser Glu	
1275 1280 1285	
ttc tcc ctg aag cca ggc act gtg ctg ccg cct cca cct tac aga cac	3942
Phe Ser Leu Lys Pro Gly Thr Val Leu Pro Pro Pro Pro Tyr Arg His	
1290 1295 1300	
cgg aat act gtg gtg taa gctcagttgt gggttttttag gtggagagac acacctgctc	4000
Arg Asn Thr Val Val	
1305	
caattttcccc accccctctt ctttctctgg tgggtcttctt tctaccccaa ggccagtagt	4060
tttgacactt cccagtggaa gatacagaga tgcaatgata gttatgtgct tacctaactt	4120
gaacattaga gggaaagact gaaagagaaa gataggagga accacaatgt ttcttcattt	4180
ctctgcatgg gttggtcagg agaatgaaac agctagagaa ggaccagaaa atgtaaggca	4240
atgctgoccta ctatcaaact agctgtcact ttttttcttt ttctttttct ttctttgttt	4300
ctttcttctt cttctttttt tttttttttt taaagcagat gggtgaaaca cccatgctat	4360
ctgttcttat ctgcaggaac tgatgtgtgc atatttagca tccctggaaa tcataataaa	4420
gtttccatta gaacaaaaga ataacatttt ctataacata tgatagtgtc tgaaattgag	4480
aatccagttt ctttccccag cagtttctgt cctagcaagt aagaatggcc aactcaactt	4540
tcataattta aaaatctcca ttaaagttat aactagtaat tatgttttca acactttttg	4600
gttttttttca ttttgttttg ctctgaccga ttcttttata tttgctcccc tattttttggc	4660
tttaatttct aattgcaaag atgtttacat caaagcttct tcacagaatt taagcaagaa	4720
atattttaat atagtgaaat ggccactact ttaagtatac aatcttttaa ataagaaagg	4780

gaggctaata tttttcatgc tatcaaatta tcttcaccct catcctttac atttttcaac 4840
 attttttttt ctccataaat gacactactt gataggccgt tgggtgtctg aagagtagaa 4900
 gggaaactaa gagacagttc tctgtggttc aggaaaacta ctgatacttt caggggtggc 4960
 ccaatgaggg aatccattga actggaagaa acacactgga ttgggtatgt ctacctggca 5020
 gatactcaga aatgtagttt gcacttaagc tgtaatttta tttgttcttt ttctgaactc 5080
 cattttggat tttgaatcaa gcaatatgga agcaaccagc aaattaacta atttaagtac 5140
 atttttaaaa aaagagctaa gataaagact gtggaaatgc caaaccaagc aaattaggaa 5200
 ccttgcaacg gtatccaggg actatgatga gagggcagca cattatcttc atatgtcacc 5260
 tttgctacgc aaggaaattt gttcagttcg tatacttcgt aagaaggaat gcgagtaagg 5320
 attggcttga attccatgga atttctagta tgagactatt tatatgaagt agaaggtaac 5380
 tctttgcaca taaattggta taataaaaag aaaaacacaa acattcaaag cttagggata 5440
 ggtccttggg tcaaaagttg taaataaatg tgaaacatct tctc 5484

<210> 18

<211> 3690

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (256)...(3690)

<400> 18

ctggaggggt ataaatacct gatggctgct gccaggggtca caactttaca gggagttgaa 60
 gactgagact ctggcccccac gggacacagt gtcactgggt tgaaacttct cagccacctt 120
 ggtgaaggga ctgagctggt agagacactt ctgaggctcc tcacgcttgg gtcttgttca 180
 ctccacggag tagcctagtc aactgcaaga gaacggagaa cgttggattt ggagcagaag 240
 tgcaaagtct cagac atg gct tgc ccc tgg aag ttt ctc ttc aaa gtc aaa 291
 Met Ala Cys Pro Trp Lys Phe Leu Phe Lys Val Lys
 1 5 10
 tcc tac caa agt gac ctg aaa gag gaa aag gac att aac aac aac gtg 339
 Ser Tyr Gln Ser Asp Leu Lys Glu Glu Lys Asp Ile Asn Asn Asn Val
 15 20 25
 aag aaa acc cct tgt gct gtt ctc agc cca aca ata caa gat gac cct 387
 Lys Lys Thr Pro Cys Ala Val Leu Ser Pro Thr Ile Gln Asp Asp Pro
 30 35 40
 aag agt cac caa aat ggc tcc ccg cag ctc ctc act ggg aca gca cag 435
 Lys Ser His Gln Asn Gly Ser Pro Gln Leu Leu Thr Gly Thr Ala Gln
 45 50 55 60
 aat gtt cca gaa tcc ctg gac aag ctg cat gtg aca tcg acc cgt cca 483
 Asn Val Pro Glu Ser Leu Asp Lys Leu His Val Thr Ser Thr Arg Pro
 65 70 75
 cag tat gtg agg atc aaa aac tgg ggc agt gga gag att ttg cat gac 531
 Gln Tyr Val Arg Ile Lys Asn Trp Gly Ser Gly Glu Ile Leu His Asp
 80 85 90

act	ctt	cac	cac	aag	gcc	aca	tcg	gat	ttc	act	tgc	aag	tcc	aag	tct	579
Thr	Leu	His	His	Lys	Ala	Thr	Ser	Asp	Phe	Thr	Cys	Lys	Ser	Lys	Ser	
		95					100					105				
tgc	ttg	ggg	tcc	atc	atg	aac	ccc	aag	agt	ttg	acc	aga	gga	ccc	aga	627
Cys	Leu	Gly	Ser	Ile	Met	Asn	Pro	Lys	Ser	Leu	Thr	Arg	Gly	Pro	Arg	
	110					115					120					
gac	aag	cct	acc	cct	ctg	gag	gag	ctc	ctg	cct	cat	gcc	att	gag	ttc	675
Asp	Lys	Pro	Thr	Pro	Leu	Glu	Glu	Leu	Leu	Pro	His	Ala	Ile	Glu	Phe	
125					130					135					140	
atc	aac	cag	tat	tat	ggc	tcc	ttt	aaa	gag	gca	aaa	ata	gag	gaa	cat	723
Ile	Asn	Gln	Tyr	Tyr	Gly	Ser	Phe	Lys	Glu	Ala	Lys	Ile	Glu	Glu	His	
			145						150					155		
ctg	gcc	agg	ctg	gaa	gct	gta	aca	aag	gaa	ata	gaa	aca	aca	gga	acc	771
Leu	Ala	Arg	Leu	Glu	Ala	Val	Thr	Lys	Glu	Ile	Glu	Thr	Thr	Gly	Thr	
		160						165					170			
tac	cag	ctc	act	ctg	gat	gag	ctc	atc	ttt	gcc	acc	aag	atg	gcc	tgg	819
Tyr	Gln	Leu	Thr	Leu	Asp	Glu	Leu	Ile	Phe	Ala	Thr	Lys	Met	Ala	Trp	
	175					180						185				
agg	aat	gcc	cct	cgc	tgc	atc	ggc	agg	atc	cag	tgg	tcc	aac	ctg	cag	867
Arg	Asn	Ala	Pro	Arg	Cys	Ile	Gly	Arg	Ile	Gln	Trp	Ser	Asn	Leu	Gln	
	190					195					200					
gtc	ttt	gac	gct	cgg	aac	tgt	agc	aca	gca	cag	gaa	atg	ttt	cag	cac	915
Val	Phe	Asp	Ala	Arg	Asn	Cys	Ser	Thr	Ala	Gln	Glu	Met	Phe	Gln	His	
205					210					215					220	
atc	tgc	aga	cac	ata	ctt	tat	gcc	acc	aac	aat	ggc	aac	atc	agg	tcg	963
Ile	Cys	Arg	His	Ile	Leu	Tyr	Ala	Thr	Asn	Asn	Gly	Asn	Ile	Arg	Ser	
			225						230					235		
gcc	atc	act	gtg	ttc	ccc	cag	cgg	agt	gac	ggc	aaa	cat	gac	ttc	agg	1011
Ala	Ile	Thr	Val	Phe	Pro	Gln	Arg	Ser	Asp	Gly	Lys	His	Asp	Phe	Arg	
		240						245					250			
ctc	tgg	aat	tca	cag	ctc	atc	cgg	tac	gct	ggc	tac	cag	atg	ccc	gat	1059
Leu	Trp	Asn	Ser	Gln	Leu	Ile	Arg	Tyr	Ala	Gly	Tyr	Gln	Met	Pro	Asp	
	255						260					265				
ggc	acc	atc	aga	ggg	gat	gct	gcc	acc	ttg	gag	ttc	acc	cag	ttg	tgc	1107
Gly	Thr	Ile	Arg	Gly	Asp	Ala	Ala	Thr	Leu	Glu	Phe	Thr	Gln	Leu	Cys	
	270				275						280					
atc	gac	cta	ggc	tgg	aag	ccc	cgc	tat	ggc	cgc	ttt	gat	gtg	ctg	cct	1155
Ile	Asp	Leu	Gly	Trp	Lys	Pro	Arg	Tyr	Gly	Arg	Phe	Asp	Val	Leu	Pro	
285					290					295					300	
ctg	gtc	ttg	caa	gct	gat	ggc	caa	gat	cca	gag	gtc	ttt	gaa	atc	cct	1203
Leu	Val	Leu	Gln	Ala	Asp	Gly	Gln	Asp	Pro	Glu	Val	Phe	Glu	Ile	Pro	
			305						310					315		
cct	gat	ctt	gtg	ttg	gag	gtg	acc	atg	gag	cat	ccc	aag	tac	gag	tgg	1251
Pro	Asp	Leu	Val	Leu	Glu	Val	Thr	Met	Glu	His	Pro	Lys	Tyr	Glu	Trp	
		320					325						330			
ttc	cag	gag	ctc	ggg	ttg	aag	tgg	tat	gca	ctg	cct	gcc	gtg	gcc	aac	1299
Phe	Gln	Glu	Leu	Gly	Leu	Lys	Trp	Tyr	Ala	Leu	Pro	Ala	Val	Ala	Asn	
	335						340					345				
atg	cta	ctg	gag	gtg	ggc	ggc	ctc	gaa	ttc	cca	gcc	tgc	ccc	ttc	aat	1347
Met	Leu	Leu	Glu	Val	Gly	Gly	Leu	Glu	Phe	Pro	Ala	Cys	Pro	Phe	Asn	

350	355	360	
ggt tgg tac atg ggc acc gag att gga gtt cga gac ttc tgt gac aca Gly Trp Tyr Met Gly Thr Glu Ile Gly Val Arg Asp Phe Cys Asp Thr 365 370 375 380			1395
cag cgc tac aac atc ctg gag gaa gtg ggc cga agg atg ggc ctg gag Gln Arg Tyr Asn Ile Leu Glu Glu Val Gly Arg Arg Met Gly Leu Glu 385 390 395			1443
acc cac aca ctg gcc tcc ctc tgg aaa gac cgg gct gtc acg gag atc Thr His Thr Leu Ala Ser Leu Trp Lys Asp Arg Ala Val Thr Glu Ile 400 405 410			1491
aat gtg gct gtg ctc cat agt ttc cag aag cag aat gtg acc atc atg Asn Val Ala Val Leu His Ser Phe Gln Lys Gln Asn Val Thr Ile Met 415 420 425			1539
gac cac cac aca gcc tca gag tcc ttc atg aag cac atg cag aat gag Asp His His Thr Ala Ser Glu Ser Phe Met Lys His Met Gln Asn Glu 430 435 440			1587
tac cgg gcc cgt gga ggc tgc ccg gca gac tgg att tgg ctg gtc cct Tyr Arg Ala Arg Gly Gly Cys Pro Ala Asp Trp Ile Trp Leu Val Pro 445 450 455 460			1635
cca gtg tct ggg agc atc acc cct gtg ttc cac cag gag atg ttg aac Pro Val Ser Gly Ser Ile Thr Pro Val Phe His Gln Glu Met Leu Asn 465 470 475			1683/
tat gtc cta tct cca ttc tac tac tac cag atc gag ccc tgg aag acc Tyr Val Leu Ser Pro Phe Tyr Tyr Tyr Gln Ile Glu Pro Trp Lys Thr 480 485 490			1731
cac atc tgg cag aat gag aag ctg agg ccc agg agg aga gag atc cga His Ile Trp Gln Asn Glu Lys Leu Arg Pro Arg Arg Arg Glu Ile Arg 495 500 505			1779
ttt aga gtc ttg gtg aaa gtg gtg ttc ttt gct tcc atg cta atg cga Phe Arg Val Leu Val Lys Val Val Phe Phe Ala Ser Met Leu Met Arg 510 515 520			1827
aag gtc atg gct tca cgg gtc aga gcc aca gtc ctc ttt gct act gag Lys Val Met Ala Ser Arg Val Arg Ala Thr Val Leu Phe Ala Thr Glu 525 530 535 540			1875
aca ggg aag tct gaa gca cta gcc agg gac ctg gcc acc ttg ttc agc Thr Gly Lys Ser Glu Ala Leu Ala Arg Asp Leu Ala Thr Leu Phe Ser 545 550 555			1923
tac gcc ttc aac acc aag gtt gtc tgc atg gac cag tat aag gca agc Tyr Ala Phe Asn Thr Lys Val Val Cys Met Asp Gln Tyr Lys Ala Ser 560 565 570			1971
acc ttg gaa gag gag caa cta ctg ctg gtg gtg aca agc aca ttt ggg Thr Leu Glu Glu Glu Gln Leu Leu Leu Val Val Thr Ser Thr Phe Gly 575 580 585			2019
aat gga gac tgt ccc agc aat ggg cag act ctg aag aaa tct ctg ttc Asn Gly Asp Cys Pro Ser Asn Gly Gln Thr Leu Lys Lys Ser Leu Phe 590 595 600			2067
atg ctt aga gaa ctc aac cac acc ttc agg tat gct gtg ttt ggc ctt Met Leu Arg Glu Leu Asn His Thr Phe Arg Tyr Ala Val Phe Gly Leu 605 610 615 620			2115

ggc tcc agc atg tac cct cag ttc tgc gcc ttt gct cat gac atc gac Gly Ser Ser Met Tyr Pro Gln Phe Cys Ala Phe Ala His Asp Ile Asp 625 630 635	2163
cag aag ctg tcc cac ctg gga gcc tct cag ctt gcc cca aca gga gaa Gln Lys Leu Ser His Leu Gly Ala Ser Gln Leu Ala Pro Thr Gly Glu 640 645 650	2211
ggg gac gaa ctc agt ggg cag gag gat gcc ttc cgc agc tgg gct gta Gly Asp Glu Leu Ser Gly Gln Glu Asp Ala Phe Arg Ser Trp Ala Val 655 660 665	2259
caa acc ttc cgg gca gcc tgt gag acc ttt gat gtc cga agc aaa cat Gln Thr Phe Arg Ala Ala Cys Glu Thr Phe Asp Val Arg Ser Lys His 670 675 680	2307
cac att cag atc ccg aaa cgc ttc act tcc aat gca aca tgg gag cca His Ile Gln Ile Pro Lys Arg Phe Thr Ser Asn Ala Thr Trp Glu Pro 685 690 695 700	2355
cag caa tat agg ctc atc cag agc ccg gag cct tta gac ctc aac aga Gln Gln Tyr Arg Leu Ile Gln Ser Pro Glu Pro Leu Asp Leu Asn Arg 705 710 715	2403
gcc ctc agc agc atc cat gca aag aac gtg ttt acc atg agg ctg aaa Ala Leu Ser Ser Ile His Ala Lys Asn Val Phe Thr Met Arg Leu Lys 720 725 730	2451
tcc cag cag aat ctg cag agt gaa aag tcc agc cgc acc acc ctc ctc Ser Gln Gln Asn Leu Gln Ser Glu Lys Ser Ser Arg Thr Thr Leu Leu 735 740 745	2499
gtt cag ctc acc ttc gag ggc agc cga ggg ccc agc tac ctg cct ggg Val Gln Leu Thr Phe Glu Gly Ser Arg Gly Pro Ser Tyr Leu Pro Gly 750 755 760	2547
gaa cac ctg ggg atc ttc cca ggc aac cag acc gcc ctg gtg cag gga Glu His Leu Gly Ile Phe Pro Gly Asn Gln Thr Ala Leu Val Gln Gly 765 770 775 780	2595
atc ttg gag cga gtt gtg gat tgt cct aca cca cac caa act gtg tgc Ile Leu Glu Arg Val Val Asp Cys Pro Thr Pro His Gln Thr Val Cys 785 790 795	2643
ctg gag gtt ctg gat gag agc ggc agc tac tgg gtc aaa gac aag agg Leu Glu Val Leu Asp Glu Ser Gly Ser Tyr Trp Val Lys Asp Lys Arg 800 805 810	2691
ctg ccc ccc tgc tca ctc agc caa gcc ctc acc tac ttc ctg gac att Leu Pro Pro Cys Ser Leu Ser Gln Ala Leu Thr Tyr Phe Leu Asp Ile 815 820 825	2739
acg acc cct ccc acc cag ctg cag ctc cac aag ctg gct cgc ttt gcc Thr Thr Pro Pro Thr Gln Leu Gln Leu His Lys Leu Ala Arg Phe Ala 830 835 840	2787
acg gac gag acg gat agg cag aga ttg gag gcc ttg tgt cag ccc tca Thr Asp Glu Thr Asp Arg Gln Arg Leu Glu Ala Leu Cys Gln Pro Ser 845 850 855 860	2835
gag tac aat gac tgg aag ttc agc aac aac ccc acg ttc ctg gag gtg Glu Tyr Asn Asp Trp Lys Phe Ser Asn Asn Pro Thr Phe Leu Glu Val 865 870 875	2883
ctt gaa gag ttc cct tcc ttg cat gtg ccc gct gcc ttc ctg ctg tgc Leu Glu Glu Phe Pro Ser Leu His Val Pro Ala Ala Phe Leu Leu Ser	2931

880							885							890							
cag Gln	ctc Leu	cct Pro 895	atc Ile	ttg Leu	aag Lys	ccc Pro	cgc Arg 900	tac Tyr	tac Tyr	tcc Ser	atc Ile	agc Ser 905	tcc Ser	tcc Ser	cag Gln	2979					
gac Asp 910	cac His	acc Thr	ccc Pro	tcg Ser	gag Glu	gtt Val 915	cac His	ctc Leu	act Thr	gtg Val	gcc Ala 920	gtg Val	gtc Val	acc Thr	tac Tyr	3027					
cgc Arg 925	acc Thr	cga Arg	gat Asp	ggc Gly	cag Gln 930	ggc Gly	ccc Pro	ctg Leu	cac His	cat His 935	ggc Gly	gtc Val	tgc Cys	agc Ser	act Thr 940	3075					
tgg Trp	atc Ile	agg Arg	aac Asn	ctg Leu 945	aag Lys	ccc Pro	cag Gln	gac Asp	cca Pro 950	gtg Val	ccc Pro	tgc Cys	ttt Phe	gtg Val 955	cga Arg	3123					
agt Ser	gtc Val	agt Ser	ggc Gly 960	ttc Phe	cag Gln	ctc Leu	cct Pro	gag Glu 965	gac Asp	ccc Pro	tcc Ser	cag Gln	cct Pro 970	tgc Cys	atc Ile	3171					
ctc Leu	att Ile	ggg Gly 975	cct Pro	ggc Gly	acg Thr	ggc Gly	att Ile 980	gct Ala	ccc Pro	ttc Phe	cga Arg	agt Ser 985	ttc Phe	tgg Trp	cag Gln	3219					
cag Gln 990	cgg Arg	ctc Leu	cat His	gac Asp	tcc Ser	cag Gln 995	cac His	aaa Lys	ggg Gly	ctc Leu	aaa Lys 1000	gga Gly	ggc Gly	cgc Arg	atg Met	3267					
agc Ser 1005	ttg Leu	gtg Val	ttt Phe	ggg Gly	tgc Cys 1010	cgg Arg	cac His	ccg Pro	gag Glu	gag Glu 1015	gac Asp	cac His	ctc Leu	tat Tyr	cag Gln 1020	3315					
gaa Glu	gaa Glu	atg Met	cag Gln 1025	gag Glu	atg Met	gtc Val	cgc Arg	aag Lys	aga Arg 1030	gtg Val	ctg Leu	ttc Phe	cag Gln	gtg Val 1035	cac His	3363					
aca Thr	ggc Gly	tac Tyr	tcc Ser 1040	cgg Arg	ctg Leu	ccc Pro	ggc Gly	aaa Lys 1045	ccc Pro	aag Lys	gtc Val	tac Tyr	gtt Val 1050	cag Gln	gac Asp	3411					
atc Ile	ctg Leu	caa Gln 1055	aag Lys	cag Gln	ctg Leu	gcc Ala	aat Asn 1060	gag Glu	gta Val	ctc Leu	agc Ser	gtg Val 1065	ctc Leu	cac His	ggg Gly	3459					
gag Glu 1070	cag Gln	ggc Gly	cac His	ctc Leu	tac Tyr	att Ile 1075	tgc Cys	gga Gly	gat Asp	gtg Val	cgc Arg 1080	atg Met	gct Ala	cgg Arg	gat Asp	3507					
gtg Val 1085	gct Ala	acc Thr	aca Thr	ttg Leu	aag Lys 1090	aag Lys	ctg Leu	gtg Val	gcc Ala	acc Thr 1095	aag Lys	ctg Leu	aac Asn	ttg Leu	agc Ser 1100	3555					
gag Glu	gag Glu	cag Gln	gtg Val 1105	gaa Glu	gac Asp	tat Tyr	ttc Phe	ttc Phe	cag Gln 1110	ctc Leu	aag Lys	agc Ser	cag Gln	aaa Lys 1115	cgt Arg	3603					
tat Tyr	cat His	gaa Glu	gat Asp 1120	atc Ile	ttc Phe	ggc Gly	gca Ala	gtc Val 1125	ttt Phe	tcc Ser	tat Tyr	ggg Gly 1130	gca Ala	aaa Lys	aag Lys	3651					
ggc Gly	agc Ser	gcc Ala 1135	ttg Leu	gag Glu	gag Glu	ccc Pro	aaa Lys 1140	gcc Ala	acg Thr	agg Arg	ctc Leu	tga				3690					

<210> 19
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 19
catcaaaggt ggccgaga

18

<210> 20
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 20
ctgtctagaa ctgcccag

18

<210> 21
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 21
tgccttgaga acttcggg

18

<210> 22
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 22
tgtcacttat ctggattt

18

<210> 23
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 23
cttgaacaga aatttcca

18

<210> 24
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 24
tctccacatt gttgttga

18

<210> 25
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 25
ctgaggttgt gatactga 18

<210> 26
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 26
agcttgacca gagattct 18

<210> 27
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 27
gtgaagtgtg tcttggaa 18

<210> 28
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 28
gcaagatttg gacctgca 18

<210> 29
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 29
ccctgggtcc tctgggtca 18

<210> 30
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 30
gccgtaatat tgggtgac 18

<210> 31
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 31
ctccttttggt accgcttc 18

<210> 32
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 32
gctcatctcc cgtcagtt 18

<210> 33
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 33
agacctgcag gttggacc 18

<210> 34
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 34
cgtgtctgca gatgtggt 18

<210> 35
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 35
aagtcgtgct tgccatca 18

<210> 36
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 36
cctctgatgc tgccatct 18

<210> 37
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 37
atcgaagcgg ccgtactt

18

<210> 38
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 38
tccatggcca cctcaagc

18

<210> 39
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 39
caggcagggc gtaccact

18

<210> 40
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 40
ctctgtgccc atgtacca

18

<210> 41
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 41
ctgcccactt cctccagg

18

<210> 42
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 42
ttgatctcaa cgacagcc

18

<210> 43
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 43
tccatgatgg tcacattc

18

<210> 44
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 44
ggaccggtat tcattctg

18

<210> 45
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 45
acgtagttca gcatctcc

18

<210> 46
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 46
gggtctccgc ttctcgtc

18

<210> 47
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 47
agcatacagg caaagagc

18

<210> 48
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 48
tgtctctgtc gcaaagag

18

<210> 49
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 49
ttcctcctcc aggcagct 18

<210> 50
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 50
ccattgccag ggcagtct 18

<210> 51
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 51
acacagcgta cctgaatt 18

<210> 52
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 52
gcttctgatc aatgtcat 18

<210> 53
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 53
tgtagtggtg cgggtccc 18

<210> 54
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 54
ctggatgtcg gactttgt 18

<210> 55
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 55
ctcttggtcac tgacccag

18

<210> 56
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 56
ctttaacccc tcctgtag

18

<210> 57
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 57
agttctgtgc cggcagct

18

<210> 58
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 58
acctcagata atgcagag

18

<210> 59
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 59
agatcccgtg ctgacaat

18

<210> 60
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 60
ctcaccaga cccaaagt

18

<210> 61
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 61
gtccccgccg ccacgaga

18

<210> 62
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 62
actgactgag aatcgctg

18

<210> 63
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 63
ctgctgttcc aggtcaga

18

<210> 64
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 64
gttatctcca gggtgccc

18

<210> 65
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 65
ccggttgatgc tcaatgct

18

<210> 66
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 66
caggtaacga aactgatt

18

<210> 67
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 67
attctccaga ggcaggta 18

<210> 68
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 68
tcataaaagtt ttgtccca 18

<210> 69
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 69
agtccaaagt ttccatct 18

<210> 70
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 70
tttaggattt ctgtcaag 18

<210> 71
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 71
tacatagact ccaccatt 18

<210> 72
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 72
aactaccatt tggtgaca 18

<210> 73
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 73
tccacatcct gaactacc

18

<210> 74
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 74
ggcaatgatt ttctgtgg

18

<210> 75
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 75
gtccttgtca aagtctgg

18

<210> 76
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 76
gtagcatctg ccgtcaca

18

<210> 77
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 77
gcctccagca cattctcg

18

<210> 78
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 78
ggtcctgagc agcctcca

18

<210> 79
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 79
ggcaaagcag tctgtgtc

18

<210> 80
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 80
aggtggttgg attgtaga

18

<210> 81
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 81
attgtgctcc agttgaaa

18

<210> 82
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 82
tgtggacatt tcttgaca

18

<210> 83
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 83
tagggcaggc acgcacac

18

<210> 84
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 84
ttaatcccat tttcttct

18

<210> 85
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 85
tgatcctgtg ccaatgcc 18

<210> 86
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 86
ctgggtctat ggcttcaa 18

<210> 87
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 87
gacgttcagt ttctctgg 18

<210> 88
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 88
ggataagcaa ggacaggc 18

<210> 89
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 89
actggaactg tagagagg 18

<210> 90
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 90
aggttgctgt tgtcagta 18

<210> 91
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 91
gttaatggta tgataata 18

<210> 92
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 92
ttctctgggtt gattgtgc 18

<210> 93
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 93
ttactattct ctggttga 18

<210> 94
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 94
ctggaacaca gatggttg 18

<210> 95
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 95
caggtcccca acagccat 18

<210> 96
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 96
tactgaagcg gcgacacg 18

<210> 97
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 97
aggttacaag actctatg 18

<210> 98
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 98
tggagccatt ctcaaact 18

<210> 99
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 99
aggccatctt ccatcttc 18

<210> 100
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 100
ctagtgggac cgttacac 18

<210> 101
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 101
tcagacccac aatgacca 18

<210> 102
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 102
atgctcttcc ttctaaca 18

<210> 103
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 103
ctgtgccact gggagtta

18

<210> 104
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 104
ccaaaagcac ctgagcca

18

<210> 105
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 105
gccacaggaa tcttcaca

18

<210> 106
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 106
tggttgggct cagacaca

18

<210> 107
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 107
tccaatgtta tccttgtg

18

<210> 108
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 108
actaagacat tacgggct

18

<210> 109
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 109
tcctccatca gcattgta 18

<210> 110
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 110
ccaaagggtca tcagttcc 18

<210> 111
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 111
catccaacat ttgaccat 18

<210> 112
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 112
actcagcagc cagttcct 18

<210> 113
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 113
gtcatttgga ctgggaag 18

<210> 114
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 114
ttccaaatcc tcttcac 18

<210> 115
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 115
gaggtgggat gttgaaag 18

<210> 116
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 116
cagcaaaacc tccatctc 18

<210> 117
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 117
ctcagcagta gcaccctg 18

<210> 118
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 118
tgggtgctac tgcctct 18

<210> 119
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 119
gtttgtctcg cataggag 18

<210> 120
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 120
ccactggatt caggtatt 18

<210> 121
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 121
ggctcattca cataactca

18

<210> 122
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 122
ttgacagtat gttgttct

18

<210> 123
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 123
ttccagtagt cagggttg

18

<210> 124
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 124
tgctgaaggg tgctccga

18

<210> 125
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 125
aggtattcag gattctct

18

<210> 126
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 126
tctgtaaggt ggaggcgg

18

<210> 127
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 127
agtgtcaaaa ctactggc 18

<210> 128
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 128
gttcaagtta ggtaagca 18

<210> 129
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 129
ctatctttct ctttcagt 18

<210> 130
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 130
atgcagagaa atgaagaa 18

<210> 131
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 131
cagcattgcc ttacattt 18

<210> 132
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 132
gtgtttcaac catctgct 18

<210> 133
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 133
tttgttctaa tggaaact 18

<210> 134
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 134
cagagcaaaa caaatga 18

<210> 135
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 135
aggatgaggg tgaagata 18

<210> 136
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 136
tactcttcag acaaccaa 18

<210> 137
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 137
gttttcctga accacaga 18

<210> 138
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 138
acatacccaa tccagtgt 18

<210> 139
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 139
aaaatggagt tcagaaaa 18

<210> 140
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 140
gcctctcatc atagtccc 18

<210> 141
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 141
gagttacctt ctacttca 18

<210> 142
<211> 18
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 142
cacatttatt tacaactt 18

<210> 143
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 143
gtaaagttgt gaccctggca 20

<210> 144
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 144
ttgcacttct gctccaaatc 20

<210> 145
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 145
ttggtaggat ttgactttga 20

<210> 146
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 146
ctcttagggg catcttgat 20

<210> 147
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 147
tcgatgtcac atgcagcttg 20

<210> 148
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 148
tgaaatccga tgtggccttg 20

<210> 149
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 149
gggtaggctt gtctctgggt 20

<210> 150
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 150
gcatgaggca ggagctcctc 20

<210> 151
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 151
ttcctccagg ccatcttggt 20

<210> 152
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 152
atgagctgtg aattccagag 20

<210> 153
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 153
cttccagcct aggtc gatgc 20

<210> 154
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 154
atttcaaaga cctctggatc 20

<210> 155
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 155
ctccagtagc atgttgcca 20

<210> 156
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 156
ccagagggag gccagtgtgt 20

<210> 157
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 157
cacattctgc ttctggaaac 20

<210> 158
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 158
ggccccgtac tcattctgca 20

<210> 159
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 159
ggagatagga catagttcaa 20

<210> 160
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 160
ccagatgtgg gtcttccagg 20

<210> 161
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 161
tctaaatcgg atctctctcc 20

<210> 162
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 162
agtagcaaag aggactgtgg 20

<210> 163
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 163
tgcttggtcac caccagcagt 20

<210> 164
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 164
actgagggtta catgctggag 20

<210> 165
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 165
gctgcggaag gcatactcct 20

<210> 166
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 166
ctggatgagc ctatattgct 20

<210> 167
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 167
tgctgagggc tctgttgagg 20

<210> 168
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 168
ggctggactt ttcactctgc 20

<210> 169
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 169
gtagctgggc cctcggctgc 7 20

<210> 170
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 170
gtgtaggaca atccacaact 20

<210> 171
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 171
tgagggttg gctgagtgag 20

<210> 172
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 172
aggcctccaa tctctgccta 20

<210> 173
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 173
ctcttcaagc acctccagga 20

<210> 174
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 174
agataggag ctgcgacagc 20

<210> 175
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 175
catctcgggt gcggtagggtg 20

<210> 176
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 176
agccactgac acttcgcaca 20

<210> 177
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 177
gcacccaaac accaagctca 20

<210> 178
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 178
agcctgtgtg cacctggaac 20

<210> 179
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 179
ctgaacgtag accttggtt 20

<210> 180
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 180
accagcttct tcaatgtggt 20

<210> 181
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 181
aagatatctt catgataacg

20

<210> 182
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 182
agagcctcgt ggctttgggc

20

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US01/01381

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 48/00; C12N 15/09, 15/85; C07H 21/04

US CL : 435/6, 375, 455; 536/24.1, 24.5; 514/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 375, 455; 536/24.1, 24.5; 514/44

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WEST, MEDLINE, BIOSIS, BIOTECHNO, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ---	PERESELENI et al. Antisense Oligonucleotides to Inducible NO Synthase Rescue Epithelial Cells from Oxidative Stress Injury. Am J. of Physiology. 1996, Vol. 270, pages F971-F977, see entire document.	1, 2, 14 -----
Y		6-10, 12
X ---	DING et al. Cutting Edge: Antisense Knockdown of Inducible Nitric Oxide Synthase Inhibits Induction of Experimental Autoimmune Encephalomyelitis in SJL/J Mice. The Journal of Immunology. 1998, Vol. 160, pages 2560-2564, see entire document.	1, 2, 4, 5, 11, 13, 14 -----
Y		6-10, 12

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

"	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"B"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

02 MAY 2001

Date of mailing of the international search report

31 MAY 2001

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

SEAN MCGARRY

Telephone No. (703) 308-0196

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	LESOON-WOOD et al. Inducible Nitric Oxide Synthase: The use of Antisense Oligodeoxynucleotides to Study It's Regulation and Role in Neoplastic Transformation. Proceedings of the American Association for Cancer Research. March 1996, Vol. 37, page 145, see entire abstract #1003.	1, 2, 14 ----- 6-10, 12
Y	US 5,872,242 A (MONIA et al) 16 February 1999, see entire document.	6-10 and 12